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C H immunoglobulin heavy chain constant gene segment 
CLL chronic lymphocytic leukemia 
CML chronic myeloid leukemia 
D H immunoglobulin heavy chain diversity gene segment 
OLCL diffuse large cell lymphoma 
IgH immunoglobulin heavy chain locus 
J|H immunoglobulin heavy chain joining gene segment 
MBR major breakpoint region 
MCR minor cluster region 
MRD minimal residual disease 
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CHAPTER 1 
t(14;18), A JOURNEY TO ETERNITY 
By Jules P.P. Meijerink 
From the department of Hematology, University Hospital "St. Radboud" 
Nijmegen, Nijmegen, the Netherlands 
Leukemia, 1997, 11, issue 12, in press 
t(14.18), a lourney to eternity 
The t(14;18) is the most frequent chromosomal aberration observed in follicular n o n -
Hodgkin's lymphoma (NHL), and less frequently in diffuse large cell lymphoma (DLCL). 
The t(14;18) does not affect overall survival in follicular NHL or DLCL. It provides an 
unique lymphoma specific marker that can be used to quantify residual disease during 
treatment, and may forward evaluation of new treatment protocols. The t(14;18) results in 
the deregulation of bcl-2, a proto-oncogene that protects against induction of 
programmed cell death (PCD). Nowadays, a whole family of bcl-2 related genes has been 
identified and consist of members which can either protect or promote induction of PCD. 
The family members form protein dimers, and the relative abundance of specific dimers 
regulates the cellular sensitivity to death signals (the rheostat model). Aberrant 
expression of different family members in several types of malignancies alter the cellular 
rheostat and thereby promote cellular resistance to chemotherapy. 
1.1 t(14;18) and non-Hodgkin's lymphoma 
Specific chromosomal abnormalities are associated with certain types of malignancies. In follicular non-
Hodgkin's lymphoma (NHL), a specific chromosomal translocation involving chromosome 14 and 18, the 
t(14;18)(q32,q21), is present in about 60% of the cases (Table 1 A) The t(14,18) has also been found in 16% 
of the cases with de novo diffuse large cell NHL (DLCL) including immunoblastic (IB) NHL (Table 1B) The 
incidence of t(14;18) in follicular NHL or DLCL may differ in the populations investigated. The incidence of 
t(14;18) in follicular NHL and DLCL as determined by either cytogenetic analysis or molecular techniques like 
Southern blot or polymerase chain reaction (PCR) is only 38 and 9% in the Japanese population versus 62 
and 18% in the rest of the world for follicular NHL and DLCL respectively'1"3). 
The t(14;18) involves the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 
and the В cell ІеикетіаЛутргюта-2 (bcl-2) gene on chromosome 18q21 (Figure 1). During the 
translocational event, the tip of chromosome 18 including the coding region of bcl-2 is coupled to one of the 
IgH joining gene segments (JH) on chromosome 14. This aberrant chromosome 14 is cytogenetically 
denoted as the 14q+ chromosome. In the reciprocal 18q" chromosome, the tip of chromosome 14 including 
the IgH variable ( н) and diversity (DH) gene segments is coupled to the shortened chromosome 18, 
downstream of the bcl-2 gene. The chromosomal breakpoints on chromosome 18 are clustered in two 
regions- a 150 bp region in the 3' untranslated region of bcl-2 which is called the major breakpoint region 
(MBR) and a 500 bp region 20 kilobases downstream of bcl-2 which is called the minor cluster region (MCR)'4-
6
>. In t(14;18) positive follicular NHLs, about 79% of the breakpoints on chromosome 18 occur within the MBR 
and about 2 1 % occur in the MCR (Table 1A). 
Detection of chromosomal abnormalities by karyotypic analysis or molecular biological 
techniques like Southern blot or PCR (Figure 2) are useful tools for detecting t(14;18) in tumor-biopsies 
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which contain a high percentage of malignant cells Cytogenetic analysis or molecular analysis both detect 
t(14;18) in an about equal number of cases in follicular NHL (Table 1A) and DLCL (Table 1B) The PCR 
technology provides an unique advantage in that it is extremely sensitive in comparison to karyotypic analysis 
or Southern blot<7'. The PCR technique may detect a single t(14,18), reflecting a single lymphoma cell, in a 
background of about one hundred thousand normal cells'8 9>. By PCR, it now becomes possible to monitor 
consecutive patient blood and bone marrow samples for minimal residual disease during treatment This will 
be further discussed in paragraph "Detection of minimal residual disease" and chapter 2-4<10·12) 
Table 1A. Frequency of t(14;18) and BCL2 expression in follular NHL (working formulation type B,C, and D) 
C o u n t r y 
USA 
USA 
USA 
World 
USA 
USA 
USA 
USA 
USA 
USA 
Japan 
Japan 
UK-
Denmark 
UK 
China 
Germany 
Germany 
USA 
Japan 
Spain 
UK 
France 
USA 
UK-
Denmark 
World 
(%) 
C y t o ­
g e n e t i c 
4/9 
29/48 
14/20 
37/64 
-
-
-
10/13 
-
-
5/10 
-
-
-
-
-
-
-
6/15 
3/5 
18/28 
11/24 
-
-
137/236 
(58 1%) 
M B R 
. 
-
-
-
9/18 
21/36 
11/17 
21/31 
11/37 
NS 
8/30 
2/16 
18/51 
5/13 
8/16 
9/17 
13/33 
56/88 
5/11 
3/5 
27/49 
30/64 
4/15 
NS 
261/547 
(47 7%) 
M C R 
. 
-
-
-
2/18 
11/36 
-
-
-
NS 
2/30 
1/16 
3/51 
3/13 
1/16 
3/17 
-
18/88 
0/11 
0/5 
2/49 
9/64 
0/12 
NS 
55/426 
(12 9%) 
T o t a l 
m o l e c u l a r 
. 
-
-
-
12/183 
32/36 
-
-
-
13/203 
10/30 
5/161 ab 
21/51 
8/13 
9/16 
12/17 
-
74/88 
5/11 
3/5 
27/49 
40/641 а с 
7/151 
27/611 
305/510 
(59 8%) 
B C L 2 + 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
60/64 
15/16de 
55/64 
130/144 
(90 3%) 
M B R + / B C L 2 + 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
37/60 
7/15 
24/51 
68/126 
(54 0%) 
Authors 
(13) 
(14 15) 
(16) 
(17) 
(18) 
(19) 
(20) 
(21) 
(22) 
(23) 
(1) 
(2) 
(24) 
(25) 
(26) 
(27) 
(28) 
(7) 
O) 
(29) 
(30) 
(31) 
(32) 
(33) 
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Table 1B. Frequency of t(14;18) and BCL2 expression in diffuse large cell NHL (working formulation type G 
and H) 
Country 
USA 
World 
USA 
USA 
USA 
USA 
USA 
USA 
Japan 
USA 
China 
Netherld 
Germany 
Japan 
Spain 
USA 
USA 
Canada 
Europe 
World 
(%) 
Cyto­
genetic 
7/29 
9/78 
7/32 
2/13 
-
-
-
-
-
35/205 
-
-
-
4/44 
1/5 
-
-
-
-
65/406 
(16 0%) 
M B R 
-
-
-
8/20 
3/30 
4/26 
5/31 
NS 
2/27 
8/61 
0/10 
NS 
2/47 
2/20 
1/5 
6/45 
3/14 
15/83 
-
59/439 
(13 4%) 
M C R 
-
-
-
-
1/30 
-
-
NS 
0/27 
0/81 
0/10 
NS 
-
0/20 
0/5 
3/45 
0/14 
-
-
4/232 
(1 7%) 
Total 
molecular 
-
-
-
-
5/30 
-
-
10/543 
2/27 
10/813 
0/10 
13/52 
-
2/20 
1/5 
9/45 
4/143 
-
-
56/338 
(16 6%) 
BCL2+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
16/181 f 
55/83 
57/83 
128/184 
(69 6%) 
MBR+/BCL2+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4/131 
2/15 
-
6/28 
(21 4%) 
Auth 
(14 15) 
(17) 
(16) 
(21) 
(19) 
(20) 
(22) 
(23) 
(2) 
(34 35) 
(26) 
(36) 
(2B) 
(3) 
(29) 
(37) 
(32) 
(38) 
(39) 
Frequency of t(14,18), as detected by karyotypic analysis or molecular analysis by Southern blot or PCR, and BCL2 
expression in follicular NHL (A) or diffuse large cell NHL (B) Abbreviations -, not determined, NS, not shown, aincludes 
bcl-2 gene rearrangements as detected with a 5' bcl-2 probe, blncludes one case with a bcl-2 gene rearrangement in a 
region between the MBR and the MCR, clncludes two cases with bcl-2 rearrangements detected with both the MBR and 
the VCR probe, dOne follicular NHL case and two DLCL cases with barely detectable BCL2 staining are shown as BCL2 
negative, e88% of cases (14/16) and *72% of cases (13/18) had intense BCL2 staining comparable with follicular mantle 
zone В cells 
1.2 Variant translocations involving bcl-2 
A number of translocations involving bcl-2 but different from the classical t(14,18) have been observed in 
cases with follicular NHL and a case with lymphoblastic lymphoma In these cases, translocation breakpoints 
have been found in a 1 5 Kb region upstream and within the first exon of bcl-2. This region has been 
denoted VCR, for variant cluster region In one case, the breakpoint was mapped about 10 Kb upstream of 
the bcl-2 locus within another transcnptionally active locus which is called follicular vanant translocation gene 
(rVM)(4°). The IgH J H 6 region was coupled to bcl-2 in one case·41', but in most cases the kappa or lambda 
immunoglobulin light chain genes (IgL) are juxtaposed to bcl-2 in a head-to-head orientation, resulting in the 
t(2,18)(p11 ;q21 ) or the t(18,22)(q21 ,q11 )(2·42·43). Based upon molecular analysis using Southern blot, the 
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Figure 1. The bcl-2 gene and the IgH gene are involved in Ihe I(14,18)(q32,q21) (A). Schematic illustration ol the bcl-
2 locus at chromosome 18q21 Exons are shown as stipled boxes The protein coding domains are shown as hatched 
boxes The three chromosomal breakpoint regions VCR, MBR and MCR are indicated as well as the DNA probes pB1 6, 
pFL-1, 2 8 KB R/H and pFL-2 which are most frequently used lor Southern blot detection ol bcl-2 rearrangements Exon 2 
and 3 are separated by an intron of 225 Kb The VCR is located upstream and within the first exon The MBR is located 
within the 3' untranslated region of the third exon The MCR is located 20 Kb downstream of Ihe MBR (B). Schematic 
illustration of a part of the IgH locus at chromosome 14q32 The position of the germlme JH gene segments, the IgH 
enhancer, the Cu switch region and Cu exons are indicated (C). Schematic illustration of an hypothetical 14q+ 
chromosome, in which the chromosomal breakpoints occured within the MBR ol bcl-2 and immedially upstream ol the 
JH4 gene segment ol Ihe IgH gene Restriction enzyme recognition sites are indicated with В for BamHI, Bg for Bglll, H 
for HinDIII and R for EcoRI The relative positions of centromeres are indicated with arrowheads 
t(2,18) and t(18,22) have been associated only recently with В cell chronic lymphocytic leukemia (B-CLL), 
and seem to occur in about 5% of the cases(Table 2). In the t(14,18), bcl-2 is coupled to J H 6 , J H 4 or less 
frequent to J H 5 or J H 3 on chromosome 14q+ (i53), and Meijennk, unpublished observation) In the reciprocal 
chromosome 18q-, a D H gene segment is coupled to remaining bcl-2 sequences'53"55) Random 
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a**- -Bcl-2 locus-
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Figure 2. Detection of the 14q+ chromomal junction of the t(14;18) by PCR. (A). Schematic illustration of the 14q+ 
chromosome of an hypothetical t(14;18) translocation in which the chromosomal breakpoints occured within the MBR of 
bcl-2 and immediately upstream of the JH4 gene segment of the IgH gene. In the enlarged fraction, the bcl-2 sequences 
and IgH JH gene segments are indicated with stippled boxes. Random nucleotides at the chromosomal junction are 
shown as a black box. The bcl-2 MBR primer and JH-concensus primer are shown as arrows. Three PCR products 
derived from the hypothetical 14q+ chromosomal junction are illustrated. (B). EtBr-staining of PCR products derived 
from the 14q+ chromosomal junction of six follicular NHL patients in a 2% agarose gel. Lane Μ: φΧ-174 Haelll marker: 
marker bands of 872 bps, 603 bps, 310 bps and 281/271 bps are shown. Lane 1-6: PCR products from 6 follicular NHL 
patients. All 6 patients had a chromosomal breakpoint within the MBR of the bcl-2 gene. For patient 1, 3-6, bcl-2 was 
rearranged to the IgH JH6 gene segment. For patient 2, bcl-2 was rearranged to the IgH JH4 gene segment. The bcl-2-
JH4-JH5 PCR product of patient 2 is also visible. 
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Translocation 
partner 
λ/κ 
-
'/'/JHa 
λ/'/JH 
λ/κ/J Η 
-
ND/K/JH9 
-
Total 
(%) 
Table 2. 
VCR 
3/32 
-
2/44 
2/55b 
4/170C 
0/16 
8/67H 
-
19/3Θ4 
(4 9) 
Bcl-2 rearrangement and BCL2 
MBR 
0/32 
0/9 
1/44 
1/55 
0/170 
0/16 
3/71 h 
-
5/397 
(13) 
MCR 
0/32 
1/9 
0/44 
0/55 
3/170<* 
0/16 
. 
-
4/326 
(12) 
expression in 
Total 
molecular 
3/32 
1/9 
3/44 
3/55 
7/170 
0/16 
NS 
-
17/326 
(5 2) 
B-CLL 
BCL2+ 
-
-
-
-
-
16/17e 1 
71/71 
3/3' 
90/91 
(98 9) 
Author 
(44 46) 
(25) 
(47) 
(48) 
(49) 
(50) 
(51) 
(32) 
NS, not shown, -, not determined, aTranslocalion partners for two cases with 5' bcl-2 rearrangements were not detected, 
bCase with t(2,18) described in Tashiro ef ai(1992)(52', cAbundant BCL2 expression in two cases, dBreakpoints occunng 
upstream ot MCR, includes (our cases with BCL2 staining equivalent to normal PBLs, '70% (12/17) ol cases had BCL2 
staining equivalent or higher in comparison with 1(14,18) carrying cell line RS11846, 9Comigration ol bcl-2 allele with 
kappa light chain in four patients and IgH JH region in one patient, lambda light chain gene rearrangements were nol 
investigated, includes two patients in which bcl-2 rearrangements were detected with VCR and MBR probes, 'BCL2 
staining was less intense in comparison with follicular mantle zone В cells 
nucleotides, denoted "N-nucleotides", are present at both transnational junctions, and resemble random 
nucleotides which are present in the VH-DH and DH-JH junctions and which are randomly inserted by 
terminal-deoxy transferase during the IgH assembly process It is now generally believed that the t(14,18) 
most likely results from a mistake during the IgH rearrangement process in the pre-B cell stage'5 54> In 
agreement with this, occasional t(14,18)s have been described which are the result of erroneous IgH 
rearrangements during either the D H to D H rearrangement process*55' and even the н to DH-JH 
rearrangement process (Chapters, <56>) Tsujimoto et a/(1985) reported the presence of two opposite sets of 
immunoglobulin gene recombination signal-like sequences in the MBR of bcl-2, which resembles a pseudo 
D H gene and may participate in the IgH recombination^7) However, about half of the translocations occunng 
in the MBR can not be explained by the presence of these signal-like sequences Alternatively, Wyatt et ä 
(1992) suggested the involvement of prokaryotic recombination signal χ-related sequences in the 
translocation mechanism χ-like sequences are present in the MBR, V|-|, D H and J H gene segments, and may 
be targets for illegitimate recombination by the VDJ recombmase complex'53) 
Breakpoints in the IgL loci frequently involves IgL recombination signals, lending strength to 
the argument that these translocations may occur as mistakes during the IgL recombination process'2 4 0 52> 
However, no heptamer or nonamer signal-like sequences have been found in the region upstream of bcl-2 
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Adachi et aA46'demonstrated that breakpoints in the 5' flanking region of bcl-2 occur in or near alternating 
punne-pynmidine stretches. These nucleotide stretches can adopt an alternative DNA conformation, which is 
called "Z-DNA conformation". Z-DNA elements have been associated with numorous homologous 
recombination, insertions and deletions processes. No such stretches have been found in the MBR or MCR 
region of bcl-2. Therefore, the mechanisms involved in the genesis of the t(14,18) and the t(2,l8) or t(18,22) 
may be different. 
1.3 The clinical significance of t(14;18) in NHL 
Chromosomal aberrations involving chromosome 2, 7 or 17 Or chromosomal breaks in 1p32-36, 1q21-23, 
6q21-25 are prognostic factors in follicular NHL or DLCL which are associated with decreased overall 
survival'23·34·58' The accumulation of several genetic hits during NHL progression leads to a further reduction 
of overall survival*34·58', probably due to dedifferentiation to a higher malignant state In one initial study 
involving 20 follicular NHL patients, a correlation was found between the presence of the t(14,18) and 
decreased overall survival. No such effect was found in many other studies involving follicular NHL or DLCL 
patients·33-35·37·39'. The t(14,18) has been con-elated in several studies with a lower incidence of complete 
remission after chemotherapy and decreased disease-free survival in follicular NHL and DLCL'23 3 5 5 Э ^ ' 
Since overall survival is not affected, these results indicate that relapses are responsive to further treatment. 
Paradoxically, one study correlated the identification of t(14,18) in DLCL at time of relapse with increased 
overall survival'34'. 
The chromosomal breakpoints in the t(14;18) cluster in small regions. The PCR is therefore 
an excellent method for easy, fast and extremely sensitive detection of residual lymphoma cells within blood 
or bone marrow samples of follicular NHL patients'8·9·55', and has been applied in several experimental as well 
as clinical studies'7 6 1 · 6 2 ' . Although t(14,18)s have been found at very low frequency in benigm hyperplastic 
lymph nodes and blood samples of normal blood donors (see section 2.3, f6 3 - 6 5)), the exact molecular 
composition of each t(14,18) is unique and can therefore be used as lymphoma specific marker in t(14,18) 
positive follicular NHL patients Monitoring of residual t(14;18) carrying lymphoma cells by PCR in bone 
marrow samples of patients who are in clinical complete remission and who had been pretreated with high-
dose chemotherapy followed by ABMT, proved very useful for identifying patients with increased risk of 
relapse. Patients with residual lymphoma cells in the autograft after extensive immuno-purging had a 
significantly reduced disease-free survival when compared to patients in whom no residual lymphoma cells 
could be detected (p<0.00001). None of 58 patients without disease in bone marrow samples after ABMT 
relapsed dunng a median follow-up of about 2 years'5 9 6 0' In contrast, disease-free survival for 35 patients 
with apparent disease after ABMT was only 15 months. No lymphoma cells were detected in consecutive 
blood samples after transplantation in patients who had been transplanted with autologous marrow without 
evidence of residual disease Thirteen out of 14 patients who had been transplanted with autologous marrow 
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Table 3. bcl-2 inhibits induction of cell death by various cytotoxic stimuli 
Cell-types (cell line) 
pro-B (LyH7, FL5.12) 
pro-myeloid (FDCP1) 
mast cell (32D) 
Τ cell (CTLL2) 
kidney carcinoma (293) 
central neural (CSM 14.1) 
sensory neurons 
hypothalamic (GT17) 
pro-B (FL5 12) 
Τ hybrydoma (2B4) 
central neural (CSM14.1) 
hepatoma (7316A) 
pheochromocytoma (PC12) 
central neural (CSM14 1) 
thymoma (WEHI7.2) 
pre-B ALL 
Burkitt lymphoma 
Τ lymphoma (S49.1) 
thymoma (WEHI7.2) 
pre-B ALL (697) 
В lymphoma (CH31) 
neuroblastoma (Shep-1) 
fibroblast (GM701) 
pro-B (FL5.12) 
cervix squamous carcinoma 
(HeLa) 
pheochromocytoma (PC 12) 
Chinese hamster ovary (CHO) 
fibroblast (Rat-1) 
mouse embryonal fibroblast 
Τ lymphoma (J3D) 
myeloid leukemia (M1) 
(BHK) 
Cytotoxic stimuli 
IL-3 deprivation 
GM-CSF deprivation 
IL-4 depnvation 
IL-2 depnvation 
Serum deprivation 
NGF depnvation 
NT-3 deprivation 
BDNF deprivation 
H202/OH radicalsa 
superoxide11 
dexamethasone 
hypoxia 
A231B7 
t-BOOH 
thapsigargin 
ТА 
5fluorodeoxyundine 
CB3717 
ICI M247496 
dexamethasone 
adnamycin 
daunomycin 
etoposide 
camptothecm 
lonomycin 
methotrexate 
1ßD-AraC 
vincristine 
staurosponne 
cyclophosphamide 
nitrogen mustard 
enediyne-5 
cisplatin 
c-myc 
E1A 
p53 
Sindbis infection 
Drug-targets 
DNA. lipids, proteins 
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with PCR-detectable disease remained positive after transplantation'59 60> 
Qualitative screening for residual t(14,18) positive lymphoma cells seems, therefore, 
sufficient to identify patients with increased risk for relapse However, residual t(14,18) positive lymphoma 
cells may remain detectable at low levels in follicular NHL patients who are in stable clinical remission'66) So 
qualitative screening may be insufficient for predicting relapse Accurate quantitative screening in 
consecutive samples may be a pre-requisite in order to predict progression or reoccurrence of disease 
(Chapter 2-4, <10'12)) Until recently, no curative treatment options were available for patients with follicular 
NHL. Now, new treatment protocols are emerging based upon high dose chemotherapy with autologous 
stem cell support, allogeneic stem cell transplantation, new purine analogues, interferon alpha or monoclonal 
antibodies Quantitative monitoring of t(14,18) carrying cells may have a major clinical impact on future 
evaluations of these treatment protocols 
2.1 bcl-2, a new type of oncogene 
The bcl-2 gene is involved as an early genetic hit in the oncogenesis of the t(14,18)-positive follicular NHL It 
spans more than 230 Kb of DNA'67', and consists of three exons of which exon 2 and a small part of exon 3 
encode for protein (Figure 1A) Exon 2 and 3 are separated by a large intron of about 225 Kb The MBR is 
located in the untranslated region of exon 3'6 8', and therefore the protein coding domain is maintained 
during the 1(14,18) Dependent on splicing of intron 2, bcl-2 encodes for two different mRNAs, Bcl-2oc and 
Bcl-2ß<69' of which only Bcl-2a seems to have biological relevance The BCL2 protein is a membrane protein 
and is located at the cytosolic site of the nuclear envelope, the endoplasmatic reticulum and the outer 
mitochondrial membrane probably near mitochondrial contact zones'7071) Bcl-2 is unique among proto-
oncogenes, and it does not promote proliferation like c-myc, nor contributes to tumongenesis upon loss-of-
function like p53 or retinoblastoma (pRB), but it prevents induction of cell death under cytotoxic 
conditions'72). The bcl-2 gene is able to prevent apoptosis induced by diverse cytotoxic conditions in various 
cell types ranging from growth factor deprivation, generation of intracellular reactive oxygen radicals, hypoxic 
conditions, many different chemotherapeutic agents and expression of cellular genes under suboptimal 
conditions (Table 3). Bcl-2 can also protect against some forms of necrotic cell death'73 74) 
The BCL2 protein is expressed in many different tissues BCL2 is expressed in early 
hematopoietic progenitor cells of all lineages BCL2 is also present in mature T-lymphocytes which reside in 
the thymic medulla, as well as in the long-lived IgM/lgD memory В cells in the germinal center follicle mantle 
zone of secondary lymphoid tissue. BCL2 is also present in the stem cells of differentiating epithelium like 
skin and intestine, in epithelial cells of hormonal responsive tissue like breast epithelium, thyroid gland 
epithelium, basal cells of prostate epithelium and acinar cells of pancreatic epithelium as well in neurons that 
are long-lived post-mitotic cells'75 76> 
Bcl-2 knock-out mice have helped in determining the function of bcl-2 These mice seem to 
have a normal embryonic development, but soon after birth they become retarded in growth, loose 
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pigmentation during the second hair follicle cycle, and acquire defects in the small intestine These mice 
ultimately die of renal failure due to severe polycystic kidney disease'77 79> В and Τ cell numbers are initially 
normal and both cell types demonstrate normal proliferative responses Massive cell death occurs in the 
lymphoid compartment soon after birth and results in lymphocytopenia*77 7 e ' Although bcl-2 seems not to be 
absolutely required for embryonal development, it is essential for long-term survival and maintenance of at 
least some cell types 
2.2 Bcl-2 expression during В cell development 
During В cell development, pro-B cells in the bone marrow differentiate into naive В cells During 
differentiation, cells rearrange their IgH chain and IgL chain loci to encode for functional antibodies After 
functional rearrangements, pre-B cells differentiate into lgM+/lgD· immature В cells and become negatively 
selected for recognition of self-antigens After differentiation into mature naive В cells, cells leave the bone 
marrow compartment and enter the periphery During Τ cell dependent antibody responses, naive В cells 
undergo affinity maturation and enter germinal centers in the spleen or lymph nodes Here, naive В cells 
populate the dark zone of the germinal center, and are now called centroblasts Centroblasts rapidly divide, 
acquire somatic mutations in their rearranged IgH and IgL alleles and enter the light zone as non-dividing 
centrocytes At this site, centrocytes are tested for antibody affinity during intimate contact with antigen 
presenting cells Most centrocytes do not survive the selection process and die by apoptosis 
Bcl-2 mRNA is expressed in most pro-B cells and in mature naive В cells, but it is temporarily 
down-regulated in the pre-B cell stage<104) In contrast, the bcl-2 homologous gene bcl-xl becomes 
upregulated during the pre-B cell stage'105· Down- and upregulation of Bcl-2 and Bcl-xl may coincide with 
several selection processes First, selection for functional rearrangements of IgH and IgL loci may coincide 
with down-regulation of Bcl-2 and upregulation of Bcl-xl Second, negative selection for recognition of self-
antigen may coincide with down-regulation of Bcl-xl and up-regulation of Bcl-2 Third, positive selection of 
centrocytes which express abundant Bcl-2 mRNA but no protein'76 1 0 6 ' ln-vitro stimuli like algM, ocCD23 plus 
rlL-1a, aCD40 or CD40-ligand, which mimic in-vivo selection stimuli induce BCL2 and BCL-X[_ upregulation in 
centrocytes or splenic В cells'1 0 5 1 0 7> 
2.3 t(14;18) deregulates bcl-2 gene expression 
Due to the 1(14,18), the bcl-2 gene is in close proximity of the IgH enhancer This results in acontinous high 
expression of the bcl-2 g e n e ' 1 8 6 8 1 0 8 1 0 9 ' (Table 1A) Remarkably, the number of follicular NHL cases 
expressing BCL2 protein (about 90%) far exceeds the number of cases with detectable t(14,18) (about 
60%) Only 54% of the cases expressing abundant BCL2 protein have detectable bcl-2 rearrangements 
Since only some of these cases with t(14,18) may have remained undetectable by cytogenetic analysis or 
molecular analysis due to alternative breakpoints in the bcl-2 locus, and since normal germinal center В cells 
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do not express BCL2 protein'75 76>, it is apparent that additional mechanisms exist which results in a 
deregulated bcl-2 gene expression 
A similar discordance between BCL2 protein expression and the presence of translocations 
involving bcl-2 exists for DLCL and B-CLL About 70% of DLCL cases express abundant BCL2, but only 2 1 % 
of BCL2 positive cases have a rearranged bcl-2 gene (Table 1B) About all B-CLL cases express abundant 
BCL2 protein (Table 2) In 70% of these cases expression of BCL2 is equivalent or even higher compared to 
the BCL2 expression of at(14,18) carrying follicular NHL cell line*50) Since only 5% of B-CLL cases have a 
bcl-2 gene rearrangement, it is unclear if high BCL2 protein expression is of pathological ongin B-CLL is 
supposed to be the malignant counterpart of normal mantle zone В cells, and high BCL2 protein expression 
in B-CLL could therefore be a mere reflection of long-lived memory В cell origin 
Since most cases of follicular NHL have at(14,18) (Table 1A) and since enforced bcl-2 
expression in transgenic mice seems oncogenic'110), it seems logical that deregulated bcl-2 expression is an 
important early step in the pathogenesis of follicular lymphoma Similar translocations are also found in benign 
hyperplastic lymph nodes'63* and blood samples of healthy blood donors at very low frequency for up to 
several years'64 6 5 ', and indicates that neoplastic development requires additional genetic hits The nature of 
these genetic defects and the developmental stage in which they become apparent remains elusive 
Antigen specificity and selection processes may play an important role in the pathogenesis of follicular NHL 
Follicular NHL cells are frozen in the centroblastic/centrocytic differentiation stage in which the somatic 
mutation machinery remains active'111"114' The somatic mutation profiles of follicular NHL cells provide 
evidence that these neoplastic cells remain under contmous affinity selection'1 1 5 1 1 6), so antigen-driven 
proliferation processes are most likely involved in the maintenance of the malignant cell population (Chapter 
5,156)) 
Bcl-2 transgenic mice are excellent tools to demonstrate the tumongenicity of deregulated 
bcl-2 gene expression In these mice, non-cycling polyclonal follicular center В cells accumulate, resulting in 
large splenic and nodular follicular center areas. В cell maturation is not inhibited and immunoblasts and 
plasma cells are present Splenic В cells have a prolonged hvespan, but m-vitro activation seems 
unaffected'117·118). Another Bcl-2 transgenic mice model demonstrates increased В cell numbers of all 
developmental stages without evidence of follicular hyperplasia'119), and probably reflects differences in the 
genetic background or bcl-2 expression cassette in both transgenic lines Bcl-2 overexpression in the В cell 
lineage prolongs antibody responses upon antigenic challence'119), and prolongs В cell memory'120) After a 
relatively long latency penod, 11% of these mice develop a monoclonal high-grade diffuse large cell 
immunoblastic lymphoma'110) This clearly demonstrates that t(14,18)s may occasionally occur in every 
individual, but these cells disappear over time or are specifically eliminated by the immune system'64 65> In 
some unfortunate cases however, these cells acquire secondary genetic defects which enable these cells to 
escape from immune surveillance and to exploit their neoplastic appearance fully resulting in follicular NHL 
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I 
I 
SURVIVAL 
DEATH 
Figure 3. The rheostat model according to Oltvai er al (1993)ί130>. 
3.1 The bcl-2 gene family 
Many different evolutionary conserved proteins have been discovered which are homologous to BCL2 and 
are recognized as the bcl-2 gene family. Family members share at least two regions of homology with BCL2 
and are called BCL2 homology domains 1 and 2 (BH1, BH2). Some family members like Ьс/-х/121), foc/-wC22), 
mc/-i(123'124), ai/b/7-i<125"127> and лг-73<128'129' provide protection against cell death-inducing stimuli. Other 
family members like Ьах<130), Ьа/<<131"133), bad^3*) and bc/-xs*121> have an opposite effect and promote cell 
death. 
Bcl-2 family members form protein dimers<130'135·136), and the formation of specific dimers 
function as a cellular rheostat to determine the cellular fate following cell death signáis'137). In this rheostat 
model, relative abundance of cell death promotors like BAX would favour BAX homodimer formation and 
thereby promote cell death. Relative abundance of survival proteins like BCL2 would favor formation of 
BCL2/BAX heterodimers or BCL2 homodimers and thereby prevent induction of cell death. Factors like BAD 
and BCL-XS compete for binding to cell death inhibiting molecules like BCL-X|_ or BCL2, thereby displacing 
BAX and facilitating BAX homodimerization and induction of cell deathC121·134) (Figure 3). 
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Figure 4. Conservation of protein domains among bcl-2 gene family members (A). Protein domains BH1-4 are 
conserved in family members with anti-apoptotic activity, whereas only BH1-3 are conserved in members with pro-
apoptolic activity (B) Alignment of homology domains (grey box residues) among different family members Conserved 
amino acid residues are shown in bold capitals Large arrows refer to amino acid residues in BH3 of ВАК which interact 
with residues (small arrows) in the hydrophobic pocket (BH1-3) of BCL-XL '1 4 9> 
3.2 BCL2 homology domains involved in regulation of apoptosis 
Protein alignment of several family members revealed at least four domains of homology, and are denoted 
BH1 to BH4 (Figure 4). These domains are involved in protein dimenzation and cell death regulation, 
although the contribution of the domains is different within different family members BH1 to BH3 are 
conserved in all family members except BAD, whereas BH4 is only conserved in family members with anti-
apoptotic activity. BH1 and BH2 are cntical for the cell death protecting function of BCL2 and BCL-X|_ 
Specific amino acid substitutions in BH1 and BH2 result in loss-of anti-apoptotic activity as well as loss-of 
binding to BAX. Mutant nonfunctional BCL2 still dimenzes with wildtype BCL2, suggesting thaï BCL2 and 
BCL-XL must dimenze with BAX to display their anti-apoptotic activity*135138) However, the ammo acid 
residues within BH1 and ВН2 that are involved in maintaining the anti-apoptotic activity of BCL2 and BCL-XL 
are partially different. Moreover, the cell death protective function of BCL-XL has been demonstrated in 
absence of heterodimenzation with BAX or ВАК'103). 
The ВНЭ domain seems to be crucial for pro-apoptotic molecules such as ВАК and BAX In 
ВАК, BH3 is sufficient for promoting death as well as dimenzation with BCL-XL^ 1 3 9 ' BAX homodimenzation 
has been demonstrated to occur by BH3 to BH3 interaction!140) Deletion of BH3 renders both BAX and ВАК 
non-functional<139i40) Moreover, a BH3 homologous domain has also been identified in pro-apoptotic 
molecules BIK/NBK(141·142», BID(143> and HRK(144>, which are distantly related to the bcl-2 gene family 
Therefore, BH3 may encode a new cntical death domain Consistent with this, BCL2 can be converted into a 
pro-apoptotic molecule upon exchange of the BH3 domain with the equivalent domain of BAX<145). 
Although the BH3 seems to be sufficient for homodimenzation of BAX and for dimenzation of 
BAX or ВАК with BCL-XL, BCL2 homodimenzation may involve all four homology domains BCL2 probably 
forms homodimers by interaction of the N-terminal portion of the protein which includes BH4 with the C-
terminal portion of the BCL2 partner protein which includes BH3, BH1 and BH2<1 3 6 1 4 S' All four homology 
domains as well as the spacing between BH3, BH1 and BH2 are vital for cell death protective function'9 5 1 4 7> 
BH4 seems not to be involved in heterodimenzation with BAXl1 4 0 1 4 6 ' Based upon studies using deletion 
mutants, the involvement of the homology domains in the formation of specific protein dimers may be 
different among family members, as summanzed in Figure 5 
The three dimensional structure of BCL-XL consists of two central hydrophobic α-helixes (a5 
and a6), that are flanked by five amphiphatic α-helixes The three conserved domains BH1 (part of a4, a5), 
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Figure 5. Hypothetical proteins interactions in BCL2 homodimers, BCL2-BAX heterodimers and BAX homodimers. The 
different homology domains are indicated, and interactions are visualized by lines. 
BH2 (part of аб, а7) and BH3 (oc2) are in close spatial proximity, and form a hydrophobic cleft'148). 
Investigating the BAK-BCL-X|_ interteraction, a synthetic peptide related to the BH3 region of ВАК was able 
to bind in the hydrophobic cleft of BCL-XL- The interaction was mediated by hydrophobic and electrostatical 
interactions between specific residues of the BH3 region from ВАК and residues from the hydrophobic cleft 
of BCL-XL- Furthermore, this peptide could inhibit the interaction between wildtype ВАК and BCL-XL 
through competition<149). These data are compatible with the model as proposed in Figure 5, and the pro-
apoptotic activity and protein interactions of ВАК or ΒΑΧ seems solely dependent on the ΒΗ3 domain. All 
four homology domains in BCL2 and BCL-XL a r e required for anti-apoptotic activity and participation in protein 
dimers, and is probably dependent of forming a hydrophobic cleft. 
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We recently found mutations in bax in about 2 1 % of human malignant hematopoietic lines 
(Chapter 6 and 7, Oso151)) Several cell lines contained a deletion or an insertion in an identical 
deoxyguanosine(GS) tract, resulting in truncation of BAX Identical mutations have recently been decribed in 
about 50% of colorectal cancers of the microsatelite mutator phenotypet152' Three different point mutations, 
G11E, G67R and G108V, were found in independent lines BAXG67R
 a n d BAXG108V Were tested for function, 
and demonstrated altered protein dimenzation and loss-of pro apoptotic activity As a consequence of the 
BAXG67R mutation, a positive charged Arginine residue is introduced in the hydrophobic site of the BH3 
domain Both neighboring residues, He66 and Aspse. are involved in the binding of ВАК to BCL-X|_'149> The 
G67R mutation may interfere with interactions of these residues with the hydrophobic pocket of BCL2 or 
BCL-XL Strikingly, this BAX mutant is indeed unable to form heterodimers with BCL-2 or BCL-X|_, but can still 
form homodimersC51' Although BH1 of ВАК or BAX does not seem to be involved in pro-apoptotic function 
or protein interactions'13914°), the BH1 BAXG 1 M V mutation resulted in a non functional protein that was 
unable to form homodimers, although heterodimenzation seemed unaffected Sattler ef al (1997) suggested 
that binding of ВАК to BCL-XL necessitates a conformational change in ВАК in order to expose the BH3 
domain to the protein surface<149> The BAXG 1 0 8 V mutation may interfere with such a conformational change of 
BAX, at least for homodimertzation Whatever residues are involved in protein dimenzation, both mutations 
demonstrate that hetero- and homodimenzation of BAX may involve different ammo acid residues of the BH3 
domain BH1 may directly be involved in protein interactions or is important for protein conformation 
4. Bcl-2 gene family and resistance to chemotherapy 
Traditionally, it has been hypothesized that chemotherapeutic agents are effective in eliminating proliferating 
cells, but from emerging data it now becomes clear that at least some of these compounds function by 
inducing apoptosis Many genes are involved in the regulation of cell death pathways, and mutations in these 
genes can contribute to cellular resistance to chemotherapeutic regiments and radiation One of these genes 
is the tumor-suppressor gene p53 This is one of the most frequently mutated genes in human 
canceK153154) In experimental systems, p53-deficiency has been associated with reduced death under 
suboptimal growth-conditions'155), treatment with chemotherapeutic compounds or gamma-radiation'156"160) 
Within hematopoietic malignancies, mutations in p53 have been associated with resistance to treatment and 
reduced survival in AML, MDS and B-CLL'161162> The mechanism by which P53 induces apoptosis remains 
enigmatic, but recently bax has been identified to be specifically upregulated by P53<1 0 2 1 6 3), and may 
participate in the p53-dependent death pathway P53-induced apoptosis Б reduced but not blocked in the 
absence of bax<164165), indicating that bax participates in the p53-dependent death pathway but that other 
death effectors are involved as well Furthermore, bax-deficiency promotes cellular transformation indicating 
that bax can act as a tumor-suppressor gene as well'164165> Reduced BAX levels and resistance to cisplatin 
induced apoptosis may be related to absence of functional p53 in progressive ovanan carcinomas'166) 
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Decreased BAX expression correlates with poor prognosis and shortened overall survival in women with 
metastatic breast cancel 1 6 7 ' , but is not correlated with p53 status'168' Enforced BAX expression in malignant 
breast cancer lines restores the sensitivity to serum depnvation and reduces tumongenicity in seid mice'1 6 8' 
The bcl-2 gene is one of the best studied family members in relation with resistance to 
chemotherapy It protects against vanous cytotoxic compounds with different mechanisms of action (Table 3) 
BCL2 does not inhibit early effects of cytotoxic compounds such as suppression of proliferation or breaks in 
chromosomal DNA Neighter does it affect DNA repair BCL2 inhibits the onset of a distal death pathway, 
leading to a reduction of apoptosis and the characteristic chromosomal DNA breakdown'89 92> Since DNA 
damage by cytotoxic drugs is not inhibited and cells continue to proliferate after drug removal'8 9 9 4 1 6 9), BCL2 
expression promotes selection of cells with additional genetic hits and therefore contributes to 
dedifferentiation of disease BCL2 overexpression also indirectly promotes chemotherapy resistance by 
increasing the intracellular GSH levels'74', and shifts the cellular redox-potantial to a more reduced state High 
GSH levels detoxify a number of chemotherapeutic compounds by reducing free-radical intermediates 
Similar to BCL2, BCL-X|_ can protect against cell death induced by various chemotherapeutic 
compounds'169 17°' However, the ineffectiveness of bcl-2 but not bcl-xl expression in repressing apoptosis 
in a murine В cell line suggests that both genes function in independent pathways'171' 
5. Concluding remarks 
The proto-oncogene bcl-2 is involved in the pathogenesis of follicular NHL and probably in other diseases 
Overexpression of BCL2 due to the t(14,18) in follicular NHL is not correlated with overall survival, but the 
t(14,18) provides at least a disease-specific marker which can be used for monitoring of residual disease This 
may not only allow individualization of therapy, but may be especially helpful in determining the effectiveness 
of future treatment protocols Bcl-2 represents a type of proto-oncogene that promotes cellular viability under 
circumstances which normally would lead to apoptosis Nowadays, a whole family of bcl-2 related genes has 
been identified and consists of anti-apoptotic members like bcl-2 and pro-apoptolic members like bax 
Proteins of this family form protein dimers The viability of a cell ts determined by the relative abundance о I 
specific dimers as explained by the rheostat model Aberrant expression or reduced expression of some 
family members contribute to cellular resistance towards chemotherapy Although much is known about the 
influence of independent members on the outcome of chemotherapy, future research should be focussed 
on the expression pattern of the entire family as a whole in relation to chemotherapy resistance Furthermore, 
a better understanding of the involvement of different homology domains in the formation of specific dimers 
and outcome on cell survival may provide potential targets for the development of new therapeutic regiments 
6. Aims of this thesis 
The cytogenetic abnormality t(14,18) is present in about 60% of follicular NHL patients The research leading 
to this thesis was aimed at the development of a sensitive assay This assay may allow accurate quantitation of 
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residual malignant cells in follicular NHL patients during and after therapy For this, we developed a method 
based upon the polymerase chain reaction The method was demonstrated on consecutive peripheral blood 
samples of several follicular lymphoma patients during treatment This method and it's application is described 
in Chapters 2-4. 
In an attempt to identify disease-specific molecular markers, we investigated a case of 
follicular non-Hodgkm's lymphoma harbouring an exceptional t(14,18) (Chapter 5). Furthermore, we 
discovered the presence of mutations in the pro-apoptotic bax gene in several malignant hematopoietic lines 
(Chapter 6) Research was aimed to investigate the extend of mutations within different hematopoietic 
diseases by analyzing a panel of cell lines and primary patient samples Since some of these mutations were 
localized in evolutionary conserved domeins, we investigated the consequences of these mutations for pro-
apoptotic function of BAX ( Chapter 7) In Chapter 8, we reviewed cellulair mechanisms by which the activity of 
bcl-2 gene family members may be modulated as well as and potential mechanisms by which bcl-2 gene family 
members may regulate programmed cell death 
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Quantitation of follicular NHL by competitive PCR 
A competitive polymerase chain reaction (PCR) technique was developed to quantify 
residual malignant cells in peripheral blood and bone marrow samples of patients with 
low-grade follicular non-Hodgkin's lymphoma carrying a translocation between 
chromosomes 14 and 18. Artificial translocation segments were constructed imitating a 
translocation between chromosome 14 and 18. These artificial translocation segments 
were used as competitor molecules in the quantitative PCR. Serial dilutions of a known 
amount of patient-derived translocation segments were coamplified with a fixed number 
of competitor molecules in order to construct a patient specific calibration curve. Patient 
samples were coamplified with an equal number of competitor molecules and the number 
of t(14;18) translocations within the samples was calculated by comparison with the 
calibration curve. The method was demonstrated on samples of four follicular non-
Hodgkin's lymphoma (NHL) patients. In a patient, transplanted with allogeneic bone 
marrow, declining numbers of residual lymphoma cells were observed. We conclude that 
the method is accurate, relatively fast and the general principle of this method can be 
applied to all malignancies with characteristic abnormalities on DNA or RNA level that are 
detectable by PCR. 
Characteristic chromosomal abnormalities occur in several human neoplasms'1 2 ' providing tumour-specific 
markers that can be used to monitor residual malignant disease A reciprocal translocation, t(14,18) between 
chromosome 14 with chromosome 1Θ is present in most low-grade follicular non-Hodgkin's lymphomas (NHL) 
depending upon the population under investigation'3) The B-cell lymphoma/Leukaemia 2 (bcl-2) proto­
oncogene locus on chromosome 18q21 is coupled to the heavy-chain of the immunoglobulin locus (IgH) on 
chromosome 14q32 by a process which frequently involves an IgH joining-segment (JH) N-nucleotides are 
inserted between the two fusion partners, resulting in a DNA pattern that is patient specific'4 5> The 
breakpoints on chromosome 18 cluster within two small regions on the DNA, the major breakpoint region 
(MBR) located in the 3' untranslated part of the bcl-2 gene, while the minor cluster region (MCR) is located 20 
Kb downstream'6·7). 
The polymerase chain reaction (PCR)'8·9' is a fast and sensitive assay capable of detecting 
the presence of as little as one malignant cell out of 105 normal cells'10) The technique therefore seemed 
well suited to investigate the influence of treatment on the number of malignant cells in the peripheral blood 
as well as to monitore the efficiency of purging of autologous bone marrow for autologous bone marrow 
transplantation provided that an accurate quantitative method can be developed 
To this end, the t(14,18) breakpoint region of cell line SU-DHL-6 was subcloned and 
modified PCR product of this artificial bcl-2/ІдН translocation was used as competitor DNA PCR product of 
the patient t(14,18) was necessary as patient-derived translocation segments for the construction of a patient 
specific calibration curve For analysis of patient samples by our competitive PCR assay, first, a patient specific 
calibration curve was constructed by coamplification of serial dilutions as of known amount of patient-derived 
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translocation segments with a fixed number of competitor molecules The PCR product ratio was 
logarithmically plotted against the initial number of patient-denved translocation segments Second, patient 
samples DNA was ceamphfied in the presence of the same number of competitor molecules and the ratio 
between final products was determined Third, the ratio of each patient sample was compared with the patient 
specific calibration curve in order to calculate the number of 1(14,18), which reflects the number of lymphoma 
cells. Samples of four patients with follicular NHL were determined to demonstrate and evaluate this 
technique. 
Materials & Methods 
Patients. Patient 1 was diagnosed as having a stage I, low-grade follicular centroblastic-centrocytic (CB-CC) 
NHL in September 1990. Bone marrow histology showed no evidence of disease and a complete remission 
(CR) was obtained after locoregional radiotherapy However she developed a slow, progressive cervical 
lymphadenopathy in February 1991 and tumour cells were found in her bone marrow. Despite treatment with 
chlorambucil from August 1991 to April 1992, residual tumour was present in lymph nodes and bone marrow 
after cessation of therapy. 
Patient 2 was diagnosed as having stage IV, follicular CB-CC NHL with bone marrow 
involvement in Apnl 1988 CR was induced following doxorubicin containing therapy which lasted until 
February 1990 when he relapsed. Treatment with chlorambucil achieved a complete clinical remission in 
October 1990, but lymphoma cells carrying t(14;18) were still detectable in the bone marrow He was 
transplanted in October 1990 with marrow from a HLA-identical, MLC non-reactive brother according to the 
ongoing protocol'11' and is now in stable remission 
Patient 3 had a diagnosis of follicular CB-CC NHL in 1980 and was treated with a variety of 
chemotherapeutic regimens for multiple relapses until June 1991 when a relapse occurred in a lymph node 
Acute myeloid leukemia (AML) was also diagnosed and the patient died 3 months later following palliative 
treatment 
A partial remission of stage IIA low-grade follicular CB-CC NHL was achieved in patient 4 in 
1987 after a course of chemoradiotherapy In January 1988 progressive disease was treated with 
chlorambucil. However, by February 1990 abdominal involvement became apparent for which radiotherapy 
was given Eleven month later hypercalcaemia developed and diffuse centroblastic NHL was diagnosed with 
histological dedifferentiation culminating in death in May 1991. 
Sample collection. Mononuclear cells were isolated from blood and bone marrow samples by density 
centrifugaron on 1.085 g/ml Percoli (Pharmacia, Uppsala, Sweden), washed and stored as pellets at -80°C 
Fresh lymph node tissue was obtained by biopsy, pressed gently through a 70 um nylon filter, washed and 
cryopreserved with 10% dimethylsulphoxide (DMSO) by means of a computerized freezing programme that 
maintened the functional and growth potential of the cells'12'. 
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DNA isolation DNA was isolated from blood, bone marrow and lymph node samples as previously described 
by Miller et al (198θ)<13> After determining the concentration, samples were stored at 4°C 
Polymerase chain reaction Amplification was performed in a DNA thermal cycler (Perkin Elmer Cetus, 
Norwalk, USA) in presence of 0 001% gelatine, 50 mM KCl, 20 rrM Tns-HCI (pH=8 4), 2 0 mM МдСІг, 500 
mM of dATP, dTTP, dGTP and dCTP, 300 pmol/ml of oligonucleotides and 25 U/ml Taq polymerase (Gibco 
BRL) in a total volume of 100 uJ Reactions were overlaid with 100 μΙ of mineral oil (Sigma) Amplification 
started with an initial denaturation step at 94°C for 5 mm followed by several cycles at 94°C for 1 5 mm, 55°C-
58°Cfor2 mm, and72°Cfor2 mm After the last cycle, extension phase was prolonged for 10 mm at 72°C, 
and the reaction was cooled to 4°C 
Oligonucleotides Oligonucleotides were synthesized on a DNA synthesizer (Applied Biosystems model 391 
EP, Warrington, UK) Oligonucleotides were deprotected, purified by two ethanol precipitations, and 
dissolved in diethylpyrocarbonate (DEPC) treated water Concentration was measured by optical density 
Sense oligonucleotides used MBR1 5'-TTA GAG AGT TGC TTT ACG TG-3', MBR2 5' TCC CTT TGA CCT 
TGT TTC TTG A, MBR3-Xhol б'-ССС TCG AGG AGC TTT GTT TCA ACC AAG TC-3, AN2S 5' GTC ACC GAT 
АТС GAA TTC CTG CAG G Antisense oligonucleotides used JH-CON 5'-ACC TGA GGA GAC GGT GAC C-
3', JH-Hmdlll 5'-TCA AGC TTA CCT GAG GAG ACG GTG ACC-3'. JH6-intron 5' CGC AGG AAA CCC CAC 
AGG CA-3', AN2A 5'-GTG ACC CTG CAG GAA TTC GAT АТС G-3' 
Preparation of artificial bcl-2/ІдН translocation segments competitor molecules 1 цд of genomic DNA of cell 
line SU-DHL-6 containing at(14,18) was amplified for 35 cycles with oligonucleotides MBR2 and JH Hindlll 
and an annealing temperature of 58°C The fragment was digested with Nsil and Hindlll and ligated into Pstl 
and Hindlll digested Bluescribe KS + vector (Stratagene®, La Jolla, USA) Vector pAN2 2 was constructed by 
ligating annealed complementary oligonucleotides AN2A and AN2S into the BstEII site Direct sequencing 
revealed that vector pAN2 2 contained two oligonucleotide AN2A-AN2S duplexes in the insert The 
construction of the vector is illustrated in Figure 1 Ten reactions containing 20 ng DNA of pAN2 2 were 
amplified for 35 cycles with oligonucleotides MBR1 and JH-CON and an annealing temperature of 55°C PCR 
product was separated from remaining oligonucleotides on a 2% agarose gel, excised, and eluted by Biotrap 
(Schleicher & Schuell) DNA was precipitated, dissolved in 800 μΙ H 2 0 and the concentration was 
determined From this, the number of artificial bcl-2/[gH translocation segments was calculated for use as 
competitor DNA in a competitive PCR 
Preparation of patient-denved translocation segments Several reactions containing 1 цд patient lymph node 
DNA were amplified for 35 cycles with oligonucleotides MBR3-Xhol and JH6 intron and an annealing 
temperature of 55°C PCR product separation from remaining oligonucleotides, determination of the 
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Figure 1 . Schemalic illustration of vector pAN2.2. The translocation region of cell line SU-DHL-6 (black and grey 
boxes) is cloned into vector Bluescribe K/S+ (white boxes). Two heleroduplexes of primers AN2A and AN2S (hatched 
box) are cloned into the BstEII site of the JH6 region. The MBR1 primer-site and the JH-CON primer-site are indicated by 
A & В respectively. PCR with this primer-pair results in a 272 bp product (or the pAN2.2 vector. 
concentration and subsequential calculation of the number of patient-derived translocation segments was as 
described for the preparation of competitor molecules. 
Assay procedure. The competitive PCR assay is outlined in Figure 2. Amplification was performed for 55 
cycles with oligonucleotides MBR1 and JH-CON in addition of 1.85 MBq/ml [a-32p]dCTP (Amersham, 111 
TBq/mmol; 370 MBq/ml). 
Patient sample reaction. 1 цд of patient sample DNA was coamplified with a fixed number of 
competitor molecules. 
Serial dilution reactions. Serial dilutions of patient-derived translocation segments were 
coamplified with a fixed number of the competitor molecules in addition of 1 цд K562 DNA (which contains no 
t(14;18)). Amplification of 1 μ9 K562 DNA served as a negative control to check for contamination. 
Analysis and quantitation of PCR products. 5 μΙ of ten fold diluted PCR product in formamide 
dye (20 mM NaOH, 1 mg/ml bromophenol blue, 1 mg/ml xylene cyanol, 10 mM EDTA (pH=B.O) in formamide) 
was applied to a 7% Polyacrylamide (PAA) (acrylamide:bisacrylamide=24:1), 7 M Urea gel in half TBE buffer. 
The gel was exposed to X-ray film (Kodak) and autoradiograms were analysed by densitometric scanning on a 
LKB laser densitometer. Peak intensities were determined using Gelscan® XL software. Ratios of the band 
intensities of the serial dilution reactions were plotted logarithmically against the initial number of patient-
derived translocation segments used. A regression curve was constructed for calibrating the number of 
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t(14,18) translocation present in each patient sample 
Sequencing Sequencing of PCR product was performed as described by Innis et al (1988)<14' with minor 
modifications 
Results 
Results obtained by the present assay and clinical data for four different follicular NHL patients are 
summanzed in Table 1 The blood sample of the first patient contained detectable numbers of t(14,18) at time 
of diagnosis Five months later she relapsed with a 17-fold increase of t(14,18) in her blood After treatment 
she remained in stable relapse and three consecutive blood samples contained virtually equal numbers of 
translocations T(14,18) was detected in a lymph node sample obtained at the time of relapse in the second 
patient and also in a blood sample taken 6 months later Complete clinical remission was achieved after 8 
months chemotherapy allowing him to receive an allogeneic BMT He remained clinically well even though 
translocations were still detectable in consecutive blood samples obtained after BMT which declined 
gradually until finally becoming negative 17 months after BMT The third patient had a relapse of follicular NHL 
as well as AML for which palliative treatment was given The lymph node sample contained t(14,18) and both 
blood and bone marrow samples were only slightly positive Three months later his disease progressed with a 
slight increase in the number of translocations at which point he died Progressive disease was manifested in 
the fourth patient who had a positive lymph node sample Few translocations were detected even after 
diffuse centroblastic NHL had been diagnosed and the patient died after 4 months palliative treatment 
The competitive PCR assay is demonstrated on several patient 2 samples using different 
conditions (Figure 3) Amplification of patient 2-denved translocation segments and different samples of this 
patient resulted in a 184 bp PCR product, and amplification of competitor molecules resulted in a 272 bp PCR 
product The correlation coefficients of the calibration curves of Figures ЗА, 3B & 3C were R= 0 999, R= 
0 990 and R= 0 934 respectively Negative controls showed no evidence of contamination (not shown) 
Amplification of the blood sample of February 1990 (lane 17, Figures ЗА, 3B & 3C) was completely inhibited 
Using 1000 competitor molecules and between 100 to 10000 patient 2-denved translocation segments 
(Figure ЗА), the product ratio for the diluted sample from the lymph node of January 1990 (lane 16) and the 
next available blood sample of July 1990 (lane 18) was brought within the range for calibration The other 
blood and bone marrow samples contained too few translocations to estimate This was overcome by 
lowenng the number of competitor molecules to 100, and therefore the competition between competitor and 
patient translocations bringing the ratio of the bone marrow sample of April 1991 (lane 19) and that of the 
blood of August 1991 (lane 20) within range The blood sample of October 1991 (lane 21) and the bone 
Figure 2, Schematic illustration of the quantitative PCR method as described in Materials & Methods A MBR-1 
primer-site, В JH-CON pnmer-sile, С MBR3-XHOI pnmer-site, D JH6-intron pnmer-site 
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CONSTRUCTION PAN2.2 PATIENT NODULE SAMPLE PATIENT BLOOD AND BONE MARROW SAMPLES 
DNA ISOLATION 
PCR PRIMER-PAIR A/B PCR PRIMER-PAIR C/D 
+ 
OD 260 OD 260 
A C A 
COMPETITOR MOLECULE PATIENT DERIVED 
TRANSLOCATION SEGMENT 
CALIBRATION CURVE 
10000-100 PATIENT DERIVED TRANSLOCATION SEGMENTS 
1000 COMPETITOR MOLECULES 
1 lig CELL LINE K562 DNA 
\rrrrrrrrrrrrrr 
1 2 Э 4 5 6 7 8 9 10 11 12 13 14 
:OLL 
\ 
PERC L 1085 
DNA ISOLATION 
PATIENT SAMPLES 
1000 COMPETITOR MOLECULES 
lpg PATIENT SAMPLE DNA 
IS 16 17 IB 19 20 21 22 
CONTROL 
rr 
COMPETITIVE PCR PRIMER-PAIR A/B 
i 
POLYACRYLAMIDE GEL ELECTROPHORESIS 
AUTORADIOGRAPHY AND SCANNING OF BAND INTENSITIES 
CALCULATION OF RATIO BETWEEN PCR PRODUCTS 
LOG INPUT PATIENT DERIVED 
TRANSLOCATION SEGMENTS 
COMPARISON RATIOS WITH 
CALIBRATION CURVE 
CALCULATION OF AMOUNT OF 
1(14,18) TRANSLOCATIONS 
WITHIN Іцд PATIENT SAMPLE 
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Table 1 Residual disease in four follicular NHL patients during treatment 
Case 
no. 
1 
2 
3 
4 
Age/ 
Sex 
52/F 
31/M 
61/M 
56 /M 
Date 
Sep-90 
Sep-90/ 
Feb-91 
Feb-91 
Jun-91 
Aug-91 
Okt-91 
Jan-92 
Apr-88 
May-88/ 
Feb-90 
Jan-90 
Feb-90 
Jul-90 
Okt-90 
Apr-91 
Aug-91 
Okt-91 
Mar-92 
Jun-91 
Sep-91 
Jan-87 
Jan-88 
Jan-90 
Feb-90 
May-90 
Jan-91 
Apr-91 
May-91 
Diagnosis 
CB-CC NHL 
CR 
Relapse 
Progression 
Progression 
no CR 
no CR 
CB-CC NHL 
CR 
Relapse 
CR 
CR 
CR 
CR 
CR 
Relapse 
CB-CC NHL 
AML 
progression 
t 
CB-CC NHL 
Progression 
Progression 
Progression 
DCB NHL 
Progression 
t 
Clinica 
stage 
IIA 
IVA 
IIA 
il Treatment Tissue 
Radiotherapy BM1 
Blood 
Blood 
Blood 
Chlorambucil LN 
Blood 
Blood 
Blood 
CHOP BM1 
LN 
Chlorambucil Blood 
Chlorambucil Blood 
BMT BM1 
BM2 
Blood 
Blood 
BM2 
Blood 
Palliative LN 
Treatment Blood 
BM1 
Blood 
Radiotherapy 
Chlorambucil 
LN 
Blood 
Palliative 
Treatment Blood 
Histology ίη(14;18)/1μα 
Negative 
Positive 
Positive 
Positive 
Positive 
Positive 
DNA (¥) 
ND 
128+ 12 
2169 + 95 
857 + 39 
Positive 
789 ± 37 
823 ± 37 
686 + 33 
ND 
Positive 
1989 1 4 4 
ND 
75 + 5 
54 + 4 
27 ± 4 
11 ± 2 
0 
Positive 
28 + 4 
44 ± 6 
99 ±10 
Positive 
3 ± 1 
1 0 ± 2 
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Legend to Table 1 Abbreviations, ND, not determined, BM1, bone marrow biopty, BM2, bone marrow aspirale LN, 
lymph node, CHOP, Cyclophosphamide, Doxorubicin (=Adnamycin), Vincristine, Prednisone, CB-CC, Centroblastic 
centrocytic, DCB, diffuse centroblastic t Death of patient, ¥Amounl of follicular lymphoma cells within 1 μg DNA of 
nucleated cells after Percoli gradient density centnfugation Lymph node samples with detectable translocations were 
indicated as positive, since cells are not distnbuted homogenously and only a small part of the node was used for DNA 
isolation 
marrow sample of October 1991 (lane 22) still contained too few translocations for optimal amplification 
Further reduction to 10 competitor molecules (Figure 3C) permitted estimation of the number of t(14,18) in 
these samples (lane 21 & 22) but led to all previous samples being beyond the range for calibration Non­
specific PCR fragments also became apparent although these had little effect on the correlation coefficient of 
the calibration curve 
Discussion 
PCR appears suitable for the detection of minimal residual disease'815', but small vanations in reaction 
conditions can lead to large differences in product yield necessitating the use of an internal standard which 
corrects for any non-specific inhibition of the reaction and for false negativity For example, the amplification 
of the peripheral blood sample of February 1990 from patient 2 (lane 17, Figures ЗА, ЭВ & 3C) was 
completely inhibited by an unknown factor within the sample DNA which was confirmed by the fact that 
amplification of the competitor molecules was also inhibited The internal standard used in the present study 
was amplified with the same primer-pair as the target DNA, for equal efficiency of amplification, a principle also 
employed by Wang et al (1989)(16> 
The PCR method employed in the present study is able to detect a single translocation 
within 1 μg genomic DNA, as is demonstrated by the senal dilution of patient-derived translocation segments 
(Figure 3C) Amplification occurs for 55 amplification cycles to ensure optimal competition for available 
enzyme, nucleotides and primer molecules, resulting in non-specific PCR fragments when very low amount 
of specific template is present at the beginning of the reaction (Figure 3C) However, this background has 
little effect on the correlation coefficient of the calibration curve Gilliland et al (1990)<17> and Thompson ef al 
(1992)<18) both added a vanable number of competitor molecules to a constant amount of patient sample and 
whenever the product yield for competitor and target molecules was the same, they assumed that the initial 
target number is equal to the number of competitor molecules added The competitor as used in their 
method was identical to the target molecule, except for a few mutations lying outside the pnmer recognition 
sites, resulting in an identical efficiency of amplification However, in their method it was necessary to digest 
the product of the competitor before relative product yield could be compared, lowering the accuracy of 
quantitation Moreover, large number of reactions are required in order to determine the equilibrium for each 
patient sample 
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1 2 3 4 б 6 7 В 9 10 11 12 13 14 15 16 17 IB 19 20 21 22 23 24 
1 2 3 4 S β Τ Β Β 10 11 12 13 14 15 IB 17 IB 19 20 21 22 23 24 
1 2 » 4 S β 7 Β Β 10 11 12 13 14 15 16 17 1β 1» 20 21 22 23 24 
164 Μ 
Figure 3. Autoradiograms (or three competitive PCRs on several patient 2 samples. 272 nt: Competitor fragment. 184 
nt: Patient 2 fragment. (A) Initial amount of competitor molecules in all lanes was 1000 molecules. Initial amount of 
patient 2-derived translocation segments in the serial dilution (lane 1-14) was 10000, 8000, 6000, 5000, 4000, 3000, 
2000, 1000, 900, Θ00, 600, 400, 200 and 100 molecules respectively in addition of 1 цд K562 DNA. Initial amount of 
separate patient 2 samples was 0.1 цд and 0.01 цд DMA of lymph node of January 1990 (lane 15 & 16), 1 цд DNA of 
separate blood samples ol February 1990, July 1990, August 1991 and October 1991 (lane 17, 1Θ, 20 & 21) or bone 
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Legend to Figure 3 continued, marrow samples of Apnl 1990 and October 1991 (lane 19 & 22) Lane 24 contained 
1 цд K562 DNA. (В) Initial amount ol competitor molecules in all lanes was 100 molecules Initial amount of patient 2-
denved translocation segments in the serial dilution (lane 1-14) was ten fold decreased as described in A in addition of 1 
цд K562 DNA Initial amount of separate palien! 2 samples (lane 15-22) or K562 DNA (lane 24) was as described in A (C) 
Initial amount of competitor molecules in all lanes was 10 molecules Initial amount of patient 2-denved translocation 
segments in the senal dilution (lane 1-14) was one hundred fold decreased as described in A, in addition of 1 μg K562 
DNA Initial amount of separate patient 2 samples (lane 15-22) or K562 DNA (lane 24) was as described in A 
By varying the initial number of patient-derived translocation segments in the coamphhcation 
reaction with a fixed number of competitor molecules, a patient specific calibration curve can be constructed 
from which the number of translocations in a patient sample can be estimated This obviates the need for 
determining equilibrium in product yield and thereby reducing the number of reactions required 
Furthermore, no corrections are necessary for any vanations in the efficiency of amplification as the result of 
differences in product length or mutations within the primer recognition sites between competitor and target 
molecules Tanaka et al (1992)09) detected mutations in the second exon of the bcl-2 gene in several 
follicular lymphoma patients It is not known whether mutations also accumulate within the translocation 
region during the course of follicular lymphoma, but it seems unlikely that sporadic mutations would lead to 
differences in amplification efficiency between samples of the same patient as long as the pnmer recognition 
sites remain untouched Consequently, the assay as described in this report is relatively fast and, once a 
serial dilution of patient-derived translocation segments is prepared, large numbers of different samples from 
the same patient can be processed simultaneously 
The correlation coefficients for all calibrations curves exceeded 0 93, indicating a high 
degree of accuracy The current PCR method was employed on DNA isolated from nucleated cells following 
density centnfugation The number of t(14,18) translocations reflects the number of lymphoma cells, it 
becomes possible to estimate their number on the assumption that 1 дд DNA is approximately equivalent to 
150000 nucleated cells Therefore, it should be possible to monitor the course of the disease in patients 
receiving an allogeneic or autologous BMT as illustrated by patient 2 The method can also be extended to 
other malignancies where the PCR technique can detect alterations on DNA or cDNA level, like the t(9,22) in 
chronic myeloid leukemia (CML)(15), the t(15,17) in acute promyelocyte leukemia (APL)'20), and the tald 
deletion at chromosome 1(21> 
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Quantitation of follicular NHL, a case report 
A competitive PCR method was developed, enabling accurate quantitation of residual lymphoma 
cells carrying the t(14;18) in blood and bone marrow samples of follicular non-Hodgkin's lymphoma 
(NHL) patients during treatment. A patient with residual lymphoma cells received an allogeneic bone 
marrow transplantation (BMT). After В MT, the patient is in continuing clinical complete remission. 
Using the competitive PCR and two-step PCR method, we were able to demonstrate a gradual decline 
in the number of lymphoma cells within consecutive patient blood and bone marrow samples after 
BMT. The competitive PCR is a suitable method for the detection of minimal residual disease. Further 
research might reveal the clinical relevance of data obtained by this method. 
The chromosomal translocation t(14,18), frequently found in follicular non-Hodgkin's lymphoma and to a 
lesser extend in diffuse B-cell lymphoma, juxtaposes the bcl-2 gene on chromosome 18 to an 
immunoglobulin heavy chain joining segment on chromosome 14 <1). Since most breakpoints on chromosome 
18 are clustered within two small regions, e g the major breakpoint region (MBR) and the minor cluster 
region (MCR), the polymerase chain reaction (PCR) seems to be a suitable method for sensitive detection of 
lymphoma cells'2-4) Recently, we developed a competitive PCR assay, by which we are able to detect and 
quantify residual lymphoma cells in patient blood and bone marrow samples during the course of 
treatment*5). 
Patients & Methods 
Patient In April 1988, a thirty year old male was diagnosed as having a stage IV low-grade follicular 
centroblastic-centrocytic (CB-CC) non-Hodgkin's lymphoma (NHL) Doxorubicin containing chemotherapy 
induced partial remission (PR) After cessation of treatment, progressive lymphadenopathy was observed, 
and a biopsy of a representative lymph node showed similar histology without signs of dedillerentiation in 
January 1990 Treatment with chlorambucil induced a PR In October 1990, the patient received an 
allogeneic bone marrow transplantation (BMT) with marrow of a HLA-identical, MLC non-reactive brother, 
according to the ongoing protocol'6) The patient achieved complete remission (CR), which is persisting ever 
since, twenty-eight months after BMT. 
Sample collection Isolation of mononuclear cells from bone marrow and blood samples was performed using 
density centnfugation, as previously described'5). 
Competitive PCR The competitive PCR method applied on several samples of this patient and subsequent 
analysis of reaction products was performed as has been previously described Is) 
Two-step PCR The two-step PCR was performed in a DNA thermal cycler (Perkm Elmer Cetus, Norwalk, 
USA ) on 1 μg of genomic DNA of several patient samples in presence of 0 001% gelatine, 50 mM KCl, 20 
mM Tns-HCI (pH=8 4). 2 0 mM МдСІг, 500 μΜ of dATP, dTTP, dCTP and dGTP, 300 pmol/mt of MBR2 (5'-
TCC CTT TGA CCT TGT TTC TTG А-Э') and JH-CON (5'-ACC TGA GGA GAC GGT GAC C-3') 
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oligonucleotides and 2 5 Units of Taq polymerase (Gibco BRL) in a total volume of 50 μΙ The reactions were 
overlaid with 100 μΙ mineral oil (Sigma) Amplification started with an initial denaturation step at 94°C for 5 
mm, followed by 35 cycles at 940C for 1 5 mm, 58°C for 2 mm and 72°C for 2 mm After the last cycle, the 
extension phase was prolonged at 72°C for 10 mm, and the reactions were cooled to 4° С After the first 
round of amplification, the reaction volume was increased to 100 μΙ by addition of gelatine, KCl, Tns-HCI 
(pH=8 4), МдСІ2, dNTP's, and oligonucleotides to the same final concentration 2 5 Units of Taq polymerase 
were added, and the reactions were amplified for another 35 cycles 
Analysis of PCR products 10 μΙ of PCR product was applied to a 2% agarose gel in 1x TAE buffer The 
products were transfered to a Hybond™ N + (Amersham) filter, using the DNA alkali blotting procedure 
according to the manufacturer The filter was hybridised with 32P-end-labeled internal oligonucleotide MBR-
INT (5'-TTT CAA CAC AGA CCC ACC CAG AGC C-3') After washing, the filter was exposed to X-ray film 
(Kodak) 
Results 
The amount of lymphoma cells carrying t(14,18) in 1 μg DNA of several consecutive bone marrow and blood 
samples, as previously determined by our competitive PCR assay'5', is summarized in Table 1 A blood 
sample taken prior to BMT, when the patient was clinically in PR, contained a considerable amount of 
lymphoma cells After BMT, when the patient was in CR, we were able to demonstrate a decline in the 
number of lymphoma cells in consecutive blood or bone marrow samples Using our competitive PCR assay, 
which has a detection limit of one t(14,18) in 1 μg DNA (approximately 150000 nucleated cells), we were 
unable to detect this chromosomal translocation m a blood sample, taken seventheen months after BMT 
For measurement at a lower detection limit, we performed a two step PCR method on DNA 
of the last four samples of this patient One reaction was positive for the patient specific t(14,18) of 12 
separately amplified reactions, when DNA of the blood sample of March 1992 or the bone marrow sample of 
February 1993 was used as template No t(14,18) was detected in the DNA of the bone marrow sample of 
October 1992 or the blood sample of February 1993 
Discussion 
The PCR is a very sensitive method to detect malignant cells carrying t(14,18) in blood and bone marrow 
samples of follicular lymphoma patients, at all stages of disease, before and after treatment'2 э 7 ' Since the 
t(14,18) has also been found in lymphoid tissue of healthy individuals with follicular hyperplasia·4', as well as 
m patients with advanced stage of disease who are in remission for several years'8), it is difficult to draw 
conclusions on the clinical relevance of detecting residual lymphoma cells in a single patient sample 
However, accurate quantitation of residual disease in consecutive samples may reveal prognostic 
significance'9' We are currently investigating a possible correlation between competitive PCR data of 
multiple samples and clinical data from a larger set of patients, during their course of treatment 
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Table 1. 
Date 
apr-88 
May-88/ 
Jan-90 
Jan-90 
Feb-90 
Jul-90 
Oct-90 
Apr-91 
Aug-91 
Oct-91 
Mar-92 
Oct-92 
Feb-93 
Residual disease 
Diagnosis 
in a patient with follicular NHL before and after BMT 
Treatment Tissue 
CB-CC NHL CHOP BMa 
PR 
Relapse 
PR 
PR 
CR 
CR 
CR 
CR 
CR 
CR 
LN 
Chlorambucil Blood 
Chlorambucil Blood 
BMT BMa 
BMb 
Blood 
Blood 
BMb 
Blood 
вмь 
BMb 
Blood 
Histology 
Positive 
Positive 
Positive 
No.t(14;18y^g DNA 
by competitive PCR 
ND 
Positive 
1989 ±44 
ND 
75 ± 5 
5 4 ± 4 
2 7 ± 4 
11 ± 2 
0 
ND 
ND 
ND 
No.t(14;18)/^gDNA 
by two-step PCR 
<0 083 
0 
<0 083 
0 
Abbreviations ND, not determined, BMa, bone marrow biopty, BMb, bone marrow aspirate, LN, lymph node, PR, partial 
remission, CR, complete remission, CHOP, cyclophosphamide, doxorubicin (=adnamycin), vincristine, prednisone 
The data of the patient demonstrated in this article, may encourage such a correlation Using 
our competitive PCR method and two-step PCR assay, we were able to detect a gradually declining number 
of lymphoma cells after allogeneic BMT, when the patient was clinically in CR This decrease in lymphoma 
cells might result from a Graft-versus-Lymphoma activity, and may be similar to the Graft-versus-Leukemia 
effect as has recently been reviewed for patients with acute or chronic leukemias'10' Alternatively, we 
cannot exclude the possibility that these cells have lost their proliferative capacity as a consequence of 
treatment, and slowly disappear over time 
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Quantitation of NHL by competitive PCR and CE 
We compared the use of capillary electrophoresis (CE) in a polymer network with the use 
of slab gel electrophoresis for the quantitative analysis of polymerase chain reaction 
(PCR) amplified DNA samples. We quantified residual lymphoma cells carrying a 
translocation between chromosomes 14 and 18, in consecutive patient peripheral blood 
samples that were amplified by competitive PCR. For CE analysis we used a 4% linear 
Polyacrylamide network. Results show that the calculated number of translocations in 
patient samples using both analyses were comparable. We conclude that CE is a 
sensitive, non-radioactive, fast and accurate method for quantitation of competitive PCR 
products. 
Tumour specific markers can be used to monitor residual disease in patients during treatment One of these 
markers is the reciprocal chromosomal translocation t(14,18), frequently found in follicular lymphomas In this 
translocation, the bct-2 gene on chromosome 18 is coupled to the immunoglobulin heavy-chain locus on 
chromosome 14 Random nucleotides are inserted between the two genes providing a patient specific DNA 
pattern!1) The polymerase chain reaction (PCR) is a sensitive method to detect the presence of lymphoma 
cells carrying t(14,18) by amplification of the translocation breakpoint!2) Since small vanations in reaction 
conditions can lead to large differences in product yield as a result of exponential amplification, an internal 
standard is needed for accurate quantitation This internal standard has to be coamplified in the same 
reaction as the target DNA using the same primers for equal amplification efficiency 
For this purpose, a competitive PCR has been developed!3) Serial dilutions of a known 
number of patient-derived translocation molecules are coamplified with a fixed number of competitor 
molecules These competitor molecules serve as an internal standard Logarithmic plotting of the ratios of the 
two PCR products against the initial number of patient specific translocation molecules results in a patient 
specific calibration curve By comparison of the ratio of PCR products from an unknown number of patient 
translocation molecules which has been coamplified with the same number of competitor molecules with the 
calibration curve, the unknown number of translocations in the patient samples can be calculated This way, 
the residual disease of a patient with a non-Hodgkm's lymphoma (NHL) could be monitored after allogeneic 
bone marrow transplantation·4) In this procedure, the competitive PCR products were analysed on 
conventional slab gels using radio-activity for detection 
The fast development of capillary electrophoresis (CE) prompted us to investigate whether 
this time consuming and laborious slab gel procedure could be replaced by automated CE analysis Recently 
a quantitative analysis using capillary electrophoresis was described by Lu et a/(1994)'5) However, they 
analyzed products of a non-competitive PCR, e g without the use of an internal standard We analyzed 
competitive PCR products of consecutive samples from a patient with lymphoma cells carrying t(14,18) using 
capillary electrophoresis as well as the traditional slab gel electrophoresis The unknown numbers of 
translocations in the patient samples were determined and compared using the two methods 
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Materials & Methods 
DNA isolation DNA was isolated'6) from a lymph node sample of patient 1 and from a lymph node sample and 
consecutive peripheral blood samples of patient 2 All samples contained lymphoma cells carrying the 
t(14,18) 
Oligonucleotides Oligonucleotides were synthesised on a 391A DNA synthesiser (Applied Biosystems, 
Warrington, UK) The oligonucleotides used for the bcl-2 region were MBR3-Xhol, 5'-CCC TCG AGG AGC 
TTT GTT TCA ACC AAG TC-3' (position 2752 for the 7th nucleotide in Gen EMBL ace M14745) and MBR2, 
5'-TCC CTT TGA CCT TGT TTC TTG A-3' (position 2826 in GenEMBL ace M14745) Oligonucleotides used 
for the immunoglobulin heavy-chain region were JH-CON, 5'-ACC TGA GGA GAC GGT GAC C-3' and JH-
Hindlll, 5'-TCA AGC TTA CCT GAG GAG ACG GTG ACC-3' (identical to JH-CON but contains 8 additional 
bases at the 5' site)*2'. 
Preparation of patient-derived molecules Several polymerase chain reactions were amplified in a Perkin-
Elmer Cetus thenmocycler 480 (Norwalk, CT, USA) Each reaction contained 1 цд lymph node DNA of patient 
1 or patient 2, 500 mM dNTP's, 30 pmol of oligonucleotides MBR3-Xhol and JH-Hmdlll and 2 5 U Taq DNA 
polymerase (Life Technologies, Gailhersburg, MD, USA) in a total volume of 100 μΙ, overlaid with 80 μΙ 
mineral oil Amplification started with an initial denaturation step at 940C for 5 mm followed by 35 cycles at 
94°C for 1 5 mm, at 55°C for 2 mm and at 72°C for 2 mm The PCR products were pooled, separated from 
oligonucleotides on a 2% agarose gel, excised and electro-eluted by Biotrap (Schleicher & Schuell, Dassel, 
Germany) After precipitation, the DNA was dissolved in 800 μΙ water The concentration was determined by 
optical density at OD260 nm and from this, the number of patient derived translocation molecules was 
calculated The translocation molecules of patient 1 were used as competitor molecules in the competitive 
PCR 
Competitive Polymerase Chain Reaction The competitive PCR was performed as previously described*3) 
Senal dilutions of a known number of patient 2 derived translocation molecules were coamplified with a fixed 
number of patient 1 derived competitor molecules in addition of 1 μg K562 DNA (contains no t(14,18) and 
serves as a negative control) Amplification was performed with 30 pmol of oligonucleotides MBR2 and JH-
CON for 55 cycles with an annealing temperature of 58°C Samples which were analysed using slab gel 
electrophoresis were amplified in the presence of 1 85 MBq/ml [a-32P]dCTP (Amersham, Buckinghamshire, 
UK) Other conditions were kept as described above 1 μg of several consecutive peripheral blood DNA 
samples of patient 2, with an unknown number of translocation molecules, were also coamplified with the 
same number of competitor molecules 
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Figure 1 Autoradiogram ol 3 different competitive PCR products before and after purification with the Magic PCR 
Preps DNA purification system Lane 1 1000 competitor molecules and 6000 patient derived translocation molecules 
before (b) and after (a) punlication, lane 2 1000 competitor molecules and 1000 patient derived translocation molecules 
before (b) and after (a) punlication, lane 3 1000 competitor molecules and 600 patient derived translocation molecules 
before (b) and after (a) punlication 
Capillary A fused silica capillary (310 mm (Le") χ 0 075 mm I D) (SGE, Ringwood, Victoria, Australia) was 
precoated with 3-methacryloylpropylmethoxysilane (Sigma, St Louis, MO, USA) Additional coating was 
performed by purging with a 4% acrylamide (4% T, 0% C) solution containing β μΙ of 10% Ν,Ν,Ν',Ν'-
tetrarnethylethylenediamine (TEMED) and 4 μΙ of 10% ammonium persulfate (APS) per ml of acrylamide 
solution f7) The acrylamide, TEMED and APS were all obtained from Bio Rad Laboratories Richmond, CA, 
USA The acrylamide solution in the capillary was placed under 15 bar, and allowed to polymerize for 18 hrs 
The filled capillary was mounted in an assembly cartridge and placed in a Bio-Rad BioFocus 3000 CE 
instrument (Bio-Rad, Hercules, CA, USA) After each run, the capillary was rinsed with water for 5 mm and 
filled again with the polymerised 4% linear Polyacrylamide by purging for 5 mm at 8 bar 
Analysis and quantitation of PCR products using Capillary Electrophoresis The competitive PCR products 
were purified with the Magic PCR Preps DNA punfication system (Promega, Madison, Wl, USA) and dissolved 
in 50 μΙ water All samples were injected electrokinetically at reversed polarity (cathode at the injection side) of 
280 V/cm for 10 s and separated under constant voltage of 425 V/cm, in a TAE running buffer (40 mM Tns-
acetate pH 8 3, 2 mM EDTA) UV absorbance was measured at 260 nm During the runs the carrousel was 
kept at 15°C and the capillary was kept at 25°C Using the BioFocus 3000 Integrator program (Bio-Rad), the 
areas under the curves (UAC) were determined Ratios of the AUC of the serial dilution reactions were 
Legend to Figure 2 Eleclropherograms ol analysis using capillary electrophoresis 1-13 as descnbed lor lane 1-13 
in Fig 3, sample 1-3 as descnbed for lane 17-19 in Fig 3 Peak 1 represents the 312 bp PCR product and peak 2 
represents the 362 bp PCR product 
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plotted logarithmically against the initial number of known patient 2 derived translocation molecules in order 
to construct a patient specific calibration curve Using this calibration curve, the number of unknown t(14,18) 
translocation molecules in the patient 2 samples could be determined 
Analysis and quantitation of PCR products using slab gel electrophoresis 5 μΙ of 10-fold diluted PCR produci 
in formamide were loaded on a 7% PAA (acrylamide bisacrylamide=24 1 ), 7 M urea gel Separation was 
performed in a half TBE running buffer (45 mM Tris borate pH θ 3, 0 1 mM EDTA) The gel was exposed to an 
X-ray film (Kodak) and the autoradiogram was analyzed by densitometnc scanning on a LKB laser 
densitometer Band intensities were determined using GelscanTM XL software and the ratios were plotted 
logarithmically against the initial number of patient 2 derived translocation molecules 
Results 
We used a competitive PCR to quantify residual lymphoma cells carrying a t(14,18) Competitive PCR 
amplification of patient 1 derived translocation molecules resulted in a 362 bp PCR product Amplification of 
patient 2 derived translocation molecules resulted in a 312 bp PCR product The 362 bp fragments were 
used as internal standard (competitor molecules) 
We analyzed the competitive PCR products by capillary electrophoresis as well as slab gel 
electrophoresis Because of electrokmetic injection, the samples analyzed by capillary electrophoresis were 
desalted prior to electrophoresis using the Magic PCR Preps DNA purification system To exclude that the 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
362 bp m - * ' r 
3 1 2 b p m» "и п. «тттттштштшшшшшштітшяаштімтЁшт - · * * 
Figure 3. Autoradiogram of analysis using slab gel electrophoresis Lane 1-14 coamplification of serial dilutions of a 
known number of patient derived translocation molecules (10000, 8000, 6000, 5000, 4000, 3000, 2000, 1000 900, 00, 
600, 400, 200 and 100) and 1000 competitor molecules in addition of 1 цд K561 DNA lane 15 control, 1000 competitor 
molecules, lane 16 control, 1000 competitor molecules and 1 цд K562 DNA, lane 17-19 coamplilication of consecutive 
patient blood samples (resp Feb "9\, Aug 91 and Jan 92) with an unknown number of translocation molecules and 1000 
competitor molecules 
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Magic PCR Preps DNA purification system had a predilection for eighter the 312 bp or the 362 bp PCR 
product, we compared different radioactive samples before and after purification (Fig 1) Results from 
densitometnc scanning of the band intensities showed no predilection for eighter of the PCR products (data 
not shown) 
Figure 2 shows the quantitative analysis using capillary electrophoresis A patient specific 
calibration curve was constructed by plotting the ratio of UACs against the initial number of patient-derived 
translocation segments on logarithmic scale (R= 0 993) The corresponding equation is log(y) = О 9Θ3 log(x) -
θ 031, where y is the ratio and χ is the initial number of known translocation molecules 
Figure 3 shows the analysis using slab gel electrophoresis Scanning of the band intensities 
and plotting of the ratios against the initial number of known patient 2 derived translocation molecules 
resulted in a patient specific calibration curve with a correlation coefficient R= 0 970 The corresponding 
equation is log(y) = 1 220 log(x) - 9 895 
The results of the calculated number of unknown translocation molecules in the consecutive 
samples of patient 2 using capillary electrophoresis and slab gel electrophoresis are summarized in Table 1 
To check the reproducibility of CE analysis using electrokinetic injection, we divided a sample 
into three equal portions which were separately injected The standard deviation of the ratio of the AUC was 
3 2% (data not shown) 
Table 1. Calculation of an unkown number of translocation molecules in consecutive samples of patient 
2, using the patient specific calibration curves 
Sample Date #t(14;18)/ug DNA #Ц14;18)/цд DNA 
Slab gel Capillary 
1 Feb'91 9964±1566 12027±987 
2 Aug'91 2854+274 31951155 
3 Jan '92 4084+444 5038±290 
Discussion 
The PCR is a sensitive method to determine the presence or absence of malignant cells carrying t(14,18) In 
the competitive PCR used in this study, translocation molecules from a patient were used as competitor 
molecules Because the length of the amplified t(14,18) breakpoint differs in each patient, the internal 
standard molecules can be distinguished from the target molecules by size This competitive PCR method 
can also be used to quantify other DNA or RNA molecules Celi et al (1993)(β> have recently described a rapid 
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and versatile method to synthesize internal standards which can be used as competitor molecules in 
competitive PCRs. 
The products of the competitive PCR are usually analyzed using conventional slab gels. The 
preparation of these gels is time consuming, laborious and they can be used only once. We therefore used 
capillary electrophoresis in a polymer network. The preparing of the capillary is easy and it can be used for 
several consecutive automated analyses'9), since the capillary can be refilled. Another advantage of CE 
compared to slab gel electrophoresis is the detection. The detection of DNA molecules by UV absorption is 
direct and the data are stored in an electropherogram, which can be immediately used for evaluation. 
Detection of DNA molecules using radioactivity is hazardous, the gel has to be exposed which takes 
additional time and the band intensities have to be scanned after exposure to obtain information about the 
quantity. Scanning and subsequent computer analysis is time consuming and only a selective part of the 
band is scanned. This means that any irregularity in the band can lead to different densitometric results. 
Another disadvantage of radioactivity and autoradiography is the non-linear dose-response relationship, e.g. 
the band intensities on an autoradiogram can reach a maximum. If the intensity of one of the bands on the 
autoradiogram reaches a maximum, the ratio of the band intensities is disturbed. Detection using UV 
absorption doesn't have this problem because there is a linear relationship between the number of 
molecules and the area under the curve (UAC). 
Previously described methods to analyze competitive PCR products are: counting the 
radioactivity present in bands excised from an agarose gel'10', or a Polyacrylamide gel'11) or densitometric 
scanning of bands of a negative film of an ethidiumbromide stained agarose gel'12'. The first two methods 
require radioactivity and have the disadvantages of slab gel electrophoresis. Furthermore, excising bands is 
delicate. The third method is based upon scanning, which has disadvantages as previously discused. 
Because samples analyzed using CE have to be run sequentially while samples analyzed 
using slab gel electrophoresis can bve run all at once, total analysis time might be disadvantage. In our study 
the analysis time for one sample was 20 min (10 min purging and 10 min running). It took about 6 hr to analyze 
all samples (n=16). The total electrophoresis time using slab gel electrophoresis is faster (2 hrs), but 
regarding the additional time needed to prepare appropriate exposures and scanning of band intensities, we 
conclude that analysis using CE is faster. Furthermore, the analysis using CE is fully automated. 
Results show that the number of translocation molecules as determined by both strategies 
are within each others range. The calibration curves show that the analysis using capillary electrophoresis is 
comparable to the analysis using slab gel electrophoresis (R=0.993 vs. R=0.970). The standard deviation of 
the AUC ratios (3.2%), obtained by injecting a sample 3 times, provides sufficient accuracy for quantification 
of DNA or RNA molecules. 
We conclude that CE is a non-radioactive, fast, accurate and sensitive method for the 
quantitation of competitive PCR products and since CE is automated it opens possibilities for genetic routine 
analysis. 
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New type of t(14,18) in follicular NHL 
In this report, a follicular non-Hodgkin's lymphoma (NHL) carrying an unusual t(14;18) is described. 
This translocation occurred most likely during the н to D - J H rearrangement process of the IgH 
locus. From the data combined with data from literature, we conclude that the chance for the 
development of a t(14;18) decreases during progression of the immunoglobulin rearrangement 
process in the pre-B-cell ontogeny. This is probably due to decreased accessibility of the bcl-2 locus 
by reduced transcription. We analysed the somatic mutation pattern of the productively rearranged 
IgH gene. Like other follicular lymphomas, somatic mutations were present in this gene and argued 
in favour of positive selection, probably for an antigen. We found no evidence for ongoing induction 
of somatic mutations during lymphoma development. We conclude that bcl-2 gene deregulation but 
not the precise moment at which this occurs during the pre-B-cell stage is of influence on the 
development of follicular NHL. 
Molecular studies at the 14Q+ chromosomal junctions from t(14;18) (q32,q21) carrying cell lines and follicular 
non-Hodgkin's lymphoma (NHL) samples revealed the rearrangement of the B-cell lymphoma/Leukaemia 2 
gene {bcl-2 gene) from chromosome 18 to the immunoglobulin heavy chain (IgH) joining ( J H ) region on 
chromosome 14<1) The breakpoints on chromosome 18 cluster in mainly two cluster regions, ι e the major 
breakpoint region (MBR) and the minor cluster region (MCR)'2"5). The expression of bcl-2 gene is elevated 
as a consequence of translocations involving this gene!4·6·7·. 
The t(14,18) most likely occurs during early IgH gene rearrangements at the pre-B cell stage 
and a J H gene segment and a diversity ( D H ) gene segment are frequently involved The presence of random 
nucleotides at the translocation junctions further supports this hypothesis'8"10· Translocations as a result of 
ontogenetically later IgH gene rearrangements are rare and are uptill now only confined to the D H to D H - J H 
rearrangement stage (9.11.12), j n e t(2;18) and the t(18,22), which most likely occur during IgL 
rearrangements, have only occasionally been described in follicular lymphoma!6'7'13). 
Studies at the normal IgH and IgL alleles of lymphoma cells have provided important insight 
in the development of the malignant phenotype. Although an expanded oligoclonal μ+ic pre-B-cell population 
in the bone marrow of a follicular lymphoma patient has been found'14), the lymphoma cells are monoclonal 
regarding their IgH and IgL chain rearrangements'15). Within these genes, somatic mutations have been 
found'1 6 - 1 9). The somatic mutation pattern provides evidence for affinity selection for antigen prior and during 
clonal expansion'20'21). Although the bcl-2 gene is deregulated in all lymphoma cells, this seems not to be 
sufficient for all cells to survive the selection process. 
The development of a monoclonal follicular NHL population out of a polyclonal pre-neoplastic 
pre-B-cell population indicates that additional mutations besides antigen selection are necessary for the 
development of the malignant phenotype This is further supported by the finding of t(14,18)s in individuals 
with benign follicular hyperplasia'22', and the continuing accumulation of genetic defects in lymphoma 
subpopulations, eventually leading to a more dedifferentiated status'23'24). Also in the transgenic mice model 
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with a deregulated bcl-2 gene, only eleven percent of mice develop a monoclonal high-grade diffuse large-
cell immunoblastic lymphoma after a relatively long latency period of twelve to twenty-four months'25' 
In this report, we describe a follicular NHL carrying an unusual t(14,18) To investigate the 
moment of translocation in the pre-B-cell ontogeny, we performed a detailed molecular study involving the 
translocation junctions of the 14Q+ and the 18Q- chromosomes To investigate the consequences of the 
deregulation of the bcl-2 gene at a relative late pre-B-cell stage on the subsequent development of follicular 
lymphoma, mutation analyses of the normal IgH allele were performed The data presented here combined 
with data available in literature provide insight in molecular events occuring in normal early B-cell 
development as well as in the development of follicular lymphoma 
Materials & Methods 
Description of Patient A 43-year old male was diagnosed as having a follicular centroblastic-centrocytic (CB-
CC) NHL of low-grade malignancy Immunological examination of a cervical lymph node showed the 
presence of 30-40% follicular lgM+/K+ lymphoma cells. This lymph node sample and a concurrent blood 
sample were used in the present study as the only matenal available 
DNA isolation DNA was isolated from blood or lymph node samples according to a standard procedure'26' 
Oligonucleotides and Polymerase Cham Reaction (PCR) Sense oligonucleotides used MBF^'2 7 ' , set of н 
family-specific oligonucleotides н1 to ц6<28), нЗ-48х· 5'-TCC CCA CCC TAG AGC TTG CT-3', NM13 5 
5'-CAG СТА TGA CCA TGA TTA CGC CAA G-3' Antisense oligonucleotides used J(-|con<27), J|-i3-intron 5'-
GGC AGA AGG AAA GCC CAT CTT-3', JH4-intron 5'-CCA AAA GTC АСА AAC CTC GAG T-3', JH5-intran 
5'-CTT TCT TTC CTG ACC ТСС AAA A-3', JH6-mtron<27), MBR18Q 5'-TGA TTT TGG CAG GAT AGC AGC 
ACA-3' PCR conditions were as described before'27) One μ g of genomic DNA was used as template, 
unless indicated otherwise 
Snd-labeling of oligonucleotides Oligonucleotides (50 pmol) were phosphorylated in the presence of 50 mM 
Tns-HCI (pH=7 5), 10 mM МдСІг, 5 mM dithiotreitol (DTT), 0 1 mM spermidine, 92 5 MBq/ml [γ-32ρ] ATP 
(Amersham, 110 TBq/mmol, 370 MBq/ml) and 20 U of T4 polynucleotide kinase (Gibco BRL), in a total 
volume of 20 μΙ at 37°C for 45 mm. After incubation, 25 μΙ 4M NH4AC, 5 μg yeast t-RNA and 250 μΙ of EtOH 
were added to the reaction sample, and the oligonucleotide was precipitated The precipitation procedure 
was repeated twice After precipitation, the oligonucleotide was dissolved in 10 mM Tris pH=8 0, 3 0 mM 
MgCl2 
Amplification of IgH VDJ gene segments Rearranged IgH VDJ gene segments were amplified using н 
family-specific pnmers in combination with the Jj-jcon or J|-|-intron primers at an annealing temperature of 
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55°C Genomic DNA (0 2 цд) from the blood or lymph node sample was used as template An aliquot of the 
PCR product, amplified with the нЗ and JH6-intron primers, was used for direct sequencing, and the 
remainder was purified using the Magic™ PCR Preps DNA purification system (Promega Corporation, 
Madison, USA) The concentration was determined by optical density Five pmol of PCR product was 
phosphorylated as described above in the presence of 2 0 mM ATP The DNA was precipitated following a 
phenol extraction and a Sevag (phenol chloroform, isoamylalcohol = 25 24 1) extraction, and dissolved 
The PCR product was subsequently treated by Klenow enzyme (Gibco BRL) to remove possible 3' non-
template directed nucleotide additions, in the precence of 100 μΜ dNTPs for 60 mm at 140C*29> The DNA 
was precipitated following a phenol extraction and a Sevag extraction, and dissolved in dH20 
Digestion and dephosphorylation of vector DNA A sample of 10 μ g of pBluescnbe KS+ (Stratagene, La 
Jolla, CA, USA) was digested with Sma-I (Gibco BRL) for 2 5 Hr at 30°C The DNA was dephosphorylated 
using Calf Intestine Alkaline Phosphatase (CIP) (Amersham, Buckinghamshire, UK) according to a standard 
protocol*30) The DNA was dissolved in dH20 to a final concentration of 20 пд/μΙ 
Ligation, transformation and screening for recombinant clones A sample of 100 ng of Sma-I digested and 
CIP-treated vector DNA and 1 цд of phosphorylated and klenow-treated PCR DNA was ligated using 800 U 
of T4 DNA ligase (Biolabs, Beverly, MA, USA) in a total volume of 20 μΙ at 14°C for 16 Hr After ligation, the 
reaction volume was increased to 50 μ I with dH20, and 25 μ I was used for the transformation of 100 μ I of 
competent Escherichia coli strain DH5a bactéries (Gibco BRL) Transformation and Blue/White screening 
were performed according to standard protocols*30' White colonies were used to inoculate 5 ml of Luria-
Bertani medium containing 50 μg/ml of ampicillin, and incubated at 37° С for 16 Hr DNA was isolated from 
all bacterial cultures using the small-scale plasmid DNA isolation procedure'30) 
Sequencing of clones Insert DNA from each recombinant clone was a-symmetncally amplified using the 
V|-|3 and NM13 5 oligonucleotides Α-symmetric DNA templates were sequenced using end-labeled нЗ, 
JHcon or J|H6-intron oligonucleotides The a-symmetnc amplification reaction and sequencing reaction were 
performed as described*31) with minor modifications 
Somatic Mutation Analysis Somatic mutations in the framework regions (FWRs) and the hypervariable 
regions of the rearranged IgH VDJ gene segments in the lymphoma cells were analysed in comparison to 
germline candidates in two separate mutation analyses'32) The hypervariable regions correlates with the 
complementary determining regions (CDRs), ι e the contact sites of the antibody with the antigen, and are 
indicated according to Kabat et al (1967) f33) The expected number of replacement (R) mutations (mutations 
which give rise to another amino acid residue) and silent (S) mutations (mutations which do not give rise to 
another amino acid residue) by a random mutation mechanism in a region which is not under selective 
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pressure is dependent on the composition of the codons'34' For the first mutation analysis, the expected 
numbers of replacement and silent mutations in the rearranged VDJ region (bp 381 to 683, Fig 2) in germline 
configuration was calculated by summing all possible replacement substitutions for each codon and devidmg 
by the total number of potential substitutions (replacement and silent) for all codons This resulted in 0 78η 
and 0 22 л respectively for η random mutations The second mutation analysis was performed on the н 
gene segment only (bp 381 to 602) For this region, the expected numbers of replacement and silent 
mutations are 0 79 η and 0 21 η respectively for л random mutations The distribution of replacement and 
silent mutations over the CDRs or FWRs in absence of selection is dependent of the relative size of CDRs 
and FWRs, assuming that all nucleotides have an equal probability to mutate For the first mutation analysis, 
the CDRs and FWRs corresponds to 38% and 62% of the total sequence respectively, and therefore RcDRs 
= 0 38R, R F W R S = 0 6 2 R . S CDRs = 0 38S, SFWRS = 0 62S For the second mutation analysis the RCDRs 
= 0 30R, R F W R S = ° 7 0 R. ScDRs = 0 3 °S and SpwRs = ° 7 °S The ρ of /rR mutations in the CDRs for л 
mutations was calculated using a binomial mutation model ρ = [NW(N-k)i]qk(l-q)N-k, whereby q is the 
chance for a replacement mutation in the CDRs and rV= л (observed) + R FWRs'35' F° r the first mutation 
analysis q = 0 78 χ 0 38 = 0 30 and for the second mutation analysis q = 0 79 χ 0 30 = 0 24 
Results 
The 14Q+ chromosomal junction of the t(14,18) was detected in the blood sample DNA in a routine 
investigation using PCR With the MBR2 and Jncon oligonucleotides, a 449 bp PCR fragment was 
generated and sequencing confirmed the origin of this fragment The fragment was partially homologous to 
the bcl-2 gene on chromosome 18 as well as the IgH J H 6 gene segment on chromosome 14 (Figure 1A) 
Between both regions of homology, a region of 44 nucleotides was inserted Comparison of this region to 
sequences of human rearranged IgH VDJ genes in the GenEMBL Database Library revealed a 15 bp region 
which is also present in the CDR3 region of Hsig4<36) Fourteen out of 15 nucleotides are present in the 
CDR3 region of Hsighdvn, and 13 out of 15 nucleotides are present in the CDR3 region of HsigL3G5 (Figure 
1B) We conclude that this region represents an IgH D H gene segment, which is most homologous to the 
germline IgH DA4 0rDA1 segmenti37) 
Since it is suggested that the t(14,18) occurs as an error during the V(D)J gene 
rearrangement process in the IgH genes, we tried to amplify the reciprocal 18Cr chromosomal junction 
making use of н family-specific oligonucleotides in combination with the MBR18Q oligonucleotide (located 
downstream of the MBR of the bcl-2 gene) Using the нЗ oligonucleotide in combination with MBR ieQ. a 
PCR fragment was generated Sequencing of this PCR fragment confirmed the juxtaposition of a нЗ family 
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< bcl-2 gene - -
C h r 18 CCIIXCCTÏXnTCCGCGGGGGCTTTCTCATGGCTGTCCTTCAGGGTCTTCCTGAAATGCAGTGGTGCTTACGCTCCACCAAGAAAGCAGG 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I h l l M I I I I I I I I I I I I I I 
C h r 14Q + CCTGCCCTTCTTCCGCGGGGGCTTTCTCATGGCTOTCCTTCAGGGTCTTCCTGAAATGCAGTGGTGCTTACGCTCCACCAAGAAAGCAGG 
C h r I B AAACCTGTGGTATGAAGCCAGACCTCCCCGGC 
Ι ι ι 11 11 1 1 1 1 1 ι ι ι 1 1 1 1 ι I I | | I I | | | | | | < N - r e g l o n > | < 
C h r 14Q+ A A A C C T G T G G T A T G A A G C C A G A C C T C C C C G G C t c r a Q t a c t Q Q a c t a g a o t Q a e c a g o o a e a g c a c c c t c c c g e ^ r A T T A r T A r T A r T A C 
l l l l l l l l l l l l l l 
C h r 14 ATTACTACTACTAC 
C h r 14Q* TACGGTATGGACGTCTGGGGCCAAGGGACCAC 
11111 [ I I ! II11111 M I 11111 M I M 111 
C h r 14 TACGGTATGGACGTCTGGGGGCAAGGGACCAC 
в 
bcl-2 N D h - r e g i o n N J h 6 
1 4 Q * GCCAGACCTCCCCGGC TCCAGTGCTG вАСТАСвОТОАСТАС GGACACCATCCTCCCCCCT ATTACTACTACT 
V h - r e g i o n N D h - r e g i o n N J h - r e g i o n 
H s i g 4 TATATTACTGTGCGAA GGATCGGGCGAAAACACCAAAT вАСТАСООТОАСИС TJEICCGACA TACTTTG ACTACT 
H s i g H D V N TGTATTACTGTGCGAG AGG OAOTACOOTOACTAC GGGAGAT TTTGACTACT 
H s i g L 3 G 5 TGTATTACTGTGCGAG CCT CTACOOTOACTAC GTGGACGAC 
9 7 D h - r e g i o n 7 9 
DA4 GCTTTTTGT GAAGGGTCCTCC TACTOTG TOACTACAQTAACTAC CACAGTG ATGAACCCAGCA GCAAAAACT 
# * * * » * ** 
D A I GCTTTTTGT GAAGGGCCCTCC TGCTGTG ТвАСТАСАОТААСТАС С й Ш Ы £ ATGAACCCAGTG ПГАААААСТ 
|<-- CDR1 >| VH-gene 3-74 |< 
C h r 14 GCCTCTGGATTCACCTTXrAGTAGCTACTGGATGCACTGGGTœGCCAAGCTCCAGGGAAGCGGCTGGTGTGGGTCTCACGTATTAATAGT 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I M I I I I I I I I I I 
Chr 18Q- GCCTCTGGATTCACCITCAGTAC<^ACTXMMT4XACTGGGTÎCGCCAAœTCCAGGGAAGGGGCTXKTX;TXKGTCTCACGTATTAATAGT 
CDR2 - - > | VH-gene 3-74 
C h r 14 GATGGGAGTAGCACAAGCTACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATG 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I M I I I I M I I I I M I I I I I I I I 
C h r 1BQ- GATGGGAGTAGCACAAGCTACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCT&CA AATG 
C h r 14 AACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCAAGAGACACAGTGAGGGAAGTCAATGTGAGCCCAGACACAAACCTGCTG 
Ш И П Щ И I || I I 1 1 N I M M M i l l I I I I I I N I I l l < - Ν r e g i o n ~ > | < 
C h r 1BQ" AACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCAAatacggcgacggctcaGCGGGCCTCAGGGAACAGAATGATCAGACCT 
1 1 1 1 1 1 1 1 1 1 1 1 E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Chr IB GCGGGCCTCAGGGAACAGAATGATCAGACCT 
CHR 14 CAGGGCACTCTAGACCAGAGGGGTGTCCTGG 
bcl-2 gene 
C h r 1BQ" TTGAATGATTCTAATTTTTAAGCAAAATATT 
1111111 111 ! I 11 [ 1111 111 M I M 1111 
C h r I B TTGAATGATTCTAATTTTTAAGCAAAATATT 
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member to the 3' untranslated region of the bcl-2 gene (Figure 1C) with insertion of random nucleotides The 
consensus sequence segment was completely homologous to the н germline gene 3-74 [DA-8'38' and 
DP53<39>] 
A search for heptamer-nonamer-hke Ig recombination signals on both sides of the breakpoint 
on chromosome 18 did not result in the identification of other signal-like sequences as described'10' (Figure 
1) Regions homologous to the chi-consensus sequence (CC[T/A]CC[T/A]GC) are present in all germline 
gene segments involved in this translocation A region directly upstream of the breakpoint on chromosome 
18 had a 5/8 match, a region directly upstream of the germline D A 4 or D A I gene segments had a 7/8 and 
8/8 match respectively, a region downstream of the signal sequences of the germline нЗ 74 or DP53 gene 
segment had a 7/8 match (Figures 1B-C) and a region within the first FWR of this gene was completely 
homologous to the с consensus sequence'39' 
The malignant lymphoma cells were further investigated by analysis of somatic mutations 
present in the productively rearranged IgH allele DNA derived from the lymph node sample, which was 
shown by immunochemistry to contain 30 to 40% of lgM+/K+ follicular lymphoma cells, and DNA from the 
blood sample were used as template for the amplification of rearranged IgH VDJ gene segments of the 
lymphoma cells Using all н family-specific oligonucleotides·28) in combination with JH-mtron specific 
oligonucleotides under stringent conditions, only the нЗ oligonucleotide in combination with the J|-|6-intron 
oligonucleotide generated a 388 bp PCR product for both tissue samples (data not shown) After 
sequencing, the нЗ gene segment of this rearrangement was compared with sequences from the 
GenEMBL Database Library, and was most homologous to germline gene segment нЗ-48(4о) The PCR 
fragment was cloned, and individual clones were used for mutation analyses 
Legend to Figure 1 (A). Comparison of the 14Q+ chromosomal junction to the MBH of the bel 2 gene® and the J H 
region ol the IgH locus'41' The N-region is shown in small characters Underlined region shares homology wilh human 
DH regions Heplamer-nonamer signal and signal-like sequences as suggested by Tsujimoto et al (1985b)'10' are 
indicated by double lines (B) Comparison of the N-region from the 14Q+ chromosomal junction to germline D H 
segments Од4 and D A I '3 7', and somatic D H segments The somatic D н segments were deduced from VDJ sequences 
Hsig4'36', Hsigl3g5 (GenEMBL accession L04332), and Hsighdvn (GenEMBL accession M65101) Gaps in sequences 
were introduced for clanty The underlined region in the Hsig4 sequence represent the D|_R5 gene segment, as indicated 
by the authors The heptamer and nonamer sequences in the germline DA4 and D A I gene segments are underlined 
Regions sharing homology to the с consensus sequence are marked by asterisks (C) Comparison ol the 18Q~ 
chromosomal junction to germline sequences ol the IgH нЗ-74 gene segment'38' and the MBH ol the bcl-2 gene'2' 
The N-region is shown in lowercase The CDR1 and CDR2 regions are indicated according to Kabat etat (1987)'33' 
The signal heptamer and nonamer sequences are underlined Regions sharing homology to the χ consensus sequence 
are marked by asterisks 
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1 18 
НЭ-48 а с 
Cons c t a t a g t a g g a g a t a t g c 
19 108 
VH3-48 a n с 
Cons aaqtagggccctccctctactgatgaaaa-ccaacccaaccctgaccct.gcagctctcagagaggtgccttagccctggattccaaggca 
109 198 
> | < l e a d e r > | < 
VH3-48 а С 
Cons teeccacttggtgaecagcactgtacacagaggactcaccATGGACTTGGGGCTGTGCTGGGTTTTCCTTGTI^TATTTTAGAAGGTga 
199 288 
leader- intron 
VH3-48 
Cons ttcatggaaaactagagagatttagtgtgtgtggatatgagtgagagaaacagtggatatgtgtggcagtttctgaccttggtgtctctt 
289 378 
>|<leader>|1< FWR-1 
VH3-48 G 
Cons tgtttgcaggtGTCCAGTGTGAGGTGCAGCTGGTGGAGTCTGGGGGAGCCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAG 
379 468 
>|< CDR1 --->|< FWR-2 >|< 
VH3-48 G G G T T 
Cons CCTCTGGATTCACCTTCAGTACCTATAACATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTTTCAAACATTAGTAGCA 
B3 С Л А А С 
B4a C A А А С 
В4Ь C A А А С 
87 C A А А С 
88 C A А А С 
89 C A А А С 
BIO C A А А С 
Kl C A А А С 
К5 C A А А С 
К7 C A А А С 
К C A А А С 
К10 C A А А С 
К12 C A А А С 
469 558 
CDR2 >|< FWR-3 
НЗ-48 AG 
Cons GTAGTOTTACCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGA 
ВЗ ОТ 
В4а GT 
В4Ь GT 
87 GT 
88 ОТ 
89 GT 
ΒΊΟ στ 
Kl QT 
K5 GT 
К7 ОТ 
К8 GT 
Kl о ОТ 
К12 ОТ 
559 648 
>|< CDR3 
НЭ 48 G 
DXP 1 Τ G G 
JH6 Τ 
Cons ACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTACGAGAGgcccacATTACCATGTTTCGGGGACTTcCTACOACGGTATGGACG 
ВЗ А С Τ С О 
В4а A T А С Τ С О 
В4Ь АО А С Τ С О 
В7 A T А С С Т С О 
В A T А С Т С О 
В9 A T А С Т С О 
BIO A T А С Т С О 
К1 А С Τ С G 
К5 A T A C T C G 
К7 А С Т С О 
KB A T A C T C G 
KIO A T A C T C G 
K12 А С Τ С О 
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649 713 
> | < FWR4 > | < JH-inLron 
JH6 G G 
Cons TCTGGGGCCAAGTGACCACGGTCACCGTCTCCTCAGgtaagaatggccaccccagggcctttgct 
B3 Τ 
В4а τ 
В4Ь τ 
Β7 Τ 
Ββ Τ 
Β9 Τ 
ΒΙΟ Τ 
κι τ 
Κ5 Τ g 
Κ7 ΤΑ 
Κ8 Τ a 
Κ10 Τ a 
Κ12 Τ 
Figure 2. Comparison of the consensus sequence and individual clones to germline counterparts Only the complete 
consensus sequence is shown Identical nucleotides are given by dots Silent mutations compared to the germline 
counterparts нЗ-4 '4°) Οχρ'ΐ'37', Jn6( 4 1 ' or the consensus sequence are shown in capitals, and replacement 
mutations are shown in bold capitals The N-regions are shown in lowercase The JH6-intron region is shown by small 
characters in italic The С residue at position 656 represents allelic vanation 
For more accurate identification of the germline counterpart of the нЗ gene segment 
present in the VDJ rearrangement, we tried to amplify this specific rearrangement with an oligonucleotide 
located upstream of the leader peptide ( нЗ-48х) in combination with the J H 6 intron oligonucleotide The 
specific VDJ rearrangement was amplified using these oligonucleotides and sequenced (see consensus 
sequence in Figure 2) The нЗ region of this VDJ rearrangement (bp 1-603), including upstream sequence 
and the leader intron, was 97 2% homologous to the mapped germline нЗ 4 gene segment and 92% 
homologous to the next most homologous mapped germline gene нЗ-7(4°) The leader intron (bp 197-299) 
was completely homologous to germline нЗ-48 gene segment The D H part of the VDJ rearrangement (bp 
610-630) was 85% homologous to germline ϋχρ'ΐ gene segment'37) For subsequent analyses, we 
assumed that the productively rearranged VDJ gene segments in the lymphoma cells were composed of 
germline counterparts нЗ-4 (4°), Dxp 1 (37> and JH6< 4 1 ) 
The consensus VDJ sequence (bp 1-713, Figure 2) contained several mutations compared 
to their germline counterparts Five mutations and a deletion were present in the region upstream of the 
leader peptide The leader peptide itself contained one replacement mutation, whereas the leader intron was 
completely conserved Twelve replacement mutations and two silent mutations compared to the germline 
genes were present in the CDRs and FWRs 
For mutation analysis, the 388 bp нЗ-48-Dxpi - J H 6 PCR product was cloned, and 
individual clones originating from blood (B3, B4a, B4b, B7, B8, B9 and B10, Fig 2) or nodule sample DNA 
(K1, K5, K7, K8, K10 and K12, Fig 2) were sequenced The clones B3, B4b, K1, K7 and K12 shared eleven 
replacement mutations at position 400, 406, 456, 474, 475, 597, 615, 619, 628, 636, 661 and two silent 
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mutations at position 446 and 467 by comparison to the germline genes А С residue at position 656 was 
also present in the JH6-region of the 14Q+ chromosome (Figure 1A), and may therefore reflect an allelic 
polymorphism rather than a mutation These clones represent lymphoma subpopulation 1 Clones B4a, B7, 
ΒΘ, B9, B10, K5, K8 and K10 all had two additional replacement mutations at position 573 and 575, and 
represent subpopulation 2 Besides these mutations shared by all members of the same subgroup, individual 
mutations and mutations shared by only two members of the same subgroup were present Clones K8 and 
K10 both had a common mutation in the JH6-intron region at position 705 Clone B4b had two additional 
replacement mutations at position 570 and 571, clone B7 had a replacement mutation at position 602, clone 
K7 had a silent mutation at position 668 and clone K5 had a mutation within the JH6-intron region at position 
699 
Lymphoma subpopulation 1 and 2 shared thirteen and fifteen mutations respectively 
compared to their germline counterparts These mutations reflect somatic mutations acquired during clonal 
evolution of both lymphoma populations These mutations were used in two mutation analyses!32 35> Since 
the germline counterpart of the D H gene segment was most likely ϋχρ' ΐ , and since not all germline D genes 
have been identified'37), we devided the analysis in two parts In one part, we analysed the mutations 
present in the entire VDJ gene (Table 1A, region bp 381-683) In the other part, we analysed the mutations in 
the V H gene segment only (Table 1B, region bp 381-602) The distribution of replacement and silent 
mutations as found in the CDRs and FWRs are summarized in Table 1A & 1B for both regions The expected 
distribution of replacement and silent mutations by a random mutation process was calculated for both 
subpopulations for both regions (see materials & methods) The distribution of mutations as found in the VDJ 
gene or the V H gene segment differ from the expected pattern of mutations The p(kR) was calculated for 
both subpopulations in both regions analysed For the VDJ rearrangement the p(9R) in subpopulation 1 was 
0 012 {k = 9, n= 13, N= 15), the p(9R) in subpopulation 2 was 0 05 (k = 9, n= 15, /V = 19), For the V H 
region the P(5R) in subpopulation 1 was 0 03 (k = 5, π = 8, N = 9), the P(5Rj in subpopulation 2 was 0 11 {k 
= 5, n=10, Λ/=13) 
Legend to Table 1 (A) For η mutations, the expected number of replacement and silent mutations in the VDJ 
rearrangement of the lymphoma cells is Re x p = 0 78 χ rr, Sexp = 0 22 χ η The expected distribution ol replacement and 
silent mutations within the FWRs and CDRs of the VDJ rearrangement is RR/VRS = 0 62 Χ R RCDRS = 0 38 Χ R, 
SFWRS = 0 62 Χ S, ScDRs = 0 38 χ S (В) For the н segment, the expected numbers of replacement and silent 
mutations are Rexp = 0 79 χ η S e x D = 0 21 χ π The expected distribution of replacement and silent mutations within 
the FWRs and CDRs of the V H region are RFWRS = 0 70 Χ R, RCDRS = 0 30 Χ R, SpWRs = 0 70 χ S ScDRs = ° 3 0 x 
S (See Materials and Methods) 
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Table 1A. Distribution of shared mutations in the rearranged VDJ gene segments of the lymphoma cells 
FWR1 FWR2 FWR3 FWR4 
Total 
FWRs 
Expected 
FWRs 
Subpopulation 1 
Replacement 
Silent 
R/S 
Subpopulation 2 
Replacement 
Silent 
R/S 
0 
0 
-
0 
0 
-
0 
1 
0 
0 
1 
0 
1 
0 
~ 
3 
0 
-
1 
0 
~ 
1 
0 
-
2 
1 
2 
4 
1 
4 
6 
2 
3 
7 
2 
35 
Subpopulation 1 
Replacement 
Silent 
R/S 
Subpopulation 2 
Replacement 
Silent 
R/S 
CDR1 
2 
0 
" 
2 
0 
-
CDR2 
3 
1 
3 
3 
1 
3 
CDR3 
4 
0 
-
4 
0 
-
Total 
CDRs 
9 
1 
9 
9 
1 
9 
Expected 
CDRs 
4 
1 
4 
5 
1 
5 
Table 1B. Distribution of shared mutations in the н region of the VDJ rearrangement of the lymphoma cells 
Subpopulation 1 
Replacement 
Silent 
R/S 
Subpopulation 2 
Replacement 
Silent 
R/S 
FWR1 
(partial) 
0 
0 
-
0 
0 
-
FWR2 
0 
1 
0 
0 
1 
0 
FWR3 
1 
0 
" 
3 
0 
-
Total 
FWRs 
1 
1 
1 
3 
1 
3 
Expected 
FWRs 
5 
1 
5 
6 
1 
6 
Subpopulation 1 
Replacement 
Silent 
R/S 
Subpopulation 2 
Replacement 
Silent 
R/S 
CDR1 
2 
0 
~ 
2 
0 
D O 
CDR2 
3 
1 
3 
3 
1 
3 
Total 
CDRs 
5 
1 
5 
5 
1 
5 
Expected 
CDRs 
2 
0 
™ 
2 
1 
2 
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Discussion 
In this study, we describe a variant 1(14,18) which was detected in a follicular NHL patient It is the first 
demonstration of a t(14,18) as the result of an error during the н to D-JH rearrangement process in a pre-
B-cell Allmost all t(14,18)s occur dunng the IgH D to J H rearrangement process and seldomly during other 
Ig rearrangement processes The reason for this phenomenon is not understood The Ig recombination 
machinery for IgH and subsequent IgL rearrangements remains active during the complete pre-B-cell stage 
and therefore both loci are highly accessible This is different for the bcl-2 locus The bcl-2 expression is 
downregulated on mRNA level·42' as well as protein level <43' upon entry of pro-B-cells at the pre-B-cell stage 
Therefore it seems likely that the reduced transcriptional rate of the bcl-2 locus is accompagnied by a 
reduced accessibility, and therefore leads to a decreased incidence of t(14,18)s during later Ig 
rearrangement processes 
Due to the temporary open chromatin structure of the bel 2 gene, the Ig recombination 
machinery may aberantly recognize target sequences on the bcl-2 locus The translocation in our case can 
not simply be explained by the presence of heptamer and nonamer signal sequences as targets of the VDJ 
recombination complex, but more likely by chi-like (χ) sequences·12' The χ consensus sequences may act 
as primary recombination targets for distant Ig gene segments in an intermediate recombination process, 
which is further processed by the VDJ recombinase complex using the classical Ig recombination signals 
These χ-like sequences are especially conserved in the FWR1 of group III н families in mammals, to which 
the human нЗ family belongs'44', in D H and J H gene segments, and have also been found in the MBR of 
the bcl-2 gene<12' Recently, proteins have been identified which bind to χ-like sequences present in the 
MBR of the bcl-2 gene<4 5 4 6 ' These sequences may have been involved in the generation of the t(14,18) in 
our case, and are present in all germline counterparts 
To study the effect of the relatively late occurence of the t(14,18) in this case on lymphoma 
development, a mutation analysis was performed The н gene segment of the lymphoma specific VDJ 
rearrangement was most homologous (97 2%) to germline нЗ-48 gene segment, and only 92% 
homologous to the next most homologous н segment нЗ-7(40' Since the map of the human Ig н locus 
is now complete and almost all the sequences are known (3e>, it is reasonable to assume that нЗ-48 
represents the germline counterpart in this case Based on homology, we assume that the germline 
counterpart of the D H gene segment is Dxp'1 (37> From amplification conditions as well as sequence 
information it is obvious that the germline J H gene segment is J H 6 < 4 1 ' 
From both mutation analyses, it is obvious that the amount of replacement mutations present 
in the CDRs of both lymphoma subpopulations exceeds the number of mutations expected in absence of 
selection As discussed by Schlomchik et al (1987b)<32', an R/S ratio higher than 2 9 indicates positive 
selection In both analyses, the R/S ratios for the CDRs of both subpopulations strongly argued in favour of 
positive selection An R/S ratio lower than 2 9 indicates negative selection, as is expected for the FWRs in 
order to maintain the function of the antibody From both mutation analyses it is obvious that a negative 
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selection pressure was acting on the FWRs of sub-population 1 Although subpopulation 2 evolved from 
subpopulalion 1, it is not clear whether a negative selective force was still maintained on the FWRs of 
subpopulation 2 Using the binomial modert35), it seems highly unlikely that the mutation pattern present in 
both lymphoma populations for both regions analyzed had occurred by chance 
Analysis of the individual mutations provides insight in the most recent selection forces which 
have been acting on the lymphoma cells However, the insert of each clone is amplified by Tao; DNA 
polymerase, and may contain unique mutations generated by this enzyme Although the amount of unique 
mutations exceeds the number expected to be induced by Taq polymerase'47), it is less than expected if the 
somatic mutation process was ongoing This frequency is estimated as 1 mutation in 1000 bps in each cell 
cycle'48', resulting in one mutation in the VDJ-region of almost every lymphoma cell Since we used 0 2 цд of 
genomic DNA in our PCR (which roughly equals 3x104 cells) and since the amount of lymphoma cells within 
the lymph node biopt was 30% to 40%, it seems highly unlikely that five out of seven clones originating from 
the blood sample DNA and two out of six clones originating from the lymph node sample DNA did not contain 
unique somatic mutations if this process was still ongoing Furthermore, the position of these mutations does 
not argue in favour of positive selection We conclude that the somatic mutation process in the lymphoma 
cells was turned off, active at a very low level or active in a minor lymphoma population at time of 
presentation, which is in contrast with some other cases of follicular lymphoma'15 1 7 21> 
In conclusion, translocations involving the bcl-2 gene which occur at other stages of the Ig 
rearrangements than the IgH D H to J H gene rearrangement process are extremely rare in follicular 
lymphoma We propose that this correlates with decreased bcl-2 transcription by pro-B cells upon entry in 
the pre-B-cell stage and a concomitant decreased accessibility of potential target sites within the bcl-2 locus 
recognised by χ or the Ig recombination machinery Like other cases, the somatic mutation machinery had 
been active in this follicular lymphoma case We therefore conclude that bel 2 gene deregulation and not the 
precise moment of deregulation during the pre-B-cell stage is of influence on the subsequent development 
towards follicular lymphoma 
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Bax mutations in hematopoietic cell lines 
Many genes are Involved in cell cycle control, DNA repair and induction of cell death. Alterations in 
these genes have been responsible for the development of cancer as well as for resistance to cancer 
therapy. Recently, an emerging family of bcl-2 like genes has been identified that plays a role in the 
regulation of cell death. Its members are highly conserved in several domains which have been 
shown to be important for homodimerization or heterodimerization. The ratio between BAX/BCL2 
heterodimers and BAX/ΒΑΧ homodimers appears to be pivotal in the decision between life or death 
of a cell. We recently detected mutations in evolutionary highly conserved domains of the bax gene 
in cell lines derived from hematologic malignancies. Similar artificially generated mutations in other 
bcl-2 like family members bcl-2, bcl-xl, or ced-9 have been shown to alter their function. This 
suggests a role for bax mutations in the multistep pathogenesis of hematological malignancies. 
Cell proliferation and cell death are two important processes involved in embryonal development, tissue 
homeostasis and regeneration One of the genes involved in the regulation of cell death is the human bcl-2 
gene, which can protect against cell death induced by a variety of death signals'1 2 ' Recently, an emerging 
family of related proteins has been identified'3'. The protein products of DC/-2'1', bcl-x№\ mcY-i'5' can protect 
against apoptosis whereas the protein products tax· 6 ' , bc7-xs'4', bad^> and bal¿e 10 ' make cells more 
sensitive for apoptosis induction. The regulation of the cell death pathway by the bcl-2 like family members 
is very conserved throughout evolution The human bcl-2 gene can partially substitute for ced-9 in nematode 
Caenorhabditis elegans in preventing developmental cell death in ced-9 loss-of-function mutants'11'. 
The different members of the bcl-2 like family can form homodimers or heterodimers with 
other members of the same family, possibly in a head-to-tail configuration'12' Three conserved domains, 
box 1 to 3 as defined by Hengartner and Horvitz (1994) '11>, seem to be important for dimenzation Mutation 
analysis of the two C-terminal homology domains, called bcl-2 homology domain 1 (BH1, which equals box 
2) and BH2 (which equals box 3), demonstrates that several amino acid residues are crucial for 
dimenzation <13' For bcl-2 and bax it has been demonstrated that their protein ratio determines the cells 
susceptibility for cell death following a death signal BAX/ΒΑΧ homodimers renders a cell more vulnerable 
for apoptosis and BCL2/BAX heterodimers provides protection'613> The model is more complex· First, the 
bax gene encodes for several protein products of which ΒΑΧα and ΒΑΧ β seem to be the most important 
ones. ΒΑΧα is a membrane-bound protein whereas ΒΑΧ β is a cytoplasmic protein '6'. Second, other family 
members are also involved and complex interactions among these proteins may dictate complex set points 
unique to each cell'1 4 '. Third, most family members are also expressed in a tissue specific manner, like bcl-x 
which seems to be predominantly expressed in neurons and thymocytes'4' Fourth, expression patterns of 
specific family members can be modulated by external signals'15', and therefore affect the specific set point 
within target cells 
Upon genotoxic stress, an intracellular defense program is activated to facilitate repair prior 
to distribution of mutations over daughter cells. This damage response pathway is regulated by the p53-
gene'1 6 1 7 ' Upon sustaining damage by chemotherapeutic agents or γ-radiation, the p53 expression is 
upregulated by a post-transcnptional mechanism and immediately blocks the cell cycle at the G1 to S phase 
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transition <16> and facilitates repair. For this, the p53 gene upregulates the expression of the wafl/cip1 
gene'18' and the gadd45 gene'19' If DNA damage is too severe, P53 can induce cell death<2°) 
Induction of apoptosis in a p53 dependent pathway is regulated by members of the bcl-2 like 
family P53 induced apoptosis is preceded by a decrease of bcl-2 gene expression and an increase of bax 
gene expression'21·22). The P53 protein can directly modulate bcl-2 and bax expression by a cis-actmg p53 
negative response element located in the 5' untranslated region of the bcl-2 gene'23) and a p53 binding-site 
located in the promotor region of the bax gene'24). 
Inactivation of the p53-dependent cell death pathway can contribute to resistance to therapy 
as well as to oncogenesis itself In nearly all human neoplasms, mutations have been found in the p53 gene 
with concomitant loss of the normal allele'2 5 2 6 ' . Germ-line mutations in the p53 tumor suppressor gene as 
found in families with Li-Fraumem syndrome have been associated with increased risk for cancer 
development'27). Mutations in the p53 gene result in loss of the tumor suppressor activity and enhancement 
of oncogenic activity by dimenzation of mutant P53 with wild-type P53 to form an inactive dimer or 
tetramer'28). This lowers the DNA binding capacity of the P53 complex to target genes and subsequent 
transcriptional activation'29) In vivo experiments as well as correlative studies have shown that mutations in 
the p53 gene also contnbute to resistance to treatment'17·30·31). 
Deregulation of downstream genes in the p53 dependent cell death pathway can also 
contribute to oncogenesis and increased resistance to treatment In many cases of human follicular 
lymphoma, the bcl-2 gene is overexpressed due to a transnational event As an effect of bcl-2 
overexpression, cells become less sensitive for induction of apoptosis and therefore have a longer lifespan 
with a simultaneous increased risk for the accumulation of secondary mutations'1) In mice, overexpression 
of bcl-2 results in the expansion of a polyclonal B-cell compartment, and occasionally dedifferentiates into a 
high-grade monoclonal disease in which the c-myc gene is frequently rearranged'32) Overexpression of bcl-
2 has also been correlated with poor prognosis to therapy in patients with non-Hodgkin's lymphoma, acute 
myeloid leukemia and prostate cancer'2) Since BCL2 and BAX have opposite effects on induction of 
apoptosis following a death signal, it seems reasonable that mutations which disturb BAX function exert a 
similar effect on cells as BCL2 overexpression. This way, aberrations in the bax gene could be involved in 
the genesis of cancer. It also seems likely that these mutations contribute to enhanced resistance to 
chemotherapy. 
In this report we describe the presence of bax mutations in cell lines derived from 
hematological malignancies. The frequency of the mutations is relatively high in the small number of cell 
lines tested. The potential role of these mutations in the pathogenesis of malignancies will be discussed 
Materials & Methods 
Cell lines Cell lines of different hematopoietic background were used in the present study and include three 
human T-ALL cell lines: СЕМ, Jurkat and HPB-ALL, a human Burkitt lymphoma cell line Daudi, and two 
human B-cell lines JM and KM3. 
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RNA-isolation RNA was isolated according to a method developed by Chirgwm et al (ІЭТЭ)'33) 
Oligonucleotides Sense oligonucleotides used bax-exon 3 5'-GTC CAC CAA GAA GCT GAG CG-3, bax-
exon 4 5 -GCC CTT TTC TAC ТТТ GCC AGC-3' Antisense oligonucleotides used bax exon 5 5'-TCC 
AGC CCA АСА GCC GCT С 3', bax-mtron 5 2 5'-GAC ACG TAA GGA AAA CGC ATT AT-3 , bax-exon 6 
5'-GCA CTC CCG CCA CAA AGA TG-3', bax-exon 6 2 5'-TCA GCC CAT CTT CTT CCA GAT-3' The C-
terminal coding region of baxtx or baxß cDNA was amplified using bax-exon 3 primer in combination with 
bax-exon 6 2 pnmer or bax-intron 5 2 primer respectively 
RT-PCR amplification 1 цд of total RNA was reverse transcnpted in the presence of 40 mM Tns-HCI (pH = 
8 3), 75 mM KCl, 3mM MgCfc. 10 mM DTT, 625 mM of dATP, dTTP, dCTP and dGTP, 5 mg/ml ohgo dT, 
1000 U/ml RNAse inhibitor RNasin (Promega, Madison, USA), 10 000 U/ml Moloney Murine Leukemia Virus 
reverse transcriptase (MMLV-RT) (Gibco BRL, Gaithersburg, USA) in a total volume of 20 μ I Reactions 
were overlaid with 60 μΙ mineral oil (Sigma, USA), and were subsequently incubated at 20°С for 10 mm, at 
42°C for 45 mm and at 95°C for 10 mm Samples were amplified by polymerase chain reaction (PCR) in a 
DNA thermal cycler (Perkin Elmer Cetus, Norwalk, USA), in the presence of 0 001% gelatine, 65 mM KCl, 
28 mM Tns-HCI (pH = 8 3), 2 6 mM МдСІг, 500 mM of dATP, dTTP, dCTP and dGTP, 300 pmol/ml of 
oligonucleotides, and 25 U/ml Taq DNA polymerase (Gibco BRL) in a total volume of 100 μΙ Amplification 
started with an initial denaturation step at 94°C for 5 mm, followed by thirty cycles at 94°C for 1 5 mm, 59°C 
for 2 mm and 72° С for 2 mm After the last cycle, extension phase was prolonged for 10 mm at 72 °C, and 
the reactions were cooled to 4° С 
Sequencing PCR products were sequenced according to the method developed by Innis et a/(1988) С34', 
with minor modifications Baxa PCR product was sequenced using oligonucleotides bax exon 4, bax-exon 5 
or bax-exon 6 Baxß PCR product was sequenced using oligonucleotides bax-exon 4, bax exon 5 or bax-
intron 5 
Antibodies BCL2 antibody 124 (Dako, Glostrup, Denmark) was a mouse IgGI, kappa BAX antiserum P-19 
(Santa Cruz Biotechnology, Santa Cruz, California, USA) is a polyclonal rabbit antiserum raised to a peptide 
corresponding to ammo acids 43-61 of the mouse bax gene, but also reacts with human bax Horseradish 
peroxidase conjugated goat anti mouse IgGI (Southern Biotechnology Association Ine, Birmingham, USA) 
and peroxidase conjugated goat anti rabbit (Jackson Immuno Research, West Grove, USA) were used as 
secondary antibodies 
SDS PAGE and immunoblottmg procedure Cells were washed once with phosphate buffered saline (PBS) 
and resuspended at a concentration of 2 χ 107 cells/ml in PBS Cells were boiled after addition of 2 χ SDS 
sample buffer One μ I of these extracts was applied to a 12 5 % Polyacrylamide gel using the fast system 
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(Pharmacia, Upsulla, Sweden). After electrophoresis the samples were blotted by diffusion for 1 hr at 60°С 
onto a 0 45 ц т nitro-cellulose membrane (Schleicher & Schuell, Dassel, Germany) in blotting buffer (25 mM 
Tris, 192 mM Glycine (pH β 3), 20 % methanol) Blocking buffer for immunological detection was prepared 
by heating 0 5 % NIP 552 blocking reagent (Amersham, Buckinghamshire, England) for 1 hr at 65°C 
Blocking buffer was cleared by centnfugation and tween-20 was added to a final concentration of 0 05% 
The membrane was blocked for 1 hr at room temperature (RT) in blocking buffer The first antiserum was 
added to a final concentration of 2 цд/ті The membrane was washed three times in PBS containing 0 05 % 
tween 20 and incubated for 1 hr at RT in 3000 fold diluted secondary antibody in blocking buffer After 5 
washes with PBS containing 0 05% tween-20, blots were developed using the ECL detection system 
(Amersham) and used for exposure on an x-ray film 
Results & Discussion 
mRNA of six hematopoietic cell lines were screened for mutations in the bax gene by an RT-PCR strategy 
We focussed on the C-terminal coding region of the bax gene in which the BH1 and BH2 domains are 
localized, and which are important for heterodimenzation of BAX with BCL2 or BCL-X|J713' The region 
containing the N-termmal homology domain Box 1<11' was not screened, although this region may also be 
important for dimenzation of bcl-2 like family members'12) We found three mutations in two out of six cell 
lines (33%) Since we didn't check the N-terminal coding region of the bax gene, the frequency may be 
underestimated 
Cell line HPB-ALL, which was derived from a patient suffering T-cell acute lymphoblastic 
leukemia (T-ALL), expressed bax mRNA in which a G to A mutation (not shown) was present at position 199 
(relative to the ATG start codon) as well as the normal allele This mutation leads to the substitution of a 
glycine residue by an arginine residue (G67R) Alignment of this region to other bcl-2 like family members 
(Figure 1A) demonstrates that this glycine residue is very conserved throughout evolution This domain is 
located between the conserved Box 1 and Box 2 regions·11>, and the functional significance of this region 
has not been determined A second С to Τ mutation was present in intron 5 at position 508 (not shown) in 
the same cell line The unmutated allele was also expressed on mRNA level Since this intron is alternatively 
spliced, this mutation only affects the BAXß vanant<6) By this mutation an arginine residue is substituted by 
a cystein residue It is not known if expression of BAXß like ΒΑΧ α renders a cell more vulnerable for 
induction of cell death, and therefore it is difficult to draw any conclusion regarding this mutation It is not 
known if both mutations occur in the same allele 
The Burkitt lymphoma cell line Daudi, expressed bax mRNA containing a G to Τ mutation in 
BH1 on position 323, but also expressed the normal allele (Figure 2) By this mutation, a glycine residue is 
substituted by a valine residue This G108V mutation is located in BH1<13> (also defined as Box 2<11>) at a 
position which is completely conserved in all known bcl-2 like family members (Figure 1B) Mutation analysis 
for the bcl-2 gene'1 3 ' and the bcl-xl gene<7> clearly demonstrates that substitution of this particular glycine 
residue by glutamate or alanine respectively results in complete loss of heterodimenzation capacity with 
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(Human) 
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(Human) 
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Figure 1. Alignment of ΒΑΧ domains which were mutated in cell lines HPB-ALL and Daudi with other bcl-2 like family 
members (A). Alignment of С elegansor С bnggsaeCED9<11', chicken BCL2<39), mouse BCL2(40', human BCL2<41>, 
human BAX<6), human BCL-XS and BCL-XL'4), chicken BCL-X<4), MCL1<42> and BAK<9> in a domain which contains the 
BAXG67R mutation ot cell line HPB-ALL (indicated by a triangle) The most conserved amino acid residues amoung the 
genes are indicated in bold lettertype (В). Alignment of the BH1 domain for bcl-2 like genes as used in Figure 1A and 
extended with chicken BCL2 Í35), mouse BAD<7), mouse A1 (43), Epstein Barr virus BHRF1 and African swine virus 
LMW5-HL(3) The BAXG108V mutation of cell line Daudi is indicated by a triangle The most conserved ammo acids are 
indicated in bold lettertype 
BAX and concomitant loss of cell death repressor function. In another mutation analysis, the nematode C. 
elegans paradoxically demonstrates a gam-of-function of CED9 upon substitution of the same glycine 
residue by glutamate. Although BCL2 normally can substitute for CED9 in С elegansW, this mutation 
renders BCL2 completely ineffective for rescue of CED9 loss-of-funclion mutations. Interestingly, the bcl-2 
gene isolated from a chicken B-cell lymphoma cDNA bank coded for a valine instead of a glycine residue a 
tthe same position'35), and it was speculated that this mutation contributed to lymphoma genesis'36) 
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СЕМ DAUDI 
G A T C G A T C 
1 H 
jCX 
A 
A 
С 
Τ 
G 
G 
G 
G/T 
С 
С 
G 
G 
G 
Τ 
Τ 
G 
Figure 2. Sequence of the BH1 region of the bax gene from cell lines СЕМ and Daudi. The G to Τ mutation present in 
one of the bax alleles in the Daudi cell line results in the BAXG108V mutation. 
Mutating this glycine residue has not only different effects in different proteins of the bcl-2 like family 
members, but it's effect is also dependent on the nature of the amino acid substitution. 
What are the consequences of mutations within the bax gene? We hypothesize that the 
mutation in the bax gene as found in the cell line Daudi is accompanied with a loss-of-function of BAX, since 
gain-of-function would lead to a dramatic increase of cell death. The protein data also argue in favour of this 
suggestion (Figure 3). Normal bone marrow cells as well as the cell lines СЕМ, Jurkat, JM, HPB-ALL and 
KM3 all express BAX as well as BCL2, although there are differences in the relative BAX/BCL2 ratio as 
measured by our assay. The situation is different in cell line Daudi, since we didn't detect any BCL2 
expression whereas BAX expression seems to be abundant. Therefore, BAX homodimers probably will be 
abundant as well, and this cell line would be extremely sensitive for apoptosis induction by normal BAX 
function which is not the case. It would be thrilling to know in what way these mutations affect BAX function. 
Do they make BAX oncogenic by more effective heterodimerization with BCL2 or BCL-X|_ or by less 
87 
Bax mutations in hematopoietic cell lines 
effective homodimerization? Do they act in a dominant negative way on the normal allele by 
BAX(mutan,)/BAX(wildtype) homodimerization and concomitant loss-of-function? Functional studies will be 
necessary to provide an answer. 
36KDa 
30KDa 
• * -
BCL2 
В 
30KDa 
BAX 
Figure 3. BCL2 and BAX detection by an immunoblot of cell lysates from 1: normal bone marrow cells; 2: HPB-ALL ; 3: 
Daudi; 4: KM3; S:CEM; 6: Jurkat; 7: JM. The immunoblot was consecutively screened for (A). BCL2 with moab 124 
(Dako) or (Β). BAX with polyclonal P-19 antiserum (Santa Cruz Biotechnology). 
The Daudi cell line is derived from a Burkitt lymphoma with a rearranged and overexpressed 
c-myc gene. Overexpresssion of c-myc induces apoptosis in fibroblasts under conditions which normally 
promote G1-arrest, and it was hypothesized that secondary defects in tumorigenesis affect the cell death 
pathway'3 7'. It has been demonstrated that ectopic expression of bcl-2 inhibits apoptosis induced by 
deregulated c-myc expression'38). Since BCL2 and BAX have opposite effects on the cells susceptibility to 
undergo cell death, it is clear that mutations which disrupt BAX function could contribute to Burkitt lymphoma 
genesis in an identical manner. This may have been the case in the patient from which the Daudi cell line is 
derived. 
Overexpression of BCL2 as a first genetic defect seems to be sufficiently tumorigenic in a 
mice model<32). Most human follicular lymphoma cases carry the t(14;18) in which the bcl-2 gene is 
deregulated. Therefore, it is important to investigate whether mutations in the bcl-2 like family member bax 
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also contribute to cancer development Mutations in the p53 gene and defects in genes which are part of the 
p53-dependent apoptotic machinery like bcl-2 provide increased resistance to chemotherapeutic agents as 
well as Y-radiat ion< 2 ' 1 7 ' 2 6 · 3 0 · 3 1 ) It therefore seems reasonable that mutations negatively affecting BAX 
function also provide increased resistance to treatment. 
In conclusion, we found mutations in the bax gene in about thirty percent of the human 
hematological cell lines tested Mutations in the conserved regions of the bax gene are probably associated 
with a loss-of-function of BAX, and may contribute as an oncogenic event to the pathogenesis of cancer as 
well as to increased resistance to treatment Thusfar these mutations have been found in hematological cell 
lines To demonstrate the frequency and importance of these mutations, it is necessary to screen a large 
panel of tumor samples derived from hematological malignancies as well as other types of cancer 
References 
I KorsmeyerSJ Bcl-2 Initiates a New Category of Oncogenes Regulators of Cell Death Blood 1992, 
2. ReedJC Bcl-2 and the regulation of programmed cell death J Cell Biol 1994,124 1-6 
3. Williams GT, Smith CA Molecular regulation of apoptosis genetic controls on cell death Cell 1993 74 777-779 
4 Boise LH, Gonzalezgarcia M, Postema CE, Ding LY, Lindsten T, Turka LA, Mao XH, Nunez G, Thompson CB 
Bcl-x, a Bcl-2 related gene that functions as a dominant regulator of apoptotic cell death Cell 1993,74 597 608 
5. Reynolds JE, Yang T, Qian LP, Jenkinson JD, Zhou P, Eastman A, Craig RW Md-1, a member of the bcl-2 
family, delays apoptosis induced by c-myc overexpression in Chinese hamster ovary cells Cancer Res 
1994,54 6348-6352 
6 Oltvai ZN, Milliman CL, Korsmeyer SJ BCL2 heterodimenzes in-vivo with a conserved homolog, BAX, that 
accelerates programed cell death Cell 1993,74 609-619 
7 Yang E, Zha JP, Jockei J, Boise LH, Thompson CB, Korsmeyer SJ BAD, a heterodimeric partner for BCL-x(L) 
and BCL2, displaces BAX and promotes cell death Cell 1995,80 285-291 
8 Farrow SN, White JHM, Martinou I, Raven T, Pun KT, Grinham CJ, Martinou JC, Brown R Cloning of a BCL2 
homologue by interaction with adenovirus E1B 19K Nature 1995,374 731-733 
9 Chittenden T, Harrington EA, Oconnor R, Flemmgton C, Lutz RJ, Evan Gl, Guild ВС Induction of apoptosis by 
the BCL2 homologue ВАК Nature 1995,374 733-736 
10 Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tornei LD, Barr PJ Modulation of apoptosis by the 
widely distributed BCL2 homologue ВАК Nature 1995,374 736-739 
I I Hengartner MO, Horvitz HR С elegans cell survival gene ced-9 encodes a functional homolog of the 
mammalian proto-oncogene bcl-2 Cell 1994,76 665-676 
12 Sato T, Hanada M, Bodrug S, Ine SJ, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG, Reed 
JC Interactions among members of the BCL2 protein family analyzed with a yeast two-hybnd system Proc Natl 
Acad Sci USA 1994,91 9238-9242 
13 Yin XM, Oltvai ZN, Korsmeyer SJ BH1 and BH2 domains of BCL2 are required for inhibition of apoptosis and 
heterodimenzation with BAX Nature 1994,369 321-323 
14 Oltvai ZN, Korsmeyer SJ Checkpoints ol dueling dimers foil death wishes Cell 1994,79 189-192 
89 
Bax mutations in hematopoietic cell lines 
15 Liu YJ, Mason DY, Johnson GD, Abbot S, Gregory CD, Hardie DL, Gordon J, Maclennan ICM Germinal center 
cells express BCL2 protein after activation by signals which prevent their entry into apoptosis Eur J Immunol 
1991,21 1905-1910 
16 Kaslan MB, Onyekwere O, Sidransky D, Vogelstem В, Craig RW Participation of P53 protein in the cellular 
response to DNA damage Cancer Res 1991,51 6304-6311 
17 Lowe SW, Ruley HE, Jacks T, Housman DE p53-dependent apoptosis modulates the cytotoxicity ol anticancer 
agents Cell 1993.74 957-967 
18 Eldeiry WS, Harper JW, Oconnor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M Hill DE, 
Wang YS, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kmzler KW, Vogelstein В Waf1/Cip1 is 
induced in p53-mediated G(1) arrest and apoptosis Cancer Res 1994,54 1169-1174 
19 Kastan MB, Zhan Q, El-Delry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstem В, Fornace AJ A 
mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia Cell 
1992,71 587-597 
20 Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M Wild-type p53 induces apoptosis of 
myeloid leukaemic cells that is inhibited by mterleukin-6 Nature 1991,353 345-347 
21. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D Immediate 
early up-regulation of bax expression by p53 but not TGFßl a paradigm for distinct apoptotic pathways 
Oncogene 1994,9 1791-1798 
22 Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman В Reed JC Tumor 
suppressor p53 is a regulator Ol öc/-2and bax gene expression in-vitro and in-vivo Oncogene 1994,9 1799-
1805 
23 Miyashita T, Hangai M, Hanada M, Reed JC Identification of a p53-dependent negative response element in 
the bc/-2 gene Cancer Res 1994,54 3131-3135 
24 Miyashita T, Reed JC Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 
1995.80 293-299 
25 Prokocimer M, Rotter V Structure and function of P53 in normal cells and their aberrations in cancer cells 
projection on the hematologic cell lineages Blood 1994,84 2391-2411 
26 Levine AJ, MomandJ, Finlay CA The p53 tumour suppressor gene Nature 1991,351 453-456 
27 Srivastava S, Zou Ζ, Pirollo К, Blatlner W, Chang E Germ-line transmission of a mutated p53 gene in a cancer-
prone lamily with Li-Fraumeni syndrome Nature 1990,348 747-749 
28 Milner J, Medcalf EA Colranslation of activated mutant P53 with wild type drives the wild-type P53 protein into 
the mutant conformation Cell 1991,65 765-774 
29 Kern SE, Pietenpol JA, Thiagahngam S, Seymour A, Kmzler KW, Vogelstem В Oncogenic Forms of p53 Inhibit 
p53-Regulated Gene Expression Science 1992, 256,827-830 
30 Lowe SW, Bodis S, McClatchey A, Remington L. Ruley HE, Fisher DE, Housman DE, Jacks Τ P53 status and 
the efficacy of cancer treatment therapy in-vivo Science 1994,266 807-810 
31 Fisher DE Apoptosis in cancer therapy crossing the threshold Cell 1994,78 539-542 
32 McDonnell TJ, Korsmeyer SJ Progression from lymphoid hyperplasia to high-grade malignant lymphoma in 
mice transgenic lor the 1(14,18) Nature 1991,349 254-256 
33 Chirgwin JM, Przybylz AE, MacDonald RJ, Rutter WJ Isolation of biologically active ribonucleic acid Irom 
sources enriched in nbonuclease Biochemistry 1979,18 5294-5299 
90 
Chapter 6 
34 Innis MA, Myambo KB, Gelfand DH, Brow MA DNA sequencing with Thermus aquaticus DNA polymerase and 
direct sequencing of polymerase chain reaction-amplified DNA Proc Natl Acad Sci USA 1988,85 9436-9440 
35 Cazals-Halem DL, Louie DC, Tanaka S, Reed JC Molecular cloning and DNA sequence analysis of cDNA 
encoding chicken homologue of the BCL2 oncoprotein Biochim Biophys Acta 1992, 1132 109-113 
36 Hengartner MO, Horvitz HR Activation of С elegans cell death protein CED9 by an amino acid substitution in a 
domain conserved in BCL2 Nature 1994,369 318-320 
37 Evan Gl, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM. Penn LZ, Hancock DC 
Induction of apoptosis in fibroblasts by c-MYC protein Cell 1992,69 119-128 
3Θ Vaux DL, Cory S, Adams JM Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to 
immortalize pre-B cells Nature 1986,335 440-442 
39 Eguchi Y, Ewert DL, Tsujimoto Y Isolation and characterization of the chicken bcl-2 gene expression in a 
variety of tissues including lymphoid and neuronal organs in adult and embryo Nucl Acids Res 1992, 20 4187-
4192 
40 Negrmi M, Siimi E, Kozak С, Tsujimoto Y, Croce CM Molecular analysis of mbcl 2 structure and expression of 
the murine gene homologous to the human gene involved in follicular lymphoma Cell 1987 49 455-463 
41 Tsujimoto Y, Croce CM Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in 
human follicular lymphoma Proc Natl Acad Sci USA 1986,83 5214-5218 
42 Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW Md-1. a gene expressed in programmed myeloid cell 
differentiation, has sequence similarity to BCL2 Proc Natl Acad Sci USA 1993,90 3516-3520 
43 Lin EY, Orlofsky A, Berger MS, Prystowsky MB Characterization of at, a novel hemopoielic-specilic early-
response gene with sequence similarity to BCL2 J Immunol 1993,151 1979-1988 
Acknowledgements. 
This work was supported by the 'Vanderes Foundation', the 'van Vhssingen foundation' and the 'Maunts and 
Anna de Коек Foundation' 
91 

CHAPTER 7 
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Mutations of BAX 
By Jules P.P. Meijerink, Ewald J.B.M. Mensink, Kuhn Wang, Thomas W. 
Sedlak, Annet W. Slöetjes, Theo J.M. de Witte & Stanley J. Korsmeyer 
From the department of Hematology, University Hospital "St. Radboud" 
Nijmegen, Nijmegen, the Netherlands; and the division of Molecular 
Oncology, Howard Hughes Medical Institute, Washington University School 
of Medicine, St. Louis, MO. 
Functional analysis of bax mutations 
The Bcl-2 gene family regulates the suspectability to apoptotic cell death in many cell types during 
embryonic development and normal tissue homeostasis. Deregulated expression of anti-apoptotic 
BCL2 can be a primary aberration that promotes malignancy and also confers resistance to 
chemotherapeutic agents. Recently, studies of bax-deficient mice have indicated that the pro-
apoptotic BAX molecule can function as a tumor suppressor. Consequently, we examined human 
hematopoietic malignancies and found that approximately 2 1 % of lines possessed mutations in bax, 
perhaps most commonly in the Acute Lymphoblastic Leukemia subset. Approximately half were 
nucleotide insertions or deletions within a deoxyguanosine (G8) tract resulting in a proximal frame 
shift and loss of immunodetectable BAX protein. Other bax mutants bore single amino acid 
substitutions within BH1 and ВНЭ domains, demonstrated altered patterns of protein dimerization, 
and had lost death promoting capacity. Thus, mutations in the pro-apoptotic molecule bax which 
confer resistance to apoptosis are also found in malignancies. 
The Bcl-2 gene family regulates cellular responsiveness to a wide variety of death inducing stimuli, including 
growth factor deprivation, glucocorticoids, anti-receptor antibody, γ- and UV irradiation and chemotherapeutic 
agents'1·2). Death antagonists including BCL2, BCL-X|_, MCL1 and A1 provide protection whereas death 
agonist members including BAX, ВАК, BAD and BCL-Xs increase sensitivity to death inducing signals The 
ratio of death agonists to antagonists determines the suspectability to death stimuli3) A prominent feature of 
the BCL2 gene family is their capability to form both homo- and heterodimers'3 5 ' Several conserved 
domains entitled BH1, BH2 and BH3 participate in the formation of various dimer pairs as well as the 
regulation of cell death'6"8' (Figure 1A). Recently, the multidimensional NMR and X-ray crystallographic 
structure of a BCL-Xj_ monomer indicated that BH1-3 correspond to α helixes which are closely juxaposed to 
form a hydrophobic pocket'9). Mutational analysis has indicated the importance of BH1 and BH2 domains for 
the anti-apoptotic function in BCL2 and BCL-X|_as well as their binding to BAX.'5·6) The BH3 domain of ВАК 
and BAX appear critical for promoting cell death and dimerization to BCL-X|_ or BCL2'7'1 0). Moreover, 
several distantly related pro-apoptotic molecules, BIK and BID, possess only a BH3 domain'1 1·1 3). These 
lend strenght to the argument that BH3 represents the critical death domain Besides BH1, BH2 and BH3 
domains, a fourth N-terminal α helical domain entitled BH4 is conserved between BCL2 and BCL-X|_, and is 
vital for death repressor function'14·15). 
Deregulated expression of some bcl-2 family members has been noted in several types of 
human malignancies and may affect clinical outcome. Bcl-2 was discovered on chromosome 18 at the site of 
translocation with the immunoglobulin heavy chain locus (IgH) in follicular lymphoma. Increased expression 
of BCL2 in cases of non-Hodgkin's lymphoma, myeloid leukemia and prostate cancer has been associated 
with a poor prognosis'1·2·16). Reduced bax RNA and protein expression has been noted in metastatic breast 
cancerC17·18), and correlates with a poor response to chemotherapy and shorter overall survival'18). Elevated 
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bcl-2/bax RNA ratios have been associated with progression of disease in B-Chronic Lymphocytic 
Leukemia'19) and low-grade urinary bladder cancer '20> 
Бах-deficient mice indicate that several normal developmental cell deaths depend on 
ßax<21) Moreover, neuronal cell death due to deprivation of neurotrophic factors proved to be dependent on 
bax<22> Induction of BAX expression can be sufficient to induce apoptosis and did not require an additional 
death stimulus'23) Induction of BAX results in the activation of Caspases,'2324), and also triggers a 
mitochondnal dysfunction program '23 25> Finally, experimental models utilizing flax-deficient mice argue that 
approximately half of certain p53-dependent cell deaths require BAX The removal of BAX substantially 
decreases apoptosis induced by a transgene expressing a truncated Τ antigen (TGT121), a previously 
documented p53-dependent death'26) Moreover, chemotherapeutic agents induce apoptosis in embryonic 
fibroblasts in a p53 dependent manner Elimination of ΒΑΧ prevents approximately half of those 
chemotherapy-induced deaths '27> 
Recently, we noted that several cell lines of human hematopoietic malignancies bore 
mutations of the bax gene <2B) Here, we extend this study to a larger panel of malignant hematopoietic lines 
Frameshift mutations eliminated the production of BAX These were focused in the same simple repeat 
sequence found to be mutated in some colon cancers with mutator phenotypes'29' Other substitution 
mutations within the BH1 and BH3 domains resulted in a loss of pro-apoptotic function and altered the 
dimenzation capabilities of BAX 
Materials & Methods 
Amplification of bax and SSCP-gel analysis Bax mRNA from cell lines of human hematopoietic malignancies 
was amplified by RT PCR either unlabeled, or alternatively in the presence of 500 μ M dATP, dTTP and 
dGTP, 125 μΜ dCTP and 100 μθι/ml [a-32P]dCTP (Amersham, 3000 Ci/mmol, 10 mCi/ml) The complete 
Bax coding region was covered by two partially overlapping PCR reactions (Figure 1B)'3' In one PCR 
reaction, flax cDNA was amplified from exon 1 to the exon 4/5 boundary using forward primer A (5'-TGG 
ACG GGT CCG GGG AGC-3') and reverse primer В (5' GCA CAG GGC CTT GAG CAC C-3 ) In a second 
reaction, Bax cDNA was amplified from exon 4 through exon 6 using forward primer С (5 -GCC CTT TTC 
TAC TTT GCC AGC-3') and reverse primer D (5'- TCA GCC CAT CTT CTT CCA GAT 3') Products were 
analyzed by SSCP-PAGE For the SSCP analysis, non-radioactive PCR products were purified on WizardTM 
PCR Preps columns (Promega) and dissolved in TE-buffer Five microliter of PCR product was mixed with 
an equal volume of loading buffer (20% EDTA, 20 mM NaOH, 0 05% xylene cyanol, 0 05% bromophenolblue 
in 96% formamide) and denatured for 10' at 95°C One microliter was separated on a 4 15% Polyacrylamide 
gradient gel or a 12 5% Polyacrylamide gel (Pharmacia LKB Phastsystem) Products were visualised by 
silver staining Alternatively, 2 μΙ of 10-fold diluted radioactive PCR products in SSCP loading buffer were 
separated on a 5% nondenaturating Polyacrylamide gel (49 1), 5% glycerol in half TBE buffer The gel was 
exposed to X-ray films (Kodak) 
95 
Functional analysis of bax mutations 
BH4 
11 30 
5 24 
BH3 BH1 BH2 
97 112 136 155 187 202 
Щ TM BCL-2 
90 106 130 149 180 196 
[&a |TM| BCL-XL 
78 94 117 136 168 184 
TM ВАК 
63 77 98 118 150 165 
tea |TM| BAX 
1 2 
-γ-
3 
377 bp 
4 5 
В 
•< 
6 
< -
D 
> 
Bax 
246 bp 
Figure 1 BCL2 homology (BH) domains within BCL2 family members (A). Schematic representaron of BCL2, BCL-XL, 
ВАК and BAX and the relative position ol the BH1, BH2, BH3, BH4 domains and trans-membrane region ™ (B). 
Schematic overview of bax open reading frame Exons are numbered BH1-3 and transmembrane domains are shaded 
Positions of PCR pnmers (Α-D) are indicated PCR amplification using primer pair А, В results in a 377 bp product PCR 
amplification using primer pair C, D results in a 246 bp product 
Immunoprecipitation Immunoprecipitation was performed as described!3) For immunoprecipitation, 50 
mg/ml of 6C8 (Hamster anti-human BCL2 Moab<30>) or 12CA5 (Mouse anti-influenza virus hemagglutinin 
protein epitope moab(31)) was used 
Preparation of constructs EcoRI sites, an upstream Kozak sequence and hemagglutinin influenza (HA) 
epitope tag were introduced by PCR using extended primers Germlme Bax cDNA sequences and were 
cloned into PCRII using the TA-Cloning kit (Invitrogen), and confirmed by DNA sequencing Identical G67R 
and G108V mutations as found in Daudi and HPB-ALL respectively were introduced by site-directed 
mutagenesis (Clontech) Mutations were confirmed by sequencing Bax and mutant Bax cDNAs were cloned 
into pSFFV-LTR neo expression vector. For yeast two-hybnd experiments, cDNAs without their C-termmal 
signal-anchor sequence were cloned into the Gal4 activation domain (AD) vector pACTII, and the LexA DNA 
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binding domain (DB) vector pBTM116)<5' Extended pnmers were used to introduce a 5' EcoRI site and a 3' 
Sail site for cloning into pBTM116 or a 5' Ncol site and a 3' Smal site for cloning into pACTII Constructs 
were confirmed by DNA sequencing The constructs for вс/-Х/.дС19, Sc/-2дС22 in pACTII, and 0с/-Х/_дС19 
in pBTM116 were previously described!5). 
Transfection and Western Blots 20 μg DNA of Xba-1 linearized pSFFV-LTR neo vector expressing HA-flax, 
HA-Ba*36™ or HA-BaxG108V was transfected into FL5 12 cells or cotransfected with 1 μg of linearized pGK-
hygro vector DNA into FL5 12-Bc/-2 cells Stable transfectant clones were selected for neomycin resistance 
(1 mg/ml G418) or hygromycin resistance (1 mg/ml) Transfected clones were analyzed for HA-BAX, НА­
ВАХОЙ
 o r HA-BAX
G 1 0 8 V
 expression by Western-blotting using polyclonal antiserum N20 (Santa Cruz, 
1 500) as primary antibody and Goat-anti-Rabbit HRPO (Caltag Labs, 1 2000) as the secondary Ab BCL2 
expression was detected by the antibody 6C8 (1 250), and a secondary Goat-anti-Hamster HRPO Ab 
(Caltag Labs, 1 2000) Immunoblots were developed by ECL (Amersham) 
Yeast Two-Hybnd analysis cDNAs cloned in pBTM116 or pACTII were co-transformed into yeast strain L40 
(MATa trp1-901 leu2-3,112 ade2 his3-A200 LYS2 (lexAop)4-HIS3 URA3 (lexA)β-LacZW using the Lithium-
Acetate method<33' After transformation, yeast cells were plated on selective media (His+, Ura", Leu", Trp") 
and incubated at 30 °C After 2-4 days, yeast colonies were transferred to nitrocellulose filters, and incubated 
for 1' in liquid N 2 Filters were dried on whatmann paper and stained with 5-bromo-4 chloro-3-indolyl ß-D-
galactoside (X-Gal) substrate solution (60 mM Na2HP04, 40 mM NaH2P04, 10 mM KCl, 1 mM MgS04, 50 
mM p-Mercaptoethanol. 1 mg/ml X-Gal, pH=7 0 for 1 to 12 hrs at 37°C 
Results 
Substitution mutations Twenty-nine cell lines derived from hematopoietic malignancies of various cell types 
were analyzed for mutations in bax by SSCP and sequencing analysis We found evidence for mutations in 7 
cell lines (Table 1) The Burkitt Lymphoma (BL) cell line Daudi expressed a mutant bax allele which 
contained a G108V mutation and a wild-type allele This mutation substitutes the central glycine within the 
BH1 domain (Figure 1A) The Plasmacytoma (PC) cell line OPM1 expressed a mutant allele with a G11E 
mutation and a wild-type allele This glycine resides in the N terminus proximal to the first predicted α helix 
The Acute Lymphoblastic Leukemic cell line HPB-ALL expressed a G67R mutant allele as well as a wild-type 
allele This mutation alters the central glycine within the BH3 domain (Figure 1A) All three cell lines 
expressed BAX protein by Western analysis 
Frameshift mutations SSCP analysis also noted a district, altered pattern common to four 
cell lines (KM3, СЕМ, Jurkat, JM*) (Table 1) DNA sequence analysis revealed the same single nucleotide 
deletion (G)7 in a simple tract of 8 deoxyguanosine residues (G)e (nt 114-121) encompassing codons 38 to 
41 of human bax (Table 1) This deletion was consistently detected in 3 or more independently amplified RT-
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Table 1. Summary of mutation analysis 
Cell-line 
Daudi 
Raji 
Ramos 
Rpmi6666 
SUDHL6 
UM1 
U266 
Rpmi8226 
IM-9 
FRAVEL 
OPM1 
HS-sultan 
MC-CAR 
ARH77 
KM3 
СЕМ 
Jurkat 
JM* 
HPB-ALL 
GH1 
PEER 
HSB2 
MOLT4 
KCL22 
KYO 
K562 
BV173 
HL60 
Kazumi 
Lineage 
В 
В 
В 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
τ 
τ 
τ 
τ 
τ 
τ 
τ 
τ 
Μ 
Μ 
Μ 
Μ 
Μ 
Μ 
Origin 
BL 
BL 
BL 
HD 
FL 
MM 
MM 
MM 
MM 
MM 
PC 
PC 
PC 
PCL 
B-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
CML 
CML 
CML-E 
CML-L 
APL 
AML-M2 
SSCP 
mutation 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
mutation 
wt 
wt 
wt 
mutation 
mutation 
2 mutations 
2 mutations 
mutation 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
Sequence 
G108V 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
G11E 
wt 
wt 
wt 
del (g114-121 
d e l ( a 1 1 4 - 1 2 1 
)§ 
)§ 
deWns(g114-121)¥ 
del/ins (a 1 1 4 - 1 2 1 ) ¥ 
G67R 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
wt 
Protein 
+ 
ND 
ND 
ND 
+ 
ND 
ND 
ND 
ND 
ND 
+ 
ND 
ND 
ND 
-
-
-
-
+ 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
+ 
ND 
ND 
The presence ol mutations in cell lines ol hematopoietic malignancies as determined by SSCP and sequence analysis 
Abbreviations BL, Burkilt's Lymphoma, B-ALL, B-cell Acute Lymphoblastic Leukemia, HD, Hodgkm's Disease, FL, 
Follicular Lymphoma, MM, Multiple Myeloma, PC, Plasmacytoma, PCL, Plasma Cell Leukemia, T-ALL, T-cell Acute 
Lymphoblastic Leukemia, CML, Chronic Myeloid Leukemia, CML-E, CML with blast crisis of Erythroid lineage, CML-L, 
CML with blast crisis of Lymphoid lineage, APL, Acute Promyelocytic Leukemia, AML-M2, Acute Myeloid Leukemia of 
M2 subtype, *JM denved from Jurkat line, §Deletion of 1 guanine residue in guanine stretch (nt^ 14-121) ¥ p e | e j l 0 n 0 j ^ 
guanine residue in guanine stretch (nt 1 1 4 ~ 1 2 1 ) on first allele and insertion of 1 guanine residue in guanine stretch 
(n|114-121)
 o n s e c o n ( j allele RT-PCR results are based upon at least 2-3 independent SSCP or sequencing analysis 
PCR products from each cell line DNA sequence of four or five independent clones from these RT-PCR 
products demonstrate the same (G)7 deletion SSCP and DNA sequence analysis of the pre-B cell ALL, KM3 
and the Τ cell ALL СЕМ only detected the (G)7 deletion and no wild type allele indicating the mutation 
hemizygous or homozygous. PCR amplification of the 3rd exon of bax from the genomic DNA of KM3 also 
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failed to reveal a wild-type allele (not shown) The (G)7 deletion frameshift generated a proximal stop codon 
Consistent with this no immunodetectable protein was observed in KM3 or СЕМ (Table 1 ) 
The Τ cell ALL Jurkat and Jurkat derivate JM<34> both displayed an additional alteration on 
3SCP which upon DN sequencing proved to be a single nucleotide insertion (G)g in the same (G)e (nt 114-
121) tract (Table I) Approximately half of the independent clones from the RT-PCR products of Jurkat and 
JM demonstrated the (G)g insertion while others the (G)7 deletion The (G)g insertion frameshift also 
generates a proximal stop codon consistent with the lack of immunodetectable protein in Jurkat and JM cells 
(Table 1) and the presence of two mutated bax alleles. 
Table 2. Yeast two hybrid interactions 
pACTII BAX G67R Gl 08V BCL2 BCL-XL 
BAX - + + + + + 
G67R - + + + + ND 
G108V - + ND + + + + 
B C L - X L - + - + ND ND 
Yeast two hybrid analysis of dimenzation capacity of wildtype BAX versus BAXGB7R and BAXG 1 0 8 V AD-fusion 
constructs are indicated accross the top lane control vector pACTII, ВАХдС19 ΒΑΧ 0 6 7 0 дсіві ЙЛХб108 дс ів BCL-
2дС22. ВС1-Х/_дс19 DB-fusion constructs are indicated in the lelt hand column ВАХдсів. SAXG67RA C 1 8 i 
flAXGi08VAç-18i ВС/_-Х/_дС19 Protein interactions as measured by X-gal substrate conversion are indicated as '-' for 
no interaction or "+" for clear positive Interactions that were enhanced are indicated as '++" or "+++" Interactions were 
tested in 2-4 independent experiments 
Protein dimenzation The BAXQ67R and BAX<31°8V mutants found in HPB-ALL and Daudi 
reside in the conserved BH3 and BH1 domain respectively, and consequently were tested for dimenzation 
capacity with BCL2 family members by means of yeast two hybrid analysis (Table 2) While the binding of 
BAXG 6 7 R to wild-type BAX appeared unaffected, it demonstrated enhanced dimenzation with itself, 
BAXG67R, in contrast, the capacity to heterodimenze with BCL2 or BCL-XL was lost ВАХ<зю did not form 
homodimers with itself, ВАХР108 , but bound to wild-type BAX BAX<31°8V demonstrated enhanced binding 
to BCL2 and B C L - X L . Thus, both mutations demonstrated altered, yet very distinct dimenzation 
characteristics. 
We next examined whether these BAX mutants demonstrated altered dimenzation within 
mammalian cells Stably transfected FL5 12-SC/2 clones expressing comparable amounts of hemagglutinin 
epitope-tagged (HA) molecules HA-BAX, HA-BAXG67R
 0 r HA-BAXG1°8V w e r e generated (Figure ЗА) When 
BCL2 was immunoprecipitated from lysates, it co-precipitated HA-BAX and the endogenous BAX (Figure 2A, 
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Figure 2 Altered dimenzation of B A X G 6 7 R and ΒΑΧ G108V ιη-νινο compared to wildtype ΒΑΧ (A). Immuno-precipitation 
of BCL2 Irom 0 2 5 % NP-40 lysates ol 3 5 s methionine/cysteine-labeled FL5 12-bc/-2 cells (Hygro) or HA-BAX HA-
BAXG67R orHA-BAXdOSV stably transfecled clones using anti-human BCL2 Moab 6 C 8 and SDS-PAGE<3) (B). 
Immuno-precipitation and SDS-PAGE analysis using anti-HA Moab 12CA5 from 0 2 5 % NP-40 lysates of S S 
methionine/cysteine-labeled FL5 12-DC/-2 cells (Hygro) or HA-BAX, HA-BAXG67R
 0 r HA-BAXG108V s t a b | y transfected 
clones 
L a n e 1) HA-BAXG108V but not HA-BAXG67R
 w a s a | s o co-precipitated with BCL-2 confirming the interactions 
suggested in yeast two-hybrid (Figure 2A, Lane 2,3) A consistent higher ratio of HA-BAXG 1 0 B V/endogenous 
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Figure 3. B A X G e 7 n and B A X G 1 0 8 V have lost cell death promoting activity. (A). Western blot analysis using anti-BAX 
polyclonal antiserum N20 upon lysates of FL5.12-bc/-2 cells (Hygro) or HA-BAX, HA-BAXG67R
 o r HA-BAX
G1°8V stably 
transfected clones. (B). Western blot analysis of the same lysates as in (A) using anti-human BCL2 Moab 6CS. (C). 
Viability assay: Transfected clones described in (A) were deprived of IL-3 and viability was determined by trypan blue 
exclusion at 0, 0.5, 1, 2, 3, 4 and 5 days following IL-3 withdrawal and plotted as the mean percent survival +/. SEM. (D). 
Western blot analysis using anti-BAX polyclonal antiserum N20 upon lysates of FL5.12 cells (Neo) or HA-BAX, HA-
BAXG67R
 o r HA-BAXG108V s t a D | y transfected clones. (E). Viability assay: Transfected clones described in (D) were 
deprived of IL-3 and viability was determined by trypan blue exclusion at 0, 12, 16, 20, 24, 36 and 48 hrs following IL-3 
deprivation and plotted as the mean percent survival +/. SEM. 
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BAX compared to HA-BAX/endogenous BAX in BCL2 immunoprecipitates is consistent with the enhanced 
binding of BAXG108V noted in the yeast two-hybnd analysis (Table 2) In the reciprocal experiment, HA-BAX, 
HA-BAXG67R or HA-BAXG108V
 w e r e immunoprecipitated with anti-HA Moab 12CA5 and all heterodimenzed 
to endogenous BAX (Figure 2B, Lane 1-3) As before, HA-BAX. and НА-ВАХОюв but not HA-BAXG67H
 c o . 
precipitated BCL2 confirming the pattern of interactions within mammalian cells (Figure 2) 
Functional analysis of Bax mutants To address the functional consequence of the BH1 and 
BH3 mutations they were assessed in an IL-3 deprivation assay using the FL5 12 line Clones of FL5 12 
(Neo) or FL5 12-Bc/-2 expressing comparable amounts of HA-BAX, HA-BAXG67R, НА-ВАХ<зюв
 w e r e 
identified by immunoblots (Figure ЗА, В and D) Addition of wild-type HA-BAX but not HA-BAXG67R
 0 r HA-
BAXG1oev was capable of promoting cell death in FL5 M-Bcl-2 cells that were protected by BCL2 (Figure 
3C) Similarly, HA-BAXG67R
 o r HA-BAXG108V did not substantially alter the survival of native FL5 12 cells 
while wild-type HA-BAX clearly enhanced apoptosis (Figure 3E) 
Discussion 
Prolonged cell survival with resistance to apoptosis can be a primary oncogenic event Transgenic mice 
bearing a bcl-2-lg minigene that recapitulated the t(14,18) found in human follicular lymphoma display В cell 
hyperplasia that progressed to gigh grade lymphoma'35' Evidence is emerging that a principal contribution 
from loss of p53 function is the elimination of a death pathway'36 37> Recent evidence suggests that BAX, a 
pro-apoptotic member of the BCL2 family can also qualify as a tumorsuppressor Bax-deficient mice display 
cellular expansions of neurons, lymphocytes, ovarian granulosa cells and spermatogonia reflecting the 
survival of cells that avoided developmental death'21) TGT121 transgenic mice which express a truncated Τ 
antigen that inhibits Rb but leaves p53 intact displayed an accelerated progression to malignancy upon a 
bax-deficient background'26) Of note, heterozygous £>ax(+/-) mice also displayed an earlier onset of 
malignancy suggesting that alteration of a single bax allele could be of functional significance An increase in 
focus formation was also documented in bax deficient versus wild-type fibroblasts when transfected with ras 
and Е?Л'27) These experimental models argue that bax can also be considered a tumor suppressor and that 
loss of this pro-apoptotic molecule promotes tumongenesis 
We found mutations in bax in approximately 2 1 % (6 of 28 independent lines with 
confirmation of the mutation in Jurkat in its derivative JM) of human hematopoietic malignancy lines No bax 
alterations were noted in thirty-five normal individuals or in eight EBV transformed lymphoblastoid lines 
indicating that the observed alterations of bax are not common polymorphisms or associated with 
immortalization Approximately half of the mutations were framehrfts confined to a single mononucleotide 
(G)e tract (nt114-121) The existence of both insertions (G)g and deletions (G)7 within the same leukemia 
(Jurkat and JM) favors a biallelic aberration and argues that the elimination of bax is a selective advantage 
Lack of immunodetectable BAX protein in other leukemias with (G)7 deletions is compatible with a 
homozygous abnormality or perhaps loss of the second allele Recently, Rampino et al (19Θ7) described the 
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Figure 4. Three dimensional structure of BH3 region of BAX. Views of a modeled surface of the BH3 amphiphatic α-helix 
of BAX, calculated and displayed using GRASP (Muchmore ef a/ (1996)). The G67R substitution as occurs in HPB-ALL 
is displayed at right. The surface is colored deep blue (23Kt>T) in the most negative, with linear interpolation for values in-
between. The model was generated using the protein building module (BUILDER) of INSIGHT II (Biosyn, San Diego) and 
minimized using DISCOVER, the forefield simulation mode. 
presence of frameshift mutations in the identical (G)e tract of bax in about 50% of human colon carcinomas 
with the microsatelite mutator phenotype (MMP)<29). Some sporadic cancers and almost all cancers 
associated with the hereditary nonpolyposis colorectal cancer syndrome (HNPCC) accumulate mutations in 
microsatelites of nucleotide repeats due to defects in the human DNA mismatch repair genes including 
hMSH2, hMLH1, hPMS1, hPMS2(3e). This raises the possibility that a subset of Acute Lymphoblastic 
Leukemia may have a mutator phenotype. 
In addition to the frameshift mutations we found missence mutations including BAX G 6 7 R in 
the BH3 and BAXG1"8V ¡n the BH1 domain. Both mutations demonstrated abnormal dimerization 
characteristics, but were nearly opposite in their pattern. This argues that the death agonist activity of BAX 
may not strictly correlate with the capacity to form any single set of homo or heterodimer pairs. Molecular 
modeling of the BH3 a2-helix revealed a classic amphiphatic α-helix. The G67R mutation would introduce a 
charged residue onto the hydrophobic face of this hellix (Figure 4). NMR analysis of wild-type and mutant 
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peptides of the ВНЭ a2-hehx of ВАК indicated critical interactions with BCL-X|_ through both hydrophobic and 
electrostatical interactions^9). The substitution of the central glycine in this a2-hehx to arginine noted here 
has a much greater effect than an alanine substitution analyzed for BIK<39) The impact of the G67R muation 
in BAX provides additional evidence that BH3 domains are critical for pro-apoptotic molecules 
The G108V substitution in the BH1 a5-hehx of BAX also resulted in the loss of pro-apoptotic 
activity While eliminating mutant/mutant dimenzation, it if anything enhanced heterodimenzation with BCL2 
and BCL-X[_. Previous substitution of this central glycine to alanine in BCL2 (G145A) and in BCL-X|_ (G159A) 
eliminated both their heterodimenzation with BAX and their anti-apoptotic activity'5·6' However, the 
comparable substitution in BAX (G108A) had no effect (unpublished observations) Thus the strong effect of 
the G108V substitution was somewhat unexpected. The G108 residue resides in the long hydrophobic α£>· 
helix felt to be part of the transmembrane helical cores responsible for the ion channel activity of BCL-X|_(4°) 
and m similar approaches also for BAX(41 4 2>. This provides an alternative role for this residue beyond 
protein interaction. 
but upon substitution into valine (BAXS108V) results in loss-of homodimenzation as well as 
death agonistic function. So glycine1 0 8 in BH1 of BAX preserves an evolutionary conserved site important for 
function and dimenzation. Glycine67 (BH3) of BAX is also critical for maintaing cell death promoting function 
and dimenzation with at least BCL-2 and B C L - X L · Glycine 67 is positioned within the hydrophobic site of 
BH3 (Fig 4) and substitution into arginine may introduce a positive charge into this region 
Oncogenes which promote proliferation contribute to cancer through gain-of-function 
alterations, while growth inhibitory tumor suppressor genes contribute principally through loss-of-function 
mutations The gam-of-function alteration of the bcl-2-lg translocation overexpressed the anti-apoptotic 
molecule BCL2 in follicular lymphoma. This suggested that pro-apoptotic molecules could contribute to 
oncogenesis by loss-of-function mutations The discovery of bax muatations in a subset of colon carcinomas 
and in hematopoietic malignancies here provide such evidence This adds evidence in human tumors to the 
prospective experiments utilizing bax-deficient mice. The loss of BAX function would confer resistence to 
programmed cell death within hematopoietic cells and could contribute to malignancy in several ways 
Extended cell survival and resistance to apoptosis would enable cells to withstand additional genetic 
alterations In this contex t loss of BAX function could be a primary oncogenic abberation for which the bax-
deficient mice provide evidence. Bax mutations could also contribute to tumor progression or the 
establishment of cell lines. Finally, chemotherapy could have selected for the loss of BAX as BAX deficiency 
would confer chemoresistence. 
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The BCL-2 GENE FAMILY, TO LIVE OR LET DIE 
The bcl-2 gene family, to live or let die 
Introduction 
Apoptosis is a genetically encoded program which causes cells to die following a characteristic morphological 
pattern of membrane blebbing, cell shrinkage, chromatine condensation and breakdown, formation of 
apoptotic bodies and phagocytosis by macrophages Apoptosis occurs throughout live and is crucial during 
embryonal development, tissue homeostasis, immunological response and aging Deregulation of this proces 
contributes to autoimmune diseases, cancer, neurodegenerative diseases and AIDS (1> 
The bcl-2 gene family is one of the most pronounced regulators of programmed cell death 
(PCD). It consists of several members of which some members protect against the onset of PCD (bcl-2, bel-
χ/, mcl-1, al, bcl-w, nr-13, bfl-1) while others promote PCD under suboptimal or cytotoxic conditions (bax, 
bak, bad, bc/-xs)<2) All family members except bad are expressed as membrane bound proteins on the 
mitochondrial outer membrane proximate to inner and outer membrane contact sites. At least BCL2 is also 
present on the endoplasmatic reticular and nuclear outer membranes The family members form protein 
dimers through interactions between conserved domains·2"4). Cellular responsiveness to cell death signals is 
regulated by the relative abundance of specific dimers and determines a specific cellular treshold (also called 
the cellular rheostat'5' (reviewed in <4 6·7>). 
Ever since the discovery of bcl-2 as the first member of this still emerging family of related 
genes, one of the most interesting issues has still not been solved: How does the bcl-2 like family regulate 
cell death? Many different mechanisms by which bcl-2 and other family members regulate PCD have been 
proposed (summarized in Figure 1), and will be reviewed in this paper. 
1. Scavengers of intracellular free radicals 
Reactive oxygen intermediates (ROI) are produced as natural spin-off during oxidative phosphorylation in 
mitochondria, and are normally detoxified by superoxide dismutase and oxidation of mitochondrial glutathion 
to prevent lipid and protein damage. Extensive production of ROIs may occur passively during apoptosis as a 
result of mitochondrial dysfunction or may be produced actively as a mechanism to execute apoptosis In 
support of (his latter hypothesis, ROI scavenger N-acetylcysteine as well as overexpression of gluthatione 
peroxidase both protect against PCD of IL-3 dependent cells following IL-3 deprivation!8) Since bcl-2 can 
protect against PCD as a result of many different cytotoxic conditions including treatment with peroxides or 
depletion of mitochondrial glutathion l8 ·9 ' and since BCL2 does not interfere with ROI production, BCL2 may 
reduce the destructive effects of ROIs probably by functioning as a direct radical scavenger!8) This 
explanation however may not suffice, and bcl-2 and bcl-xl are also protective against various cytotoxic stimuli 
under hypoxic conditions during which ROIs are not produced!10"12). Alternatively, ROIs may promote the 
nuclear translocation of transcription factor NF-κβ as an alternative mechanism to induce PCD Nuclear 
translocation of NF-κβ may activate a specific death gene. Bcl-2 may inhibit PCD by interfering with the 
nuclear translocation of NF-κβ directly!13) or indirectly!14). On the other hand, apoptosis can be observed in 
most cell types in the presence of protein synthesis inhibitor cycloheximide, so cells may allready express all 
constituents for PCD in a constitutive manner!15·. 
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2. Regulators of intracellular calcium balance 
The intracellular calcium balance is regulated by storage and release from intracellular organelles like the 
endoplasmatic reticulum (ER) and influx through voltage independent calcium-channels in the plasma 
membrane. Following cellular activation, cytoplasmic calcium levels are temporarily increased through 
depletion of stores and influx of extracellular calcium. Calcium fluxes have also been observed during cell-kill 
by cytotoxic Τ cells and apoptosis of self-reactive thymocytes, so calcium may play a role in cell death as 
wellt16). Transient sequestering of calcium in mitochondria may be a mechanism to regulate mitochondrial 
function'1 7·1 8 ', or may coordinate cytoplasmic calcium fluxes'19). In several studies, it was suggested that 
BCL2 inhibits cell death by regulating the intracellular calcium fluxes Dunng growth factor deprivation of IL-3 
dependent cells, intracellular calcium is repartitioned from cytoplasm and ER to mitochondria prior to the 
onset of apoptosis. BCL2 is able to inhibit or reduce calcium repartitioning'20'. In agreement with this, BCL2 
may inhibit the release of calcium from the ER'21'. 
If BCL2 is indeed able to inhibit programmed cell death by controlling cellular calcium fluxes, 
overexpression of BCL2 could reduce or inhibit other calcium-dependent processes like lymphocyte 
activation by antigens. This has not been observed, on the contrary, lck-bcl-2 transgenic mice have an 
increased rather than a decreased Τ cell response towards superantigens'22·23' Recently, BCL2 has been 
implicated in the regulation of mitochondrial permeability transition (section 3), and bcl-2 associated calcium 
effects may more likely be a consequence rather than a direct site of regulation. Opening of the mitochondrial 
voltage dependent membrane pore is facilitated by high mitochondnal calcium levels'24·25) and by reduced 
mitochondrial calcium efflux'26). Bcl-2 may regulate the mitochondrial transition pore directly (discussed in 
section 3), inhibiting calcium entry in mitochondria in order to prevent permeability transition in some 
models'20·21), or promoting maximum calcium influx without inducing mitochondrial permeability transition 
and respiratory damage in other models'27'. Alternatively, BCL2 may be a membrane pore itself (discussed 
in section 3), optimizing mitochondrial calcium efflux during suboptimal conditions in order to prevent 
mitochondrial permeability transition Furthermore, bcl-2 expressing cells may exhibit a higher mitochondrial 
membrane potential'2 8). High membrane potentials further reduce the probability of mitochondrial 
permeability transition'29), and as a result may facilitate higher calcium levels'19'. 
Legend to Figure 1. Summary of various mechanisms as proposed tor the bcl-2 gene lamily in order to signal (or live or 
death Decision between live or death may depend on critical protein interactions, phosphorylation or dephosphorylation 
events of a death or survival substrate, regulation of ion or protein transport across mitochondrial membranes or 
regulation of cell cycle. 
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3. Regulators of mitochondrial permeability transition 
The mitochondrial permeability transition pore is an non-specific high conductance channel in the 
mitochondrial inner membrane, and may be identical to the mitochondrial megachannel as found by 
patchclamp techniques. Opening of the pore results in the release of solutes up to 1 5 kDa in size, in the 
collapse of the proton electrochemical gradient and in the cessation of ATP production'30·31). In a cell-free 
system, a strict correlation was found between reduction of the mitochondrial membrane potential (Αψητη) 
due to mitochondrial permeability transition and induction of nuclear apoptosis'32) Loss-of Δ φ ^ as a result 
of treatment with various cytotoxic drugs is an early event in apoptosis as well as necrotic processes and 
precedes other apoptotic features like uncoupling of electron transport from ATP production, genomic DNA 
degradation, alterations of nuclear morphology, changes in membrane integrity and the formation of 
apoptotic bodies (33-36) j n e s e latter apoptotic features may also depend on ROI formation, and are reduced 
by conditions under which production of ROIs is inhibited'36'. 
Loss-of Д уті ісап be inhibited by overexpression of bcl-2 or bcl-xl but not by cytokine response 
modifier A (CrmA) or other specific cysteine protease inhibitors Permeability transition due to pore opening 
may therefore occur independently of caspases and probably precedes activation of caspases in the 
apoptotic cascade. Bcl-2 or bcl-xl does not protect against loss-of ΔψπίΛ during Fas-mediated apoptosis'37"39' 
or TNF-mediated apoptosis'40>, arguing that the bcl-2 gene family and the fasAnf-a supertamily participate in 
independent death pathways. Bongkrekic acid (BA), which is a specific antagonist of mitochondrial 
permeability transition, inhibits loss-of Δψπιιΐ and nuclear apoptosis induced by several compounds in the 
cell-free system'32). BA is able to inhibit induction of apoptosis in thymocytes by various cytotoxic stimuli. 
BCL2 and BA inhibit permeability transition induced by identical compounds, raising the possibility that BCL2 
inhibits mitochondrial permeability transition by interacting with the adenine nucleotide translocator (ANT) as 
constituent of the transition pore'32). 
Recently, the three dimensial structure of BCL-XL was resolved by X-ray crystallography and 
nuclear magnetic resonance. B C L - X L consists of two antiparallel hydrophobic α-helixes surrounded by five 
amphipathic helixes. The BH1, BH2 and BH3 domains are organized in close spatial proximity and form a 
hydrophobic pocket that can function as a docking-site for other family members. The position of the N-
termmal BH4 domain is variable due to the presence of a flexible loop between BH4 and BH3 which is 
designated the loop domain and comprises a serine phosphorylation site'4 1·4 2) Since other BCL2 like 
proteins share conserved domains, they may adopt a similar conformation The structure of B C L - X L 
resembles the pore-forming domains of bacterial toxins like diphtheria toxin or cohcins A and E1, which form 
membrane-pores upon dimenzation'41). Likewise, B C L - X L and BCL2 are able to form cation-specific 
channels under physiological pH. Several channels with multiple conduction states are observed that are 
probably the result of different oligomenc states of BCL2 and B C L - X L l n membranes'43·44). In analogy to 
diphtheria toxin which translocates the ADP nbosylating A-subunit into the cytosol through the formation of a 
membrane pore'45), bcl-2 family members may control cell death by transporting ions or proteins over the 
mitochondrial membrane. 
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During apoptosis, several mitochondrial factors are released into the cytosol. In a cell-free 
system based upon cytosolic fractions, Liu et al (1996) identified two factors which are stimulated by the 
addition of dATP and activate the cysteine protease CPP32 and nuclear apoptosis. One of these factors 
denoted Apaf-2 was identified as cytochrome C, and is released from the mitochondrial intermembrane 
space upon induction of apoptosis'46). The identity of second factor denoted Apaf-1 is still unknown, but is 
probably the same factor designated AIF (for apoptosis inducing factor) as recently identified by Susin et al 
(1996). This cysteine protease of about 50 kDa resides under normal conditions in the mitochondrial 
intermembrane space. AIF is different from other cysteine proteases like ICE or CPP32 since it does not 
degrade CPP32 specific substrates like polyadenosme diphosphate-nbose polymerase (PARP) and Lamm 
A/B and it is not inactivated by ICE or CPP32 specific inhibitors. AIF triggers genomic DNA degradation and 
nuclear apoptotic morphology'47). 
It is attractive to speculate that the bcl-2 gene family regulates the release of mitochondrial 
factors as a mechanism to regulate PCD. BCL2 is able to inhibit or to retard the release of holocytochrome С 
and AIF from the mitochondria upon induction of apoptosis. In contrast to AIF which is released upon 
collapse of Δ ψ ^ . release of holocytochrome С from the mitochondria to the cytosol is a relatively early event 
during apoptosis. It probably precedes loss-of Δ ψ me. activation of caspases like CPP32, cleavage of 
protease specific substrates and fragmentation of DNA'48·49). BCL2 and its family members may not only be 
involved in the regulation of mitochondrial permeability transition pore opening or release of mitochondrial 
death factors, they may also function by recruiting various cytoplasmic proteins to the mitochondrial 
environment. 
4a. Docking sites for cytoplasmic proteins 
The bcl-2 gene family may regulate PCD by the formation of specific homodimers and heterodimers A 
number of genes not belonging to the bcl-2 gene family have been identified that can interact with bcl-2 gene 
family members at the protein level. Among these genes is the protein kinase raf-1 (for Ras-aclivated factor-
1)'5°), the phosphatase-2B calcmeurin'51), bag-1 (for BCL2 associated athanogene-1 <52'), ced-4 (for cell 
death gene-4'53-55)), bik/nbk (for BCL2 interactive killer or natural born killer)'5 6·5 7', bid (for BH3 interacting 
domain death agonist)!58), hrk (for hankiri)'59), bbp/53bp2 (for BCL2 binding protein or p53 binding protein 
2t60)) and three uncharactenzed cDNAs,nip-1, nip-2 and nip-3 (for E1В 19K interacting proteins'61 )). Some of 
these genes may be involved in the modulation of the anti-apoptotic or pro-apoptotic activity of bcl-2 gene 
family members, while others may be directly involved in cell survival or death. 
BCL2 can bind to RAF1<50·62), and may be dependent on cell-type ' 6 3 >. The BCL2-RAF1 
interaction is probably facilitated by a third protein denoted BAG1, and may result in the formation of a tn-
molecular complex. BAG1 is unique among cellular proteins in that it not only binds to BCL2<52>, the 
hepatocyte growth factor (HGF) receptor, the platelet-derived growth factor (PDGF)'64) and RAF1 <65>, it also 
potentiates the anti-apoptotic effect of BCL2, HGF or PDGF during drug-induced apoptosis as well as the 
phosphorylation of RAF1 substrate MAPK/ERK kinase (MEK) Both RAF1 and BAG1 bind to the BH4 domain 
of BCL2. In a mitochondrial environment, RAF1 is able to enhance the anti-apoptotic effect of BCL2'50). 
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Destabilization of the complex by phosphorylation of RAF1 and BCL2 upon taxol treatment result in loss-of 
anti-apoptotic function <62 66> Recruitement of RAF1 may serve several functions First, RAF1 may modulate 
the activity of some bcl-2 gene family members such as BAD<50 67> Second, RAF1 may also be involved in 
the activation of critical death or survival effectors Since BCL2 is also able to recruit phosphatase-2B 
Calcineunn to the mitochondrial environment<51), such downstream effectors are subjected to extensive 
phosphorylation and dephosphorylation events 
The downstream effectors in the cell death cascade may involve members of a new bcl-2-
related gene family One of these members denoted bik/nbk binds to BCL2 family members except BAX 
BIK/NBK contains a BH3 domain, but shares no further domains of homology with the bcl-2 gene 
family'56 57> Recently, two other members denoted bid and hrk have been identified'58 59> Their general 
expression in most cell types is consistent with their possible function as downstream effectors in the cell 
death or survival pathway, although the expression of hrk is limited to bone marrow and spleen Unlike the 
other two genes, Bid has no putitive membrane-spanning domain Bik/nbk, bid or hrk induce apoptosis upon 
transient transfection that can be blocked by BCL2 or BCL-X|_<56 59> At present it is unclear how these 
proteins signal for death These proteins may resemble BAX and ВАК in signalling for death!56 s? 59)_
 o r a c t 
as specific death substrates when bound to pro-apoptotic bcl-2 gene family members'58' 
4b. Regulators of Caspase activation 
Other protein interactions by which the bcl-2 gene family may regulate cell viability has been provided by the 
nematode Caenorhabditis elegans model Three genes denoted ced-9, ced-3 and ced 4 have been identified 
so far that are essential for developmental cell death Ced 9 is the nematodian homologue of the human bcl-
2 gene'6 8 ', whereas ced-3 and ced 4 are able to activate apoptosis Ced-3 is homologous to IL 1β -
converting enzyme ice (caspase-1<69 70>), but no human homologue of the ced-4 gene have been identified 
so far The ced-9 gene is able to inhibit the function of ced-3 and ced-4, suggesting that ced 9 functions 
upstream of ced-3 and ced-4 <71> For this, CED9 and BCL-XL may bind to CED4 directly Mutations in CED9 
and BCL-XL which result in a loss-of-function phenotype also result in loss-of-bmding to CED4 The binding 
site for CED4 involves the BH1-3 domains of CED9 or BCL-XL, a r , d т а У require a hydrophobic pocket 
conformation<53"55) Since CED4 binds to CED3, a tn-molecular complex can be formed This way, B C L - X L 'S 
able to recruit pro-ICE (caspase-1) and pro-FLICE (caspase-9) but not pro-Yama (caspase-3) or pro-Mch2 
(caspase-6) to mitochondria, thereby inhibiting the activation of caspases by CED4<55) ΒΑΧ may signal for 
death by competing with CED4 for binding to BCL-XL, allowing the CED4/caspase complex to enter the 
cytosol and to activate the protease by CED4 
Different death pathways converge to the activation of caspases and it is now generally 
accepted that caspases are involved in the executioner-phase of the cell death cascade However, recently it 
was demonstrated that cells can still be induced to die by apoptosis in the presence of cysteine protease 
inhibitors following expression of specific oncogenes, DNA damage or lethal expression of ВАК or ΒΑΧ but 
not upon ligation of Fas/Apo-1'72 73> After the induction of a cytotoxic stimulus, cells retain functional 
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mitochondria and intact cell membranes, do not demonstrate chromatine condensation, DNA fragmentation 
or degradation of protease substrates like nuclear PARP (poly(ADP nbose) polymerase) and cytoplasmic D4-
GDI (GDP dissociation inhibitor for the rho family) in the presence of cysteine protease inhibitor ZVAD-fmk 
for at least 48 hours after onset of membrane blebbing'73'. ZVAD-fmk treated cells finally die after several 
days displaying an apoptotic phenotype although chromatine condensation, DNA fragmentation and 
cleavage of protease substrates may be reduced'73'. Therefore, caspases are important for a fast and 
irreversible execution of cell death, but the actual decision between live and death precedes the activation of 
caspases. 
5. Regulators of cell cycle 
Tissue homeostasis demands a balance between cell renewal (cell division) and cell death (apoptosis), but at 
present it is unclear how these processes are connected Such a connection seems logical since active 
cycling cells are especially sensitive to undergo apoptosis by cytotoxic compounds. The recent observation 
that bcl-2 family members can affect cell cycle entry may provide new insight in the communication between 
these processes. By making use of cell line models and transgenic mice models'74 7 7 ' , several groups found 
that bcl-2, bcl-xlox E1B-19K retard cell cycle entry from Go phase and/or prolong the G1 cell cycle phase 
This results in reduced numbers of cells m S or G2/M phase and in a prolongation of total cell cycle time Bcl-
2 mutants which are incapable to promote survival'78) are unable to aflect entry of cells from the quiescent 
stage into the cell cycle'75). So domains which are required for regulation of cell death are also involved in 
regulation of cell cycle Moreover, bax transgenic mice display an increased percentage of thymocytes in S 
phase'79' and cell cycle regulation may therefore not be regulated by a single bcl-2 family member, but may 
be dictated by the relative abundance of specific dimers. 
How does the bcl-2 family interact with the cell cycle machinery' A direct interaction has not 
been proven yet, but the effects of bcl-2 on cell cycle appears to correlate with a hypophosphorylated pRB 
status'74' Hypophosphorylated pRB may be related with persistent cyclin/Cdk2-inhibitor p27K'Pl expression 
during in-vitro Τ cell activation'76' Likewise, increased cell cycle entry of Sax-transgenic thymocytes during 
in-vitro activation has been correlated with faster decrease of p27K|P1 levels'79'. The p21waM expression 
level is not affected The mechanism by which the bcl-2 family regulates the levels of p27K|P1 is unclear, but 
may involve activation of a specific caspases. BCL2 also reduces nuclear translocation of nuclear factor of 
activated Τ cells (NFAT)'76', by recruiting calcineurm to the mitochondria'51' resulting in reduced IL-2, IL-3 
and GM-CSF production However, addition of exogenous IL-2 has no compensatory effect on reduced cell 
cycle entry by BCL2'76>. 
Concluding remarks 
Many components of the cell death cascade have been identified during the last years, and their relative 
position in the cascade is better understood. The bcl-2 gene family is an important point of convergence of 
the cellular pathways that are intermingled with a decision between live and death Although several different 
mechanisms have been proposed by which the bcl-2 gene family signals for live or death, none of those have 
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been indisputably proven yet At present it is still unclear if signaling by the bcl-2 gene family requires a 
critical protein interaction or involves the regulation of cellular processes like ion or protein transport from 
mitochondria (and ER) to cytoplasm and vice versa Future research to provide answers about this still 
enigmatic issue will require close scientific cooperation between the molecular biology research field and the 
physiology research field. 
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SUMMARY 
i 
Summary of this thesis 
The t(14;18)(q32;q21) is found in the majority of follicular lymphoma patients. This translocation has been 
recognized as one of the cntical steps in the development towards malignancy (reviewed in Chapter 1). 
Cloning of the chromosomal breakpoint regions resulted in the discovery of the bcl-2 gene, a new type of 
proto-oncogene that is able to regulate the lifespan of a cell The discovery of this gene led to a new concept 
of cancer development. One started to realize that cancer was not only the result of uncontrolled cellular 
proliferation but it may also result from neglect of programmed cell death. 
A whole family of bcl-2 related genes has been identified, consisting of members which 
protect against cell death like bcl-2, but also of genes which promote programmed cell death, such as the bax 
gene. Although the bcl-2 gene is the only gene from this family that has been correlated with the 
pathogenesis of disease until now, deregulated expression of at least some members have been correlated 
with increased cellular resistance of some cancer types to chemotherapy and γ-radiation 
The t(14;18) is a tumor specific marker, and it provides an excellent opportunity to monitor 
residual tumor burden during the course of disease, provided that accurate quantitation is feasible 
Moreover, quantitation of residual disease may be very helpful in designing effective treatment strategies in 
future. For this purpose, we developed a quantitative method based upon the polymerase chain (Chapter 
2). The polymerase chain reaction is extremely sensitive, and the detection of a single t(14,18) which is 
equivalent to one lymphoma cell in a background of about 150,000 normal cells is feasible. A major 
advantage of the quantitative method is that the amplification of each sample is internally checked for 
amplification fidelity by the application of an internal standard. Using the competitive assay (Chapter 3), 
declining numbers of residual lymphoma cells were detected in consecutive blood samples of a follicular non-
Hodgkm's lymphoma patient after allogeneic bone marrow transplantation This progressive decline may 
reflect specific immunity of the donor graft to residual lymphoma cells, e.g graft-versus-lymphoma activity 
The method was further improved by the coupling of polymerase chain reaction technology with capillary 
electrophoresis (Chapter 4) This enabled non-radioactive and fully automated analysis of assay products 
In Chapter 5, we described the cloning of both translocational junction regions of an 
unusual t(14,18) which was identified in a follhcular non-Hodgkin's lymphoma patient. We concluded that this 
translocation was the result of an aberrant rearrangement during the immunoglobulin heavy chain 
rearrangement process in the pre-B cell stage that had happened during an attempted н to D H - J H 
rearrangement. Since the majonty of t(14,18)s occur as mistakes during relatively earlier immunoglobulin 
rearrangement processes, we studied the pathogenesis of this lymphoma case by analyzing the somatic 
mutation pattern in the functionally rearranged immunoglobulin heavy chain. Like other follicular lymphoma 
cases, somatic mutations were present providing evidence for antigen-driven selection of lymphoma cells. 
The rarity of t(14;18)s during relatively later immunoglobulin heavy chain rearrangement processes compared 
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to the DH to J H joining process may coincide with reduced transcription rate and accessibility ol the bcl-2 
locus during the pre-pre-B cell stage 
In Chapter 6, we reported the presence of point mutations in the pro-apoptotic bel 2 family 
member bax in several malignant hematopoietic lines One mutation (G10BV) was localized in an evolutionary 
conserved domain previously denoted as BCL2 homology domain 1 (BH1) Equivalent mutations in bcl-2 or 
bcl-x resulted in complete loss of anti-apoptotic function, so an equivalent mutation in bax may have major 
implications for function Protein alignment of several bcl-2 family members predicted that another point 
mutation (G67R) was also localized in a region with extensive protein conservation This region has recently 
been identified as acntical death domain of bcl-2 family members with pro-apoptotic activity and denoted 
BH3 Furthermore, we observed clustering of somatic frameshift mutations in a single mononucleotide 
stretch consisting of eight deoxyguanosme residues in at least three independent malignant cell lines 
(Chapter 7) Clustenng of identical frameshift mutations have recently been described in patients with 
colorectal cancer, and is associated with the microsatelite mutator phenotype Functional analyses ol two bax 
mutants having a mutation in the BH1 (G108V) or BH3 (G67R) region respectively, demonstrated that both 
mutations were associated with altered protein binding and loss of pro-apoptotic function of mutant BAX 
In chapter 8, we reviewed the cellular mechanisms by which the bcl-2 gene family may 
regulate cell death Several different mechanisms have been proposed like scavenging of intracellular 
reactive oxygen radicals, control of intracellular calcium balance, regulation of mitochondrial permeability 
transition by a direct interacting with the mitochondrial transition pore or by serving as membrane pore, 
binding of intracellular proteins which are involved in signal transduction or caspase activation, or by 
regulation of cell-cycle 
Future research perspectives 
Future research will be directed to clarify the relation between mutations in bax and cellular resistance to 
chemotherapy For this purpose, we shall test wildtype bax and mutant bax transfected cell lines for sensitivity 
to chemotherapeutic regiments Wildtype and mutant bax-transgenic mice are currently being developed, 
and will be used in in-vivo experiments for testing cellular sensitivity to chemotherapeutic regiments These 
mice will be monitored for tumour development in a longterm cohort study to further investigate a potential 
relationship between loss-of-function mutations in the pro-apoptotic gene bax and cancer development 
Both loss-of-function mutants of BAX as described in chapter 7 provides a powerful model to 
investigate the mechanism by which BAX regulates cell death We shall attempt to identify downstream 
effectors in the cell death cascade For this, we are currently performing a differential screening of an 
expression library by means of the yeast-two-hybrid technique Furthermore, wildtype and mutant bax 
transfectants will be used to investigate a direct role of bax in the regulation of mitochondrial permeability 
transition 
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Research has already been directed to optimize the quantitation of residual lymphoma cells 
during treatment of follicular lymphoma patients by introduction of recently developed Taqman chemistry 
This will result in a faster and almost fully automated quantitation assay, in which contaminations are less likely 
to occur This method will be used to monitor residual tumor burden in patients with follicular non-Hodgkm's 
lymphoma which have been treated according to various experimental treatment protocols 
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Samenvatting 
De chromosomale translocatie t(14,18)(q32,q21) is in de meeste folliculair non-Hodgkin's lymfoom patiënten 
aanwezig Deze translocatie wordt gezien als één van de belangrijkste stappen in het ontstaan van deze 
ziekte (zie overzicht in Hoofdstuk 1) Het bcl-2 gen is gevonden door klonering van de chromosomale 
breekpunten van de translocatie Het bleek een nieuw type proto-oncogen, en is van belang voor regulatie 
van geprogrammeerde celdood Celdood is een actief cellulair proces, waarbij de cel dood gaat middels een 
karakteristiek morfologisch patroon dat ook wel "apoptose" genoemd wordt De ontdekking van dit gen heeft 
geleid tot een kompleet nieuw inzicht in het ontstaan van kanker Tot nu toe zag men kanker als het resultaat 
van ongecontroleerde celgroei, maar nu bleek kanker ook te kunnen ontstaan door een defect in het 
celdood programma waardoor de getransformeerde cel een verlengde levensduur krijgt 
Tegenwoordig zijn er meerdere genen bekend die verwant zijn aan bcl-2, en vormen 
tesamen de bcl-2 gen familie Deze familie betsaat uit genen die de cel kunnen beschermen tegen de 
inductie van het celdood programma zoals het bcl-2 gen, maar ook uit genen die de inductie van dit 
programma juist stimuleren, zoals bijvoorbeeld het baxgen Het bcl-2 gen is tot nu toe het enige gen uit de 
genfamilie dat gekoppeld is met een ziektebeeld Echter, de expressie van bcl-2 of andere familieleden 
kunnen in sommige kankertypen verhoogd zijn en aanleiding geven tot een resistentie tegen 
chemotherapie of bestraling 
De t(14,18) is een lymfoomcel-specifieke genafwijking Hierdoor is het mogelijk om residuale 
lymfoom cellen aan te tonen en te kwantificeren tijdens de behandeling van het ziekteproces Nauwkeurige 
kwantificering van residuale kanker cellen is belangrijk voor het bepalen van de effectiviteit van nieuwe 
behandehngs-strategieén Hoofdstuk 2 beschrijft een kwantitatieve methode, die gebaseerd is op de 
polymerase kettingreaktie Deze methode kan residuale lymfoomcellen kwantificeren in bloedmonsters van 
lymfoom patiënten De polymerase ketting reaktie is een specifieke en zeer gevoelige methode, waarmee 
een enkele t(14,18) overeenkomend met één lymfoomcel in een achtergrond van 150 000 normale cellen 
aangetoond kan worden De toepassing van een interne standaard om het verloop van de reaktie te 
kontroleren biedt een belangrijk voordeel Deze assay toonde een langzame afname aan van residuale 
lymfoomcellen in het bloed van een patient met een folliculair non-Hodgkin's lymfoom patient na allogene 
beenmergtransplantatie (Hoofdstuk 3) Deze afname was mogelijk het gevolg van specifieke immuniteit 
van donorcellen tegen residuale lymfoomcellen, en wordt dan ook "graft-versus-lymphoma" activiteit 
genoemd De methode werd verder verbeterd door de toepassing van capillaire electroforese voor de 
analyse van de reaktieprodukten (Hoofdstuk 4), waardoor het mogelijk is om de reaktieprodukten zonder 
toepassing van radionucliden bijna volledig geautomatiseerd te analyseren 
De klonering en analyse van beide translocatie breekpunten van een zeldzame t(14,18) van 
een patient met een folliculair non-Hodgkin's lymfoom, is beschreven in Hoofdstuk 5 De translocatie is 
waarschijnlijk het resultaat van een foutieve rangschikking van gensegmenten tijdens het Immunoglobuline 
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zware keten rangschikkingsproces, mogelijk tentijde van een н naar D H - J H gensegment koppeling Vnjwel 
alle t(14,18)s zijn het gevolg van fouten in relatief vroegere gensegment rangschikkingsprocessen Daarom 
bestudeerde WIJ dit lymfoom door analyse van somatische mutaties in het functionele zware keten 
immunoglobuline-gen Het somatische mutatiepatroon vormde een bewijs voor antigeen-selectie tijdens de 
ontwikkeling tot folliculair non-Hodgkm's lymfoom Het sporadische voorkomen van t(14,18)s tengevolge van 
relatief late Immunoglobuline zware keten rangschikkingen hangt mogelijk samen met verminderde 
transcriptie en daardoor mindere toegankelijkheid van het bcl-2 locus in het pre-B cell stadium 
In diverse kwaadaardige hematopoietische cellijnen werden puntmutaties in het pro-
apoptotische bax gen aangetoond, zoals beschreven in Hoofdstuk 6 Een van de puntmutaties, de 
G108V-mutatie zoals aanwezig in de cellijn Daudi, is gelegen in een evolutionair geconserveerd domein dat 
het "BCL2 homologie domein 1 (BH1)" genoemd wordt De G108V mutatie in bax heeft mogelijk 
consequenties voor de pro-apoptotische activiteit van dit gen Equivalente mutaties in het bcl-2 of bel χ gen 
leiden tot een verlies van anti-apoptotische activiteit Een andere puntmutatie, de G67R mutatie zoals 
aanwezig in de cellijn HPB-ALL, is gelegen in een andere geconserveerd domein dat het BH3 domein 
genoemd wordt Recentelijk is aangetoond dat BH3 van cruciaal belang is voor de activiteit van BAX In drie 
cellijnen van acute lymfatische leukemie origine werden frameshift mutaties aangetoond die geklusterd 
waren in een mononucleotide stretch bestaande uit acht opeenvolgende deoxyguanosme residuen 
(Hoofdstuk 7) Recentelijk zijn identieke frameshift mutaties in het bax gen aangetoond in patiënten met 
dikke darmkanker Beide bax mutaties, G67R en G108V, zijn getest op functionaliteit Beide mutaties bleken 
te leiden tot veranderde eiwit dimensaties en verlies van pro-apoptotische activiteit 
Hoofdstuk 8 is een samenvatting van verschillende mechanismen waarmee de bcl-2 gen-
familie de celdood kan reguleren, zoals binding van reaktieve zuurstof radicalen, regulatie van de 
intracellulaire calcium balans, regulatie van mitochondriale permeabiliteits transitie door een direkt interaktie 
met de mitochondriale transitie porie of door pone-vormende activiteit van de bcl-2 gen familie, door binding 
van cellulaire eiwitten die betrokken zijn bij de signaal-transduktie en activatie van caspases, of door regulatie 
van de cel cyclus 
128 
Dankwoord-Epilogue 
Dankwoord - Epilogue 
Het "dankwoord" is een speciaal onderdeel van vele proefschriften. Meestal is het een verzameling van 
namen van collega's die op een of andere wijze hebben bijgedragen aan het ontstaan van het proefschrift U 
zou misschien geneigd zijn te zeggen dat het daardoor een verplicht en saai onderdeel is Naar mijn mening 
is echter niets minder waar. ledere keer wanneer een nieuw proefschnft in mijn omgeving wordt uitgedeeld, 
zie ik bijna iedereen als eerste bladeren in dit onderdeel, het dankwoord daarmee tot het meest gelezen deel 
makende. Wat zegt LP Dat de rest nog minder gelezen wordt iets zegt over de mate van aantrekkelijkheid7 
Geen commentaar' 
Als eerste wil ik graag mijn promotor, prof. dr T. de Witte, bedanken voor het mogelijk maken 
van mijn promotie-plaats. Theo, bedankt voor jouw steun en vertrouwen Ik ben echter nog steeds van 
mening dat een goed onderzoeker een zekere mate van naïviteit nodig heeft t a ν zijn of haar experimenten 
Veel dank ook aan mijn beide co-promotoren Ewald Mensink en John Raemaekers Ewald, met name JIJ bent 
als begeleider het meest direkt betrokken geweest bij mijn werk Met groot plezier denk ik niet alleen terug 
aan onze gezamenlijke wetenschappelijke inspanningen, maar ook aan de "gezellige ambiance" die je wist te 
creëren (de tempelier, de hond van de buren, gezang in de trein) waann vele wetenschappelijke ideeën hun 
oorsprong vonden John, jij bedankt voor het clinische aspect binnen het onderzoek, en de vele 
inspanningen die JIJ hebt gedaan voor het leggen van goede samenwerkingscontacten met pathologie (José 
Bogman), cytogenetica (Ad Geurts van Kessel) alsook de farmaceutische industrie (Schering-Plough, Robert 
Alferink, bedankt·) Veel dank ook verschuldigd aan mijn direkt betrokken AlO-collega's Toon Smetsers, 
Peter Willems (Peewee) en Aldy Kuypers. We mogen elkaar niet altijd begrepen hebben, een levendige en 
enerverende club was het wel Bedankt ook de mensen die direkt betrokken zijn geweest bij mijn Projekten: 
Ruth Knops, Arjen Nooteboom, Helger Yntema, Annet Sloetjes, Evelien Tonnissen, Agnes Zoetbrood, 
Gerard Goverde, Louis van de Locht, Ellen Stevens-Lmders, Peter Donnely en Aniek de Graaf alsook de 
overige mensen van de DNA-club Verder wil ik alle medewerkers van de afdeling Hematologie alsook van 
het Centraal Hematologisch Laboratorium bedanken voor deze fijne jaren van samenwerking 
Furthermore, I'm deeply indebted to all people of the Stan Korsmeyer lab, and especially to 
Stan Korsmeyer, Ying Li, Ben Yu, Kun Wang, Tom Sedlak, Curt Milliman, Jailing Xiang, Deb Kane, Mary 
Pichler, Kazuhito Yamamoto, Julie Rinkenberger, Jiping Zha, Elizabeth Yang, Gary Brown and James Stan, 
thank you very much for the opportunity you gave me to perform part of the work as outlined in this thesis on 
your lab and for the way you made a better scientist out of me, thanks! Gary and Lisa, Ying, Ben, Dan and 
Doreen, Kathy and Vince, Jailing, thank you very much for all those non-scientific moments we shared in St. 
Louis 
Tenslotte Nicole, bedankt voor al die jaren van ondersteuning en eindeloos geduld die het 
mogelijk maakte om dit proefschrift tot een goed einde te brengen 
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Stellingen 
behorende bij het proefschrift: 
The role of the bcl-2 gene family in malignant hematopoiesis 
and their use for monitoring of disease 
door J.P.P. Meijerink 
17 december 1997 
1. Door middel van de polymerase ketting reaktie is het mogelijk om residuale lymfoom cellen met een 
chromosomale translocatie tussen chromosoom 14 en 18, de t(14,18), in folliculaire non-Hodgkin 
lymfoom patiënten te kwantificeren tijdens het ziekte verloop met een gevoeligheid van tenminste 1 
lymfoomcel op de 150 000 normale cellen 
Dit proefschrift 
2. Het is aannemelijk dat het gemeten aantal lymfoomcellen met een t(14,18) in het bloed van folliculaire 
non-Hodgkin lymfoom patiënten tijdens het ziekteproces een goede maat is voor ziekte-activiteit 
Dit proefschrift 
3. De kans op het ontstaan van een t(14,18) tengevolge van een foutieve koppeling tijdens het 
Immunoglobuline zware keten rangschikkingsproces neemt af naarmate dit proces verder gevorderd 
is. 
Dit proefschrift 
4. Ongeveer 20% van de hematopoietische cellijnen van maligne origine bevat een mutatie in het pro-
apoptotische bax gen, waardoor een met-functioneel BAX eiwit gevormd wordt. 
Dit proefschnft 
Het voorkomen van identieke insertie/deletie mutaties in een monodeoxyguanosme stretch in het bax 
gen van cellijnen van acute lympfatische leukemie (ALL) origine zoals ook gevonden bij 50% van de 
colon kanker patiënten met het microsaleliet mutator fenotype (MMP+) suggereert het bestaan van 
een MMP+ ALL subpopulatie. 
Rampino et al, Science, 14 februari 1997,en dit proefschrift 
Het BH1 domein van BAX is in tegenstelling tot het BH1 domein van BAK wel degelijk van belang voor 
de pro-apoptotische activiteit van BAX. 
Dit proefschrift 
Het ontrafelen van het werkingsmechanisme waarmee de bcl-2 gen familie celdood reguleert, zal 
leiden tot de ontwikkeling van nieuwe therapeutische behandelingen van kanker. 
Succes in de wetenschap is mede afhankelijk van de naïviteit van de onderzoeker. 
Iedereen rondt in het leven zijn of haar eigen Kaap Hoorn. 
Henk van de Velde (solozeiler) 
De verhoging van de accijns op benzine ter verbetenng van de infrastructuur van het Nederlandse 
wegenstelsel zou beter aangewend kunnen worden voor het subsidiëren van het openbaar vervoer, 
waardoor het fileprobleem effectiever benaderd wordt. 
Fight like a brave, don't be a slave, 
No one can tell you, you have got to be afraid. 
Red Hot Chili Peppers 
Nil volentibus arduum (níets is te moeilijk voor hen die willen). 


